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ABSTRACT 
Inflammatory bowel disease is a common gastro-intestinal disorder marked with 
chronic inflammation of intestinal epithelium, damaging mucosal tissue and manifests 
into several intestinal and extra-intestinal symptoms, mainly related to oxidative stress, 
inflammation and autoimmune type [Mowat, 2011; Pawar, 2011]. Currently used 
medical therapy of inflammatory bowel disease aim to induce and maintain the patient 
in remission and ameliorate the disease’s secondary effects, rather than modifying or 
reversing the underlying pathogenic mechanism [Engel, 2010; Pithadia, 2011]. 
Furthermore, their use may result in severe side effects and complications, such as an 
increased rate of malignancies or infectious diseases [Engel, 2010]. The main objective 
of the study is to evaluate the influence of a set of new drugs in inflammatory bowel 
disease, like erythropoietin, thiadiazolidinone-8 and hemin, through of an experimental 
colitis model induced by TNBS in rodents, contributing to facilitate a more effective and 
selective treatment than the currently known. Experimental colitis is induced by 
intracolonic administration of TNBS as described by Morris method [Morris, 1989]. The 
mice with colitis are treated with and without daily doses of erythropoietin, 
thiadiazolidinone-8 and hemin. The evaluated parameters are clinical symptoms/signs, 
colon length, fecal hemoglobin, ALP, urea, creatinine, ALT, MPO, TNF-α, IL-1β, IL-10 
and histopathological score. TNBS-induced colitis was developed in 4 days, providing 
an acute intestinal inflammation model. These mice presented an increase of MPO, 
TNF-α, IL-1β and fecal hemoglobin. Erythropoietin treatment had a positive influence in 
the development of experimental colitis in all evaluated parameters, thus reducing its 
severity and extension. Thiadiazolidinone-8 derivate and hemin treatments had also a 
positive influence in the development of experimental colitis, but not in all evaluated 
parameters. All tested drugs significantly inhibit acute inflammatory response 
associated to the TNBS-induced colitis model. 
 
 
 
 
 
 
KEY-WORDS: TNBS-induced colitis, Inflammation, Erythropoietin, Thiadiazolidinone-8, 
Hemin. 
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RESUMO 
A doença inflamatória intestinal é um distúrbio gastrointestinal caracterizado por 
inflamação crónica do epitélio intestinal com ulceração recorrente, manifestando 
inúmeros sintomas intestinais e extraintestinais, principalmente relacionados com 
stress oxidativo, inflamação e do tipo autoimune [Mowat, 2011; Pawar, 2011]. O 
tratamento farmacológico atualmente utilizado tem por objetivo induzir e/ou manter o 
doente em remissão e melhorar os efeitos secundários da doença, no entanto não 
modifica ou reverte o mecanismo patogénico subjacente [Engel, 2010; Pithadia de 
2011]. A sua utilização pode resultar em efeitos colaterais graves e complicações, tais 
como um aumento da taxa de malignidades ou doenças infeciosas [Engel, 2010]. 
Assim, a pesquisa de novas abordagens farmacológicas pode promover avanços 
importantes no tratamento da doença inflamatória intestinal. Neste sentido, um número 
cada vez maior de modelos animais de doença têm sido utilizados para estudos pré-
clínicos, os quais apresentam manifestações clínicas semelhantes às observadas em 
humanos. No caso da doença inflamatória intestinal, o modelo de colite induzida por 
TNBS é um método eficiente, uma vez que mimetiza o padrão de inflamação 
característica da doença em humanos, produzindo a doença de forma rápida, fiável e 
reprodutível. Assim, o objetivo principal deste estudo é avaliar o efeito de um conjunto 
de novas moléculas na doença inflamatória intestinal, como eritropoietina, 
tiadiazolidinona-8 e hemina, por meio de um modelo de colite experimental induzida 
por TNBS em roedores, contribuindo para um tratamento mais eficaz e seletivo do que 
o atualmente conhecido. 
 
Para tal, utilizaram-se ratos machos CD-1, com 30-40 g de peso e de 6-10 semanas 
de idade. A colite experimental é induzida por uma administração única intra-rectal de 
TNBS, de acordo com o método de Morris [Morris, 1989]. Os grupos experimentais 
foram estruturados com base nos principais objetivos do estudo. Os murganhos com 
colite são tratados com e sem doses diárias de eritropoietina, tiadiazolidinona-8 e 
hemina. Foram ainda formados grupos de referência para servirem de controlo na 
comparação dos resultados com os grupos de tratamento. No final do período 
experimental, os ratos foram anestesiados e foram recolhidas amostras de sangue por 
punção cardíaca. Em seguida, os murganhos foram sacrificados por deslocação 
cervical e necropsiados. Foram avaliados alguns parâmetros, como a hemoglobina 
fecal, fosfatase alcalina, ureia, creatinina e alanina aminotransferase através do 
sistema automático ADVIA® Chemistry XTP. A mieloperoxidase, TNF-α, IL-1β e IL-10 
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são determinados por ELISA. O score histopatológico foi atribuído com base em 
critérios adaptados de Corazza e colaboradores (1999) e Seamons e colaboradores 
(2013). A pontuação histopatológica das lesões foi parcialmente atribuída (0-4 
gravidade crescente) de acordo com: (1) presença de perda de tecido / necrose, (2) 
gravidade da lesão da mucosa epitelial, (3) inflamação, (4) extensão 1 - a 
percentagem de intestino afetado em qualquer maneira e (5) extensão 2 - a 
percentagem de intestino afetado pela lesão mais grave. A gravidade da colite é 
finalmente calculada pela soma das pontuações parciais das lesões, promovendo um 
score final (pontuação máxima = 20). Foram ainda avaliados a manifestação de 
sintomas/sinais clínicos e comprimento do cólon. 
 
Como primeiro objetivo a atingir tínhamos o desenvolvimento e padronização do 
modelo de colite induzida por TNBS, uma vez que o aparecimento da lesão intestinal 
mais grave causada pelo TNBS pode variar entre 3 dias a uma semana após a 
indução. Dois grupos independentes de colite induzida por TNBS foram então 
monitorizados sob as mesmas condições específicas, sendo que um grupo de 
murganhos foi sacrificado no dia 4 e o outro no dia 6, após a indução. O objetivo era 
identificar o dia em que a lesão intestinal aguda máxima teria sido alcançada pelo 
método de indução usada no presente estudo. Relativamente aos resultados obtidos 
nesta experiência, verificou-se que a colite induzida por TNBS foi então desenvolvida 
em 4 dias, proporcionando um modelo de inflamação intestinal agudo. O grupo TNBS 
apresentou uma alteração da motilidade intestinal caracterizada por diarreia, edema 
grave do ânus e morbilidade moderada, enquanto os grupos controlo permaneceram 
sem alterações. Estes murganhos apresentaram ainda uma diminuição progressiva do 
peso corporal, um comprimento do cólon reduzido e um aumento da concentração de 
hemoglobina fecal. A indução de colite por TNBS promoveu, ao fim de 4 dias, um 
aumento dos mediadores inflamatórios, tais como a mieloperoxidase, TNF-α e IL-1β, 
bem como a diminuição de uma citocina anti-inflamatória como a IL-10. A análise 
histopatológica revelou uma necrose transmural difusa com hemorragia grave, 
envolvendo a submucosa, camada muscular da mucosa e serosa e, muitas vezes, 
associada a peritonite. Estas lesões eram consistentes com uma indução correta de 
colite experimental por TNBS. 
A eritropoietina foi testada neste modelo de colite induzida por TNBS. Após 4 dias de 
tratamento diário com eritropoietina, os nossos resultados demonstram que a 
eritropoietina exerce efeitos anti-inflamatórios sobre este modelo de colite 
experimental específica. O tratamento com eritropoietina apresentou um efeito 
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benéfico no desenvolvimento de colite experimental em todos os parâmetros 
avaliados, reduzindo assim a gravidade e extensão das lesões. Mais precisamente, a 
eritropoietina promoveu uma diminuição da perda de peso, hemoglobina fecal, 
fosfatase alcalina, mieloperoxidase, citocinas pró-inflamatórias (TNF-α e IL-1β) e score 
histopatológico. Por outro lado, a eritropoietina também induziu um aumento do 
comprimento do cólon e de citocinas anti-inflamatórias como a IL-10, bem como 
regulou as funções renal e hepática. No nosso estudo, foram utilizadas duas doses 
diferentes de eritropoietina, nomeadamente, 500 UI/kg e 1000 UI/kg, que são 
consideravelmente mais baixas do que normalmente é utilizado nestes estudos 
experimentais. Esta opção justifica-se, uma vez que o tratamento com eritropoietina 
pode afetar o nível de hematócrito e promover assim efeitos adversos 
cardiovasculares. Logo, optou-se por utilizar as doses mais baixas possíveis para 
produzir efeito no modelo, para além do que as doses administradas são relevantes 
para a prática clínica num contexto de farmacologia translacional. Ainda assim, o nível 
de hematócrito após o tratamento com eritropoietina foi avaliado e os resultados foram 
normais. Estes dados indicam que a eritropoietina inibe significativamente a resposta 
inflamatória aguda na colite experimental, sem eventos adversos relacionados com o 
aumento da viscosidade sanguínea. 
A tiadiazolidinona-8 é outra molécula que foi testada no modelo de colite induzida por 
TNBS. O tratamento com tiadiazolidinona-8 foi capaz de modular o desenvolvimento 
de colite experimental. Particularmente, promoveu uma redução da hemoglobina fecal, 
fosfatase alcalina, mieloperoxidase e citocinas pró-inflamatórias (TNF-α e IL-1β). Além 
disso, também foi capaz de aumentar a expressão de citocinas anti-inflamatórias (IL-
10), bem como regulou as funções renal e hepática. De acordo com a análise 
histopatológica, o tratamento com tiadiazolidinona-8 só produziu uma ligeira 
diminuição da extensão da doença. No entanto, os resultados obtidos com a 
concentração de citocinas sugerem e confirmam o seu efeito benéfico na redução da 
gravidade da doença. Estes dados indicam que a tiadiazolidinona-8 inibe 
significativamente a resposta inflamatória aguda na colite experimental. 
 
A hemina também foi testada no modelo de colite induzida por TNBS. No final do 
período experimental, o tratamento com hemina apresentou uma influência benéfica 
no desenvolvimento da colite experimental, diminuindo a sua gravidade e extensão. A 
hemina promoveu uma redução da hemoglobina fecal, fostase alcalina, 
mieloperoxidase e citoquinas pró-inflamatórias (TNF-α e IL-1β). Foi também capaz de 
aumentar a concentração de uma citocina anti-inflamatória (IL-10), bem como regular 
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as funções renal e hepática. Além disso, o tratamento com hemina produziu uma 
diminuição estatisticamente significativa da taxa de mortalidade reduzindo para 0% as 
mortes no grupo de tratamento, promovendo resultados semelhantes aos obtidos com 
os murganhos saudáveis. Estes resultados sugerem que a hemina inibe 
significativamente a resposta inflamatória aguda na colite experimental, reduzindo 
completamente a mortalidade associada à doença. 
 
Em conclusão, todas as moléculas avaliadas neste estudo inibem significativamente a 
resposta inflamatória aguda no modelo de colite experimental induzido por TNBS. Este 
estudo permitiu ainda explorar o efeito destas novas moléculas no desenvolvimento da 
doença inflamatória intestinal, bem como a sua influência sobre os mecanismos de 
resposta à lesão intestinal. Além disso, representa uma contribuição inovadora para o 
tratamento farmacológico da doença inflamatória intestinal, permitindo enriquecer a 
investigação de outras possibilidades terapêuticas no âmbito desta doença. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PALAVRAS-CHAVE: Colite induzida por TNBS, inflamação, eritropoietina, 
tiadiazolidinona-8, hemina.  
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INTRODUCTION 
 
Inflammatory bowel disease, which includes Crohn’s disease and ulcerative colitis, are 
chronic inflammatory diseases characterized by recurrent ulceration of the bowels 
[Pithadia & Jain, 2011]. Specifically, inflammatory bowel disease is a common gastro-
intestinal disorder marked with chronic inflammation of intestinal epithelium, damaging 
mucosal tissue and manifests into several intestinal and extra-intestinal symptoms, 
mainly related to oxidative stress, inflammation and autoimmune type [Mowat et al., 
2011; Pawar et al., 2011]. 
 
Inflammatory bowel disease is a common gastrointestinal disorder affecting, 
statistically, 7–10% of people worldwide, mainly of Caucasian descent [Hanauer, 2006; 
Spiegel, 2009]. Ulcerative colitis incidence has been increasing around world, even in 
(previously) low-incidence areas like Eastern Europe, Asia and developing countries. 
The Crohn’s disease incidence is variable with 1/100.000 in Asia, South America until 
7/100.000 in the USA. One hypothesis for the difference in incidence between 
developed and developing nations is the “hygiene hypothesis,” which suggests that 
persons less exposed to childhood infections or unsanitary conditions lose potentially 
“friendly” organisms or organisms that promote regulatory T cell development, or 
alternatively do not develop a sufficient immune repertoire as they do not encounter 
noxious organisms. Such individuals are associated with a higher incidence of chronic 
immune diseases, including inflammatory bowel disease [Bernstein et al., 2015]. 
 
Although the etiology don´t be completely clear, it is generally agreed that a complex 
interplay between genetic predisposition, an environmental trigger and an aberrant 
immune reaction contributes to disease initiation and its progression [Wirtz & Neurath, 
2007; Mayer, 2010]. Regarding to genetic factors, to date four genes have been 
associated with Crohn’s disease (eg. CARD15, SLC22A4/5, DLG5, PPARG) and one 
with ulcerative colitis (eg. MDR1). The common threads are that the implicated genes 
regulate several important biologic functions, including immuno regulation, mucosal 
barrier integrity and microbial clearance and/or homeostasis [Sartor, 2006; Wirtz & 
Neurath, 2007]. Studies have implicated several environmental factors in the 
pathogenesis of inflammatory bowel disease [Loftus, 2004]. These factors include 
smoking, diet, the use of antibiotics and non-steroidal anti-inflammatory drugs, stress 
and infection. Unfortunately, the mechanisms by which these factors initiate the onset 
of disease or reactivate quiescent inflammatory bowel disease are not well understood. 
From a broad perspective, these triggering factors alter mucosal barrier integrity, 
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immune responses, or the luminal microenvironment, each of which have an impact on 
susceptibility to inflammation [Sartor, 2006]. About to immunological factors, 
inflammatory bowel disease patients have activated innate (macrophage, neutrophil) 
and acquired (T and B cell) immune responses and loss of tolerance to enteric 
commensal bacteria. Particularly, Crohn’s disease is a pre-dominantly Th1- and Th17-
mediated process, while ulcerative colitis seems to be an atypical Th2 disorder. 
Inflammatory bowel disease is characterized by enhanced recruitment and retention of 
effector macrophages, neutrophils and T cells into the inflamed intestine, where they 
are activated and release pro-inflammatory cytokines. Accumulation of effector cells in 
the inflamed intestine is a result of enhanced recruitment as well as prolonged survival 
caused by decreased cellular apoptosis [Sartor, 2006]. Briefly, pathogenesis of 
inflammatory bowel disease is not fully understood but, currently, it’s well accepted that 
inflammatory bowel disease is indeed characterized by an abnormal mucosal immune 
response but that microbial factors and epithelial cell abnormalities can facilitate this 
response [Strober, Fuss & Mannon, 2007]. 
 
Nowadays, used medical therapy of inflammatory bowel disease consists in salicylates, 
corticosteroids, immunosuppressants and biological therapy. These drug treatments 
aim to induce and maintain the patient in remission and ameliorate the disease’s 
secondary effects, rather than modifying or reversing the underlying pathogenic 
mechanism [Engel & Neurath, 2010; Pithadia & Jain, 2011]. Actually, their use may 
result in severe side effects and complications, such as an increased rate of 
malignancies or infectious diseases [Engel & Neurath, 2010]. Drug delivery to the 
appropriate site(s) along the gastrointestinal tract also has been a major challenge, and 
second-generation agents have been developed with improved drug delivery, 
increased efficacy, and decreased side effects [Pithadia & Jain, 2011]. For many years 
there have been numerous efforts to find a new effective method that would allow 
controlling specifically unwanted immune responses that occur during autoimmune 
reaction [Szczepanik et al., 2012]. 
 
Thus, there are some new drugs, like erythropoietin, thiadiazolidinone-8 and hemin, 
that can modulate some important metabolic pathways in the establishment and 
development of inflammation and, for this reason, the evaluation of its influence in 
inflammatory bowel disease is relevant. These drugs may inhibit or stimulate the 
expression of these inflammatory pathways, contributing perhaps to facilitate a more 
effective and selective treatment than the currently known. 
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Erythropoietin, the principal hormone promoting the survival and differentiation of 
erythroid progenitor cells, is currently being used in the therapy of patients with chronic 
renal failure suffering from anemia [Cody et al., 2001; Nairz et al., 2011]. However, 
erythropoietin also bears extrahematopoietic properties that are transduced by 
erythropoietin receptors expressed on various nonerythroid tissues [Brines & Cerami, 
2005; Jelkmann, 2007]. In experimental colitis, erythropoietin-erythropoietin receptors 
interaction decreases the production of NF-κB inducible immune mediators, thus 
limiting tissue damage and ameliorating disease severity. These immune-modulatory 
effects of erythropoietin may be of therapeutic relevance in inflammatory disease [Nairz 
et al., 2011]. Erythropoietin benefits have been studied in cardiovascular, neurologic, 
retinal, auditory, pancreatic, renal and liver injuries [Sanchis-Gomar et al., 2014; 
Chatagner, Huppi, Ha-Vinh Leuchter & Sizonenko, 2010; Loeliger, Mackintosh, Matteo, 
Harding & Rees, 2011; Olgun et al., 2013; Ucan et al., 2009; Imamura, Isaka, Ichimaru, 
Takahara & Okuyama, 2007; Sepodes et al., 2006]. Thus, the evaluation of the 
influence of erythropoietin in the inflammatory bowel disease is relevant and current.    
 
Thiadiazolidinone-8 is the first non-ATP competitive GSK-3β inhibitors with highly 
effectivity and selectivity [Martinez, Alonso, Castro, Perez & Moreno, 2002; Dugo, 
Collin & Thiemermann, 2007]. In vivo studies, thiadiazolidinone-8 already has 
demonstrated that can substantially reduce the renal dysfunction, hepatocellular and 
lung injury [Dugo et al., 2005]. They already were tested in inflammatory bowel disease 
and the results revealed that the thiadiazolidinone-8 administration promoted a 
reduction of the colonic inflammation, of tissue injury and a reduced decline in body 
weight [Whittle et al., 2006]. Although it has been found the existence of multiple 
beneficial effects of thiadiazolidinone-8, the clinical utility of these drugs awaits animal 
and human trials [Martinez, Castro, Dorronsoro & Alonso, 2002]. 
  
Hemin is well known as an inducer of heme-oxygenase-1 and many studies have 
reported its protective effect in various animal models [Guan, Wen, Zhang, Wang & 
Zhao, 2009; Naito, Takagi, Uchiyama & Yoshikawa, 2011; Hualin et al., 2012]. Heme-
oxygenase-1 expression can also confer cytoprotective, antiapoptotic and anti-
inflammatory properties, suggesting thus that heme-oxygenase-1 can be a possible 
therapeutic target in several kinds of gastrointestinal diseases [Naito et al., 2011]. In 
inflammatory bowel disease, it is known that heme-oxygenase activity and heme-
oxygenase-1 gene expression increase markedly after TNBS induction and the 
administration of tin mesoporphyrin, an heme-oxygenase inhibitor, potentiate the 
colonic damage as well as decrease heme-oxygenase-1 activity. These results indicate 
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that heme-oxygenase-1 plays a protective role in the colonic damage induced by TNBS 
enema [Wang et al., 2001]. However, more studies are needed to evaluate the 
influence of hemin in the inflammatory bowel disease [Naito et al., 2011]. 
 
The main objective of this study is the evaluation of the influence of a set of new drugs 
in inflammatory bowel disease, like erythropoietin, thiadiazolidinone-8 and hemin, 
through of an experimental colitis model induced by TNBS in rodents, contributing to 
facilitate a more effective and selective treatment than the currently known.  
 
Thus, we developed the work that is presented in this thesis. The exhibition of the 
thesis was divided into three chapters of literature review, one chapter of methodology, 
four chapters of presentation and discussion of results related to the development of 
the model and the effect of each molecule under evaluated, one chapter of the final 
discussion and main conclusions and, finally, one last chapter of the references. 
Therefore: 
- Chapter I: state of the art description of inflammatory bowel disease, including its 
classification, diagnosis and prognosis, as well as pharmacological treatment currently 
recommended; 
- Chapter II: relevance of studies in animal models, presentation of existing animal 
models of experimental colitis and characterization of the chemically induced models 
most commonly used in experimental colitis; 
- Chapter III: exhibition of new therapeutic approaches in inflammatory bowel disease, 
which their effect will be tested in this work; 
- Chapter IV: description of the used methodology, such as the induction method, 
experimental groups, evaluated parameters and statistical tests; 
- Chapter V: presentation of the results and respective discussion of the development 
of experimental colitis induced by TNBS; 
- Chapter VI: presentation of the results and respective discussion of the erythropoietin 
effect in inflammatory bowel disease; 
- Chapter VII: presentation of the results and respective discussion of the 
thiadiazolidinone-8 effect in inflammatory bowel disease; 
- Chapter VIII: presentation of the results and respective discussion of the hemin effect 
in inflammatory bowel disease; 
- Chapter IX: synthesis, discussion and the main conclusions of the work, as well as 
future prospects; 
- Chapter X: all references used in the preparation of the thesis. 
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CHAPTER 1 - INFLAMMATORY BOWEL DISEASE 
 
1. DEFINITION OF INFLAMMATORY BOWEL DISEASE 
Inflammatory bowel diseases (IBD) are chronic idiopathic gastrointestinal inflammatory 
disorders involving the recurrent ulceration of the bowels [Doherty & Cheifetz, 2009; 
Pithadia & Jain, 2011]. IBD, which include Crohn’s disease (CD) and ulcerative colitis 
(UC), are common gastro-intestinal diseases marked with chronic inflammation of 
intestinal epithelium, damaging mucosal tissue and manifests into several intestinal 
and extra-intestinal symptoms, mainly related to oxidative stress, inflammation and 
autoimmune type [Mowat et al., 2011; Pawar et al., 2011]. 
The typical intestinal injuries of IBD reveal different characteristics and location, 
depending on whether CD or UC (FIGURE 1). Namely, CD is characterized by a chronic 
transmural inflammation of all or any part of the gastrointestinal tract involving mucosa, 
submucosa, muscular and connective tissue [Mowat et al., 2011]. Some patients with 
UC will have inflammation of the terminal ileum, which can make it difficult to 
distinguish from CD [Kornbluth & Sachar, 2010]. Nevertheless, UC is a chronic 
inflammatory condition causing continuous mucosal and sub-mucosal inflammation of 
the colon without granulomas on biopsy, affecting the rectum and a variable extent of 
the colon in continuity, which is characterised by a relapsing and remitting course 
[Silverberg et al., 2005; Mowat et al., 2011]. 
                  
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 1. Differences between Crohn’s disease and ulcerative colitis  
[adapted of Tresca, 2015]. 
 
The arbitrariness of some of the definitions is recognized, but the European Crohn´s 
and Colitis Organisation Consensus considers it useful to agree the terminology 
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[Dignass et al., 2012]. Other terms are used such as IBD unclassified and/or 
indeterminate colitis. IBD unclassified is the term best suited for the minority of cases 
where a definitive distinction between UC, CD or other cause of colitis cannot be made 
after the history, endoscopic appearances, histopathology of multiple mucosal biopsies 
and appropriate radiology have been taken into account [Silverberg et al., 2005; 
Satsangi, Silverberg, Vermeire & Colombel, 2006]. There are about 5% of patients with 
IBD unclassified after considering clinical, radiological, endoscopic and pathological 
criteria, because they have some features of both conditions [Silverberg et al., 2005]. 
On the other hand, indeterminate colitis is a term reserved for pathologists to describe 
a colectomy specimen which has overlapping features of UC and CD [Price, 1978; 
Satsangi et al., 2006]. It has distinct prognostic factors related to further surgery 
[Dignass et al., 2012]. 
1.1. CLASSIFICATION 
The definitions of CD and UC acknowledge the revised Montreal classification which 
attempts to more accurately characterize the clinical patterns of IBD [Silverberg et al., 
2005; Satsangi et al., 2006].  
 
CD is classified according Montreal classification, which considers the age of onset (A), 
disease location (L) and disease behaviour (B) as the predominant phenotypic 
elements (TABLE 1) [Silverberg et al., 2005]. There is some evidence to suggest that 
patients stratified by age have different outcomes. Patients diagnosed before the age 
of 16 had a more aggressive initial course, while older age at diagnosis was found to 
be associated with a lower risk of colectomy [Barreiro-de-Acosta et al., 2010; Solberg 
et al., 2009].  
 
TABLE 1. Montreal classification of Crohn’s disease [adapted of Silverberg et al., 2005]. 
AGE AT DIAGNOSIS LOCATION BEHAVIOUR 
 
A1 < 16 years L1 Ileal B1 Non-stricturing, non-penetrating 
A2 17 - 40 years L2 Colonic B2 Stricturing 
A3 > 40 years L3 Ileocolonic B3 Penetrating 
 L4 Isolated upper disease* P Perianal disease modifier** 
 
Legend: *L4 is a modifier that can be added to L1-L3 when concomitant upper gastrointestinal disease 
 is present; **P is added to B1-B3 when concomitant perianal disease is present. 
 
The presentation of CD is highly variable. A single episode may not be followed by 
further episodes or the patient may experience continuous, unremitting disease. The 
time between the onset of complaints and the initial diagnosis may be as long as 3 
PHARMACOLOGICAL MODULATION OF INFLAMMATION ASSOCIATED WITH INFLAMMATORY BOWEL DISEASE 
CHAPTER 1 – INFLAMMATORY BOWEL DISEASE   7 
years. For this reason, Crohn's disease activity index (CDAI) is an additional tool that 
should be considered in patients with CD (ANNEXE 1). The CDAI is not a rating of CD, but 
is a numerical estimate of the interpretation of the patient's symptoms, defining the 
severity of the disease activity. The calculation of CDAI is the sum of the products of a 
list of eight items, multiplied by weighting factors, the total of which defines the severity 
of disease activity [Freeman, 2008]. Since the classification of CD can be complex, the 
guidelines classify the severity of active CD by the presence of several signs and 
symptoms (TABLE 2) [Hanauer & Sandborn, 2001].  
 
TABLE 2. Grading of disease activity in Crohn’s disease [adapted of Dignass et al., 2012]. 
MILD MODERATE SEVERE 
 
CDAI of 150 – 220 
(eg. ambulatory, eating and 
drinking, < 10% weight loss) 
CDAI of 220 – 450 
(eg. intermittent vomiting or 
weight loss > 10%) 
CDAI > 450 
(eg. cachexia (BMI < 18 Kg m-2 ) or 
evidence of obstruction or abscess) 
No features of obstruction, 
fever, dehydration, abdominal 
mass or tenderness 
Treatment for mild disease 
ineffective or tender mass. 
No overt obstruction 
Persistent symptoms despite 
intensive treatment 
CRP increased above the 
upper limit of normal 
CRP elevated above the 
upper limit of normal 
CRP increased 
 
Legend: CDAI - Crohn’s Disease Activity Index; BMI - Body mass index; CRP - C reactive protein. 
 
UC is classified incorporating an assessment of disease extent and severity. The 
Montreal classification of disease extent of UC allows extent to be defined into three 
subgroups (TABLE 3), according to the maximal extent of inflammation observed at 
colonoscopy, because this is most clearly related to the risk of complications, including 
dilatation and cancer [Silverberg et al., 2005].  
 
TABLE 3. Montreal classification for ulcerative colitis extent [adapted of Silverberg et al., 2005]. 
 
EXTENT ANATOMY 
 
Ulcerative proctitis 
Involvement limited to the rectum (that is, proximal extent of 
inflammation is distal to the rectosigmoid junction) 
Left sided UC (distal UC) Involvement limited to a proportion of the colorectum                    
distal to the splenic flexure 
Extensive UC (pancolitis) Involvement extends proximal to the splenic flexure 
 
Legend: UC – Ulcerative colitis. 
 
Although a typical clinical picture of UC can be described, there is a wide range of 
presentation, from mild abdominal cramping with frequent small-volume bowel 
movements to profuse diarrhea. Most patients with UC experience intermittent bouts of 
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illness after varying intervals with no symptoms. Only a small percentage of patients 
have continuous unremitting symptoms or have a single acute attack with no 
subsequent symptoms. Complex disease classifications are generally not used in 
clinical practice for UC. The arbitrarily determined distinctions of mild, moderate and 
severe disease activity are generally used and these are largely determined by clinical 
signs and symptoms (TABLE 4) [Collins & Rhodes, 2006; Kornbluth & Sachar, 2010]. 
Thus, the Montreal classification also classified the UC severity [Silverberg et al., 
2005]. 
 
TABLE 4. Montreal classification for ulcerative colitis severity [adapted of Dignass et al., 2012]. 
 
MILD MODERATE SEVERE 
 
BLOODY STOOLS/DAY < 4 4 or more if ≥ 6 and 
PULSE < 90 bpm ≤ 90 bpm > 90 bpm or 
TEMPERATURE < 37.5˚C ≤ 37.8˚C > 37.8˚C or 
HAEMOGLOBIN > 11.5 g/dl ≥ 10.5 g/dl < 10.5 g/dl or 
ESR < 20 mm/h ≤ 30 mm/h > 30 mm/h or 
CRP Normal ≤ 30 mg/L > 30 mg/L 
 
Legend: ESR - Erythrocyte sedimentation rate; CRP - C reactive protein. 
 
1.2. EPIDEMIOLOGY 
 
IBD is a common gastrointestinal disorder affecting, statistically, 7–10% of people 
worldwide, mainly of Caucasian descent [Hanauer, 2006; Spiegel, 2009]. IBD can 
affect any age group, however there is a bimodal age-related incidence [Thoreson & 
Cullen, 2007; Lichtenstein, Hanauer & Sandborn, 2009], with the larger peak occurring 
between 15 to 30 years of age [Abraham & Cho, 2009] and a smaller peak occurring 
later in life [Thoreson & Cullen, 2007]. 
The incidence of IBD varies according to geographic location with higher rates 
occurring in more developed countries such as northern Europe, the United Kingdom, 
and North America and lower rates occurring in developing countries, Asia and 
southern Europe [Baumgart & Carding, 2007; Bernstein et al., 2015]. However, the 
incidence is rising in less-developed countries with the expansion of industrialization 
[Thoreson & Cullen, 2007]. 
One hypothesis for the difference in incidence between developed and developing 
nations is the “hygiene hypothesis,” which suggests that persons less exposed to 
childhood infections or unsanitary conditions lose potentially “friendly” organisms or 
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organisms that promote regulatory T cell development, or alternatively do not develop a 
sufficient immune repertoire as they do not encounter noxious organisms. Such 
individuals are associated with a higher incidence of chronic immune diseases, 
including IBD [Bernstein et al., 2015]. 
In Portugal, IBD prevalence has increased from 86 per 100 000 in 2003 to 146 in 2007 
and this increase was consistent in all Portuguese districts. No north–south 
geographical distribution gradient is detected at the national level. The districts more 
affected by IBD are Lisbon and Oporto, with a prevalence that reached 173 and 163 
per 100 000 in 2007, respectively. The estimated prevalence of UC increased from 42 
per 100 000 in 2003 to 71 in 2007; and the prevalence of CD increased from 43 per 
100 000 in 2003 to 73 in 2007. Furthermore, the prevalence of UC was higher in the 
40–64 age range, whereas the prevalence of CD was higher in the 17–39 age range. 
Females had slightly higher prevalence than males [Azevedo et al., 2010]. 
 
There is an interesting discussion in the literature about the hypothesized ‘north–south 
gradient’ [Sonnenberg, McCarty & Jacobsen, 1991; Shivananda et al., 1996; Loftus & 
Sandborn, 2002; Loftus, 2004; Binder, 2004; Lakatos & Lakatos, 2006; Lakatos, 2006] 
in IBD epidemiology. However, the data contradicts this hypothesis because in 
Portugal, a southern European country, a lower prevalence would eventually be 
expected and because a geographical north–south gradient at a national level was not 
evident [Azevedo et al., 2010]. 
1.3. ETIOLOGY 
The exact etiology of IBD is unknown. However, it is generally agreed that a complex 
interplay between genetic predisposition, an environmental trigger, an aberrant immune 
reaction and an infectious environment contributes to disease initiation and its 
progression [Wirtz & Neurath, 2007; Thoreson & Cullen, 2007; Mayer, 2010]. Evidence 
has suggested that IBD is the result of an abnormal immune response to intestinal 
bacteria in a genetically susceptible host [Abraham & Cho, 2009]. 
1.3.1. GENETIC FACTORS 
Evidence for the contribution of genetic factors to IBD susceptibility was first identified 
through familial clustering of IBD cases and concordance studies in twins [Baumgart & 
Carding, 2007]; however, there is no evidence of classic Mendelian inheritance 
[Thoreson & Cullen, 2007]. Molecular studies have identified a number of different 
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genetic determinants of susceptibility for both the development of IBD and for variants 
that may determine disease phenotypes [Gaya, Russell, Nimmo & Satsangi, 2006]. 
These genetic abnormalities are thought to cause defects in the function of the 
epithelial barrier, immunoregulation, and clearance of bacteria [Abraham & Cho, 2009] 
that disturb the normal regulation of the intestinal immune system [Ponsky, Hindle & 
Sandler, 2007]. 
To date, four genes have been associated with CD and one with UC (TABLE 5); these 
data have been replicated. Strong associations with other chromosomal regions and 
genes (e.g. NF-κB1, TLR5) have yet to be replicated, but such associations make it 
highly likely that many additional genes will be implicated in the pathogenesis of IBD, 
while others will be associated with extra-intestinal disease (e.g. HLA-B27 and HLA-
DR0103 human leukocyte antigen haplotypes) and with responses to pharmacologic 
treatment (e.g. pharmacogenomics) [Sartor, 2006; Wirtz & Neurath, 2007]. 
 
TABLE 5. Genes with functions associated with inflammatory bowel diseases                                        
and experimental colitis [adapted of Sartor, 2006]. 
GENE CHROMOSOME FUNCTION 
 
CROHN’S DISEASE 
CARD15 16 
NF-κB activation and/or regulation, killing of intracellular 
pathogens, paneth-cell function, α-defensin production 
SLC22A4/5 5 
Organic cation, carnitine transporters, possibly transport 
xenobiotic substances 
DLG5 10 Epithelial scaffolding protein 
PPARγ 3 Intracellular inhibitor of NF-κB and cellular activation 
 
ULCERATIVE COLITIS 
MDR1 7 
Efflux transporter for drugs and, possibly, xenobiotic 
compounds 
 
Legend: CARD15 - Caspase recruitment domain family, member 15 (formerly NOD2);  
DLG5 - Discs large homolog 5 (Drosophila); MDR1 - Multidrug resistance 1; PPARγ - Peroxisome proliferative-activated 
receptor gamma; SLC22A4/5 - Solute carrier family 22 (organic cation transporter),  
members 4 and 5 (formerly OCTN1 and OCTN2). 
 
1.3.2. ENVIRONMENTAL FACTORS 
 
Epidemiological studies of worldwide trends have strongly supported a supporting role 
for environmental factors in the pathogenesis of IBD [Loftus, 2004; Lakatos, 2009]. 
These factors include diet, hygiene, smoking, the use of non-steroidal anti-
inflammatory drugs (NSAID) and infection. Unfortunately, the mechanisms by which 
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these factors initiate the onset of disease or reactivate quiescent IBD are not well 
understood [Sartor, 2006]. From a broad perspective, these triggering factors alter 
mucosal barrier integrity, immune responses, or the luminal microenvironment, each of 
which have an impact on susceptibility to inflammation [Sartor, 2006]. 
A westernized diet (eg. low-fiber, high-sugar, high animal fat) has been proposed as a 
risk factor for the development of IBD. These theories are the result of an increasing 
incidence of IBD in areas such as Eastern Europe and Asia where westernized diets 
have been increasingly adopted. Dietary additives such as aluminum and iron have a 
well-described adjuvant activity and stimulate bacterial virulence [Perl, Fogarty, Harpaz 
& Sachar, 2004]. Other studies have reported links between various foods such as 
refined sugar, fast food, margarine, corn flakes, and some dairy products; however, 
there has been no conclusive evidence to suggest that any specific dietary factor or 
food directly contributes to the development of IBD [Lakatos, 2009]. 
Because IBD is more common in developed countries and urban areas, some evidence 
has suggested that improvements in hygiene and sanitation diminish exposure to 
environmental antigens, thereby impairing functional maturation of the mucosal 
immune system as well as disturbing normal development of immune tolerance. This 
may result in an inappropriate immune response when reexposure to these antigens 
occurs at a later time [Baumgart & Carding, 2007]. 
 
Smoking is perhaps the most thoroughly documented environmental contributor to IBD, 
but its opposite effect on CD and UC is difficult to understand, namely is detrimental in 
CD, but is protective in UC [Sartor, 2006]. Smoking has been shown to have a 
detrimental effect on CD [Lakatos, 2009]. CD patients who smoke tend to have a more 
severe course of disease with an increased incidence of fistulas, strictures and 
exacerbations [Baumgart & Carding, 2007]. Interestingly, the effect of smoking on UC 
appears to be protective and has been shown to postpone the onset of disease. 
Studies have shown that current smoking reduced the risk of UC [Thoreson & Cullen, 
2007; Lakatos, 2009]. The risk of developing UC in smokers is approximately 40% of 
that in nonsmokers [Sandler & Eisen, 2000]. Nicotine, carbon monoxide (CO) and 
hypoxia have all been suggested to be mediators of the effects of smoking on IBD 
[Birrenbach & Bocker, 2004; Cosnes, 2004].  
Infection and NSAID can transiently initiate nonspecific inflammation, break the 
mucosal barrier and activate innate immune responses. These events could then lead 
to enhanced uptake of commensal bacterial antigens and adjuvants that stimulate 
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protracted T-cell-mediated intestinal inflammation in the genetically susceptible host 
[Berg et al., 2002]. In the case of NSAID, the increased risk seems to be present for 
cyclooxygenase (COX)-2 inhibitors as well as COX-1 inhibitors, however it is unclear 
whether COX-2 inhibitors may be somewhat safer in select patients with IBD [Bonner, 
2002; Mahadevan, Loftus, Tremaine & Sandborn, 2002]. 
Other environmental factors have been studied and have been implicated as playing a 
role in the pathogenesis of IBD including stress, oral contraceptive use and childhood 
immunizations; however, study results have been inconclusive [Lakatos, 2009].  
1.3.3. IMMUNOLOGICAL FACTORS 
The intestinal immune system is a complex system of humoral factors and a variety of 
lymphoid and nonlymphoid cell populations [Baumgart & Carding, 2007]. In persons 
with normal intestinal immune function, exposure to foreign antigens, bacteria and food 
is regulated through intestinal epithelial cells [Lakatos, 2009] that are covered by a 
mucus layer embedded with commensal microbes, protecting against disease. In IBD, 
the normal immune homeostasis of the intestine is disrupted at multiple levels starting 
with luminal antigens entering the underlying mucosa through a leaky barrier 
[Baumgart & Carding, 2007]. A cascade of events then causes an imbalance between 
the local mucosal production of proinflammatory cytokines and anti-inflammatory 
cytokines [Abraham & Cho, 2009], resulting in a cycle of uncontrolled inflammation 
[Thoreson & Cullen, 2007]. 
1.3.4.  MICROBIAL FACTORS 
Microorganisms and intestinal infections have been proposed as contributing factors to 
the pathogenesis of IBD by causing an inflammatory response to the infectious source. 
Bacteria that have been implicated include Mycobacterium paratuberculosis, 
Pseudomonas species, and Listeria species (in CD) and Bacillus species, adhesive 
Escherichia coli and Fusobacterium varium (in UC); however, evidence is inconclusive 
[Thoreson & Cullen, 2007]. 
Dysbiosis, a breakdown in the balance between normal enteric flora and harmful 
intestinal bacteria, has been theorized as a causal factor in the development of IBD. 
The beneficial effects seen with antibiotic use have supported this theory, but also 
symptomatic improvements that have been induced when the fecal stream is diverted 
away from inflamed bowel loops with recurrence of inflammation when intestinal 
continuity is restored. Other studies have found diminished bacterial diversity and a 
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greater number and concentration of bacteria in the bowel of patients with IBD 
[Lakatos, 2009]. 
1.4. PATHOGENESIS 
Pathogenesis of IBD is not fully understood but two broad hypotheses have arisen 
regarding its fundamental nature. The first contends that primary dysregulation of the 
mucosal immune system leads to excessive immunologic responses to normal 
microflora. The second suggests that changes in the composition of gut microflora 
and/or deranged epithelial barrier function elicit pathologic responses from the normal 
mucosal immune system. Currently, it’s well accepted that IBD is indeed characterized 
by an abnormal mucosal immune response but that microbial factors and epithelial cell 
abnormalities can facilitate this response [Strober et al., 2007].  
IBD patients have activated innate (macrophages, neutrophils) and acquired (T and B 
cells) immune responses and loss of tolerance to enteric commensal bacteria [Sartor, 
2006]. Substantial progress has been made in characterizing immune cell populations 
and inflammatory mediators in patients with IBD (FIGURE 2), demonstrating that innate 
immune factors play an important role in the induction of mucosal inflammation [Strober 
et al., 2007]. 
 
 
 
 
 
 
 
FIGURE 2. The disease-related pathogenic role of cytokines with pro-inflammatory,  
anti-inflammatory and pro-fibrogenic effects in ulcerative colitis and Crohn’s disease  
[adapted of Műzes, Molnár, Tulassay & Sipos, 2012]. 
Legend: LIGHT - Lymphotoxins; IL - Interleukin; TNF-α - Tumor necrosis factor α;  
TL1A - TNF-like factor; TGF-β - Transforming growth factor-β.  
 
In general, IBD are characterized by enhanced recruitment and retention of effector 
macrophages, neutrophils and T cells into the inflamed intestine, where they are 
activated and release pro-inflammatory cytokines. Accumulation of effector cells in the 
inflamed intestine is a result of enhanced recruitment as well as prolonged survival 
caused by decreased cellular apoptosis [Sartor, 2006]. However, CD and UC present 
PHARMACOLOGICAL MODULATION OF INFLAMMATION ASSOCIATED WITH INFLAMMATORY BOWEL DISEASE 
CHAPTER 1 – INFLAMMATORY BOWEL DISEASE  14 
different cellular responses in the context of intestinal inflammation (FIGURE 3). CD is a 
dominantly T helper (Th)1- and Th17-mediated process, while UC seems to be an 
atypical Th2 disorder [Sartor, 2006].    
More precisely, CD is characterized by the generation of Th1- and Th17-polarized T cell 
responses [Fuss et al., 1996; Plevy et al., 1997; Cottrez, Hurst, Coffman & Groux, 
2000]. Dendritic cells and macrophages are activated by interferon-γ (IFN-γ), which is 
produced by the activated Th1 cells. Activated dendritic cells and macrophages 
produce cytokines such as interleukin (IL)-1β, IL-6, IL-12, IL-18, IL-23 and tumor 
necrosis factor- α (TNF-α). Th17-polarized cells secrete IL-17 and IL-22 [Valatas, Vakas 
& Kolios, 2013]. The biological action of TNF-α and IL-6 is the main factor in the 
pathogenesis of CD and the regulation of this process is very important in controlling 
the disease [Desreumaux et al., 1997; Fiocchi, 1998; Sandborn & Hanauer, 1999]. 
TNF-α and IL-6 induce the expression of adhesion molecules in the vascular 
endothelium and invasion of inflammatory cells into the mucosal layer subsequently 
occurs. Selectins, intercellular adhesion molecule-1 (ICAM-1), and vasculocellular 
adhesion molecule-1, which are expressed at the surface of vascular endothelium, are 
involved in this process [Koizumi et al., 1992]. Thus, recruitment of inflammatory cells 
from the circulation is an important process in augmenting inflammatory response 
[Springer, 1994]. 
In contrast, the mucosa of patients with UC is characterized by an atypical Th2-
polarized T cell and natural killer T cells response mediated by IL-5 and IL-13 [Fiocchi, 
1998]. Polarized T cell responses initiate an inflammatory cascade that involves 
endothelial activation, chemokine production and white blood cell (WBC) recruitment. 
Inappropriate triggering and maintenance of these pathogenic responses has been 
associated with innate immunity defects that include defective type I IFN production 
and lack of efficient control by anti-inflammatory cytokines such as IL-10 and 
transforming growth factor-β produced by regulatory T cells, macrophages, B cells, and 
stromal cells [Valatas et al., 2013]. 
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FIGURE 3. Inflammatory and regulatory pathways involved in inflammatory bowel disease 
[adapted of Valatas et al., 2013]. 
Legend: AB - Antibody; CD - Cluster of differentiation; CTLA-4 - Cytotoxic T lymphocyte antigen-4;  
ICAM-1 - Intercellular adhesion molecule-1; MAdCAM-1 - Mucosal addressin cell adhesion molecule-1;  
pDC - Plasmacytoid dendritic cell; VCAM-1 - Vascular cell adhesion molecule-1. 
 
Moreover, it is well known that superoxide radical production and granular release are 
induced by the recruited leukocytes, especially granulocytes, and nonspecific 
inflammatory substances are subsequently produced. The main substances are 
arachidonic acid metabolites (such as thromboxane A2, leukotriene B4, and 
prostaglandin (PG) E2), reactive oxygen metabolites, free radicals, and nitric oxide 
(NO). These substances also play an important role in direct injury against the 
intestinal mucosa [Grisham, 1994; Cuzzocrea et al., 2001]. 
Thus, therapy can be directed towards blocking effector activation, blocking biologic 
activity of pro-inflammatory cytokines and their receptors, inhibiting T cell–APC 
interactions, selectively blocking effector cell entry, inducing apoptosis of activated 
effector cells or enhancing regulatory cell activity [Sartor, 2006]. 
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2. DIAGNOSTIC ON INFLAMMATORY BOWEL DISEASE 
Diagnosis of IBD is based on history and physical findings supported by characteristic 
endoscopic (sigmoidoscopy or colonoscopy) and histologic findings on biopsy once an 
infectious disorder has been ruled out as a potential cause [Kornbluth & Sachar, 2010]. 
The examination should include relevant questions regarding whether there is a family 
history of IBD, a history of blood or mucus in the stool, the frequency and consistency 
of the stool, nocturnal diarrhea, weight loss, extra-intestinal manifestations, foreign 
travel, nonsteroidal anti-inflammatory drug use and smoking [Collins & Rhodes, 2006; 
Kornbluth & Sachar, 2010]. 
Cardinal symptoms of IBD include bloody diarrhea, rectal urgency and tenesmus 
[Kornbluth & Sachar, 2010]. Lower abdominal pain also may be present when there is 
proximal extension of the disease [Thoreson & Cullen, 2007]. In mild disease, rectal 
bleeding may be absent and there are less than 4 stools a day. Severe disease 
involves more than 6 bloody stools per day along with systemic symptoms such as 
fever, tachycardia, anemia or hypoalbuminemia [Collins & Rhodes, 2006]. 
Associated extra-intestinal manifestations involve inflammation of the joints 
(sacroileitis, ankylosing spondylitis), eyes (anterior uveitis, episcleritis), skin (erythema 
nodosum, pyoderma gangrenosum) or bile ducts of the liver (primary sclerosing 
cholangitis) [Collins & Rhodes, 2006]. Toxic megacolon is a severe complication of IBD 
that can occur soon after diagnosis. Typical signs and symptoms include fever, 
abdominal tenderness and distension, hypotension, altered level of consciousness, 
anemia or leukocytosis [Thoreson & Cullen, 2007]. 
Laboratory tests for the evaluation of suspected IBD include a complete blood count 
with differential (to evaluate for anemia and infection), liver function tests, 
sedimentation rate and C-reactive protein [Carter, Lobo & Travis, 2004]. An elevated 
white blood cell count, platelet count and C-reactive protein level are consistent with 
extensive active intestinal inflammation, but these laboratory findings may be absent in 
left-sided UC [Nikolaus & Schreiber, 2007]. Other recommended laboratory testing 
includes microbiologic studies for bacterial infection, including specific assays for 
Escherichia coli, and parasitic infestation, along with serologic testing for ameba if 
indicated. Testing for Clostridium difficile toxin is indicated in patients who have been 
recently hospitalized or treated with antibiotics [Kornbluth & Sachar, 2010]. 
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Proctosigmoidoscopy or colonoscopy with biopsy can diagnose the presence of colitis 
and help rule out other noninfectious or infectious causes [Kornbluth & Sachar, 2010]. 
When a complete colonoscopy cannot be performed, ultrasonography may be used in 
conjunction with flexible sigmoidoscopy to determine the extent of the disease, which 
can help guide treatment [Dietrich, 2009]. 
Alternative imaging modalities, such as magnetic resonance imaging and computed 
tomography may be beneficial when colonoscopy is not possible or the results are 
equivocal. In some cases, they can confirm the diagnosis, determine the extent of 
disease, evaluate complications and rule out other etiologies [Mackalski & Bernstein, 
2006; Nikolaus & Schreiber, 2007]. 
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3. CURRENT PHARMACOTHERAPY IN INFLAMMATORY BOWEL DISEASE 
To treat IBD properly, the clinician must have a clear concept of realistic therapeutic 
goals for each patient. These goals may relate to resolution of acute inflammatory 
processes, resolution of attendant complications (e.g. fistulas and abscesses), 
alleviation of systemic manifestations (e.g. arthritis), maintenance of remission from 
acute inflammation, or surgical palliation or cure. The approach to the therapeutic 
regimen differs considerably with varying goals, so there is no evidence-based 
approach that applies to every clinical situation, as well as with the two diseases, UC 
and CD. Thus, treatment recommendations may differ for each patient and are 
individualized based on the patient's symptomatic response and tolerance to a specific 
therapy [Lichtenstein et al., 2009; Dignass et al., 2012]. 
In general, currently used medical therapy in IBD consists in salicylates, 
corticosteroids, immunosuppressants and biological therapy (FIGURE 4). These drug 
treatments have aim to induce and maintain the patient in remission and ameliorate the 
disease’s secondary effects, rather than modifying or reversing the underlying 
pathogenic mechanism [Engel & Neurath, 2010; Pithadia & Jain, 2011]. Actually, their 
use may result in severe side effects and complications, such as an increased rate of 
malignancies or infectious diseases [Engel & Neurath, 2010]. Drug delivery to the 
appropriate site(s) along the gastrointestinal tract also has been a major challenge, and 
second-generation agents have been developed with improved drug delivery, 
increased efficacy and decreased side effects [Pithadia & Jain, 2011]. 
 
 
 
 
 
 
 
FIGURE 4. Therapeutic pyramid for the management of IBD  
[adapted of Aloi, Nuti, Stronati & Cucchiara, 2014]. 
Legend: AZA – Azathioprine; 6-MP – 6-Mercaptopurine; MTX – Methotrexate; 5-ASA – 5-Aminosalicylic acid. 
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3.1. AMINOSALICYLATES 
The archetype for this class of medications is sulfasalazine, which consists of an agent 
that combines sulfapyridine (sulfonamide antibiotic) and mesalamine (5-aminosalicylic 
acid – 5-ASA) in the same molecule linked by an azo bond. When it reaches the colon, 
the diazo bond is cleaved by bacterial azoreductase, liberating 5-ASA (which mostly 
remains in the colon and is excreted in stool) and sulfapyridine (which is mostly 
absorbed and excreted in the urine) [Sandborn & Hanauer, 2003; Buning & Lochs, 
2006; Hanauer, 2006b].  
 
5-ASA is the active therapeutic moiety, while sulfapyridine contributes little to the 
therapeutic effect. The mechanism of action of mesalamine is not well understood. 
COX or lipoxygenase inhibition alone does not entirely account for the agent’s effects 
[Podolsky, 2002]; indeed, traditional NSAID may actually exacerbate IBD [Pithadia & 
Jain, 2011]. Many potential sites of action have been demonstrated in vitro, including 
inhibition of IL-1 and TNF-α production, inhibition of the lipoxygenase pathway, the 
scavenging of free radicals and oxidants, and inhibition of nuclear transcription factor 
kappa B (NF-κB), a transcription factor pivotal to the production of inflammatory 
mediators [Barnes & Karin, 1997; Podolsky, 2002]. Because the mechanism of action 
of sulfasalazine is not related to the sulfapyridine component, and because 
sulfapyridine is believed to be responsible for many of the adverse reactions to 
sulfasalazine, several second-generation 5-ASA compounds have been developed 
[Sandborn & Hanauer, 2003]. They are divided into two groups: pro-drugs and coated 
drugs [Pithadia & Jain, 2011].  
 
Pro-drugs contain the same azo bond as sulfasalazine, but replace the linked 
sulfapyridine with either another 5-ASA (olsalazine) or an inert compound (balsalazide). 
These compounds act at similar sites along the gastrointestinal tract as sulfasalazine. 
The alternative approaches employ either a delayed-release formulation or a pH-
sensitive coating, where mesalamine can be used alone. Delayed-release mesalamine 
is released throughout the small intestine and colon, whereas pH-sensitive mesalamine 
is released in the terminal ileum and colon. The different distributions of these drugs 
following delivery have potential therapeutic implications. In general, newer 5-ASA 
preparations have similar therapeutic efficacies with fewer side effects. 5-ASA can also 
be used in combination with steroids to induce and maintain remission in patients with 
IBD [Pithadia & Jain, 2011]. 
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3.2. CORTICOSTEROIDS 
Corticosteroids are potent anti-inflammatory agents for moderate to severe relapses of 
IBD. They act through inhibition of several inflammatory pathways like suppressing IL 
transcription, induction of inhibitory κB (IκB) that stabilises the NF-κB complex, 
suppression of arachidonic acid metabolism and stimulation of apoptosis of 
lymphocytes within the lamina propria of the gut [Mowat et al., 2011]. Thus, 
corticosteroids are believed to modulate the immune system and inhibit production of 
inflammatory cytokines and others inflammatory mediators [Hofer, 2003].  
 
Corticosteroids have been widely used in IBD, given parenterally, orally or rectally 
[Friend, 1998]. The glucocorticoid properties of hydrocortisone and prednisolone are 
the mainstay of IBD treatment. The preferred steroid is prednisolone, administered in 
emergency situations. Hydrocortisone also can be given once or twice daily, delivering 
80 mg hydrocortisone per application. This formulation can be useful in patients with 
very short areas of distal proctitis and difficulty retaining fluids [Pithadia & Jain, 2011]. 
Budesonide is a controlled release formulation designed to release in the terminal 
ileum [Greenberg et al., 1994; Hofer, 2003]. It is thought to deliver adequate steroid 
therapy to a specific portion of the inflamed gut while minimizing systemic side effects 
caused by extensive first-pass hepatic metabolism to inactive derivatives [Hofer, 2003]. 
 
Corticosteroids can be used either alone or in combination with a suitable mesalamine 
formulation to induce and maintain remission in IBD [Faubion, Loftus, Harmsen, 
Zinmeister & Sandborn, 2001; Pithadia & Jain, 2011]. Steroids are sometimes used for 
prolonged periods to control symptoms in steroid dependent patients. However, failure 
to respond to steroids with prolonged remission (i.e., a disease re-lapse) should prompt 
consideration of alternative therapies, including immunosuppressants and infliximab 
[Steinhart, Ewe, Griffiths, Modigliani & Thomsen, 2003]. Also, steroids are 
inappropriate for long term use, because of their side effects and inability to maintain 
remission in all patients [Steinhart et al., 2003; Pithadia & Jain, 2011]. Thus, their 
significant side effects have led to an increased emphasis on limiting the duration and 
cumulative dose of steroids in IBD. In this case, an alternate-day regimen can be 
helpful [Pithadia & Jain, 2011]. 
 
Adrenal insufficiency can be triggered in patients who have been recently tapered off of 
corticosteroids. Visual changes can occur because of steroid-induced hyperglycemia. 
Early cataract formation is another possible side effect. Aseptic joint necrosis, which is 
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the most dreaded side effect, usually occurs in patients receiving long-term, high-dose 
corticosteroid therapy [Pithadia & Jain, 2011]. 
3.3. IMMUNOSUPPRESSANTS 
Immunosuppressant drugs can be an invaluable adjunct therapy for the treatment of 
patients with intractable IBD or complex, inoperable perianal disease. Although 
immunosuppressant agents have significant side effects, they are safer and better 
tolerated than long-term corticosteroid therapy. However, these agents should not be 
used in young patients who are candidates for surgery or in patients who are 
noncompliant and refuse to return for periodic monitoring. Before immunosuppressant 
therapy is initiated, side effects and other treatment alternatives should be discussed 
with the patient. At this stage, it is best to set a definable goal, such as closure of a 
fistula or tapering the patient off of corticosteroids, and a minimum three-month time 
frame should be set to reach that goal [Pithadia & Jain, 2011]. 
Azathioprine or mercaptopurine are widely used in IBD as adjunctive therapy and as 
corticosteroid-sparing therapies, although they are unlicensed therapies for IBD. Their 
slow onset of action precludes usage as sole therapy for active disease. Purine 
antimetabolites inhibit ribonucleotide synthesis, but the mechanism of 
immunomodulation is by inducing T cell apoptosis by modulating cell (Rac1) signalling. 
Azathioprine is non-enzymatically metabolised to mercaptopurine, which involves loss 
of a nitro-imidazole side chain; this is thought to explain some of the side effects seen 
with azathioprine and which may be less of a problem with mercaptopurine. 
Mercaptopurine is subsequently metabolised to 6-thioguanine nucleotides. 6-
thioguanine nucleotides have been used for treatment of IBD, but caution is 
appropriate because of potential hepatotoxicity [Mowat et al., 2011]. 
Polyglutamated metabolites of methotrexate inhibit dihydrofolate reductase, but this 
cytotoxic effect does not explain its anti-inflammatory effect. Inhibition of cytokine and 
eicosanoid synthesis probably plays a role. At present methotrexate is positioned as a 
second-line immunosuppressive agent in patients resistant or intolerant of azathioprine 
or mercaptopurine, although it is currently unclear whether thiopurines are any more 
efficacious than methotrexate for induction or maintenance of remission in IBD [Mowat 
et al., 2011]. 
Cyclosporine is an inhibitor of calcineurin, which is a potent immunosuppressant drug 
used in organ transplantation. Since the mid-1980s, this drug has also been used to 
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treat patients with IBD [Pithadia & Jain, 2011]. It acts to prevent clonal expansion of T 
cell subsets. At this time, cyclosporine is effective in severe UC that has failed to 
respond adequately to glucocorticoid therapy. In such patients, intravenously 
administered cyclosporine is highly effective for rapid disease control, and it may allow 
patients to avoid surgery [Mowat et al., 2011]. However, after one year, 70 to 80% of 
these patients may still require surgery. Thus, in many patients, the role of cyclosporine 
is to change a risky emergency operation into a less urgent procedure. Cyclosporine is 
effective in specific clinical settings in IBD, but the high frequency of significant adverse 
effects limits its use as a first-line medication [Pithadia & Jain, 2011]. 
3.4. MONOCLONAL ANTIBODIES 
Biological response modifiers are drugs that interfere with the inflammatory response. 
There are presently two biological agents licensed for the treatment of IBD; both are 
monoclonal antibodies against TNF-α (anti-TNF) [Mowat et al., 2011]. Although many 
pro- and anti-inflammatory cytokines are generated in the inflamed gut in IBD, there is 
some rationale for targeting TNF-α, because it is one of the principal cytokines 
mediating the Th1 immune response characteristic of CD. The administration of 
humanized monoclonal antibodies is an entirely new and potentially highly successful 
concept for treating IBD [Pithadia & Jain, 2011].  
The first such product, infliximab, is a chimeric immunoglobulin (75% human IgG and 
25% murine) that binds to and neutralizes TNF-α, and it represents a new class of 
therapeutic agents for treating IBD [Targan et al., 1997]. Infliximab (infused 
intravenously) decreases the frequency of acute flare-ups in approximately two-thirds 
of patients with moderate to severe CD and facilitates the closing of enterocutaneous 
fistulas associated with CD [Present et al., 1999; Pithadia & Jain, 2011; Mowat et al., 
2011].  
Adalimumab is an anti-TNF agent similar to infliximab and decreases inflammation by 
blocking TNF-α. In contrast to infliximab, adalimumab is a fully humanized anti-TNF 
antibody (no mouse protein). Adalimumab is administered subcutaneously instead of 
intravenously, but is comparable to infliximab in effectiveness and safety for inducing 
and maintaining remission in patients suffering from CD that has failed to respond to 
standard immunosuppression (e.g, corticosteroids and thiopurine or methotrexate 
therapy). Adalimumab is also effective in healing anal fistulas in patients with CD. It is 
well tolerated and has been shown to be effective for patients who cannot tolerate 
infliximab [Mowat et al., 2011; Pithadia & Jain, 2011]. 
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4.  TREATMENT PROTOCOLS ON INFLAMMATORY BOWEL DISEASE 
4.1. TREATMENT PROTOCOL FOR CROHN´S DISEASE 
Management of CD often proves more difficult than management of UC, partly because 
of the greater complexity of presentation with CD (FIGURE 5). The disease may involve 
any segment of the gastrointestinal tract, from mouth to anus, and may involve other 
visceral structures and soft tissues through fistulization. There is a greater reliance on 
drug therapy with CD, because ressection of all involved intestine may not be possible. 
Unfortunately, recurrence of CD is common following surgery with reported rates of up 
to 64% recurrence following surgical resection of affected areas of bowel [Hancock, 
Windsor & Mortensen, 2006]. 
 
FIGURE 5. Treatment algorithm for the management of CD [adapted of Dipiro et al., 2008]. 
 
The goal of treatment for active CD is to achieve remission; however, in many patients, 
reduction of symptoms so the patient may carry out normal activities, or reduction of 
the steroid dose required for control, is a significant accomplishment. In the majority of 
patients, active CD is treated with sulfasalazine, mesalamine derivatives, or steroids, 
although azathioprine, mercaptopurine, methotrexate, infliximab, and metronidazole 
are frequently used [Pithadia & Jain, 2011].  
 
Sulfasalazine is more effective when CD involves the colon [Hanauer & Sandborn, 
2001]. In these circumstances, sulfasalazine is as effective as prednisone [Sandborn, 
2003; Kornbluth & Sachar, 2004; Gionchetti, 2006]. Mesalamine formulations have the 
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ability to act in the small bowel, thus targeting ileal disease. However, these 
formulations have demonstrated variable results in patients with active CD [Sandborn, 
2003; Gionchetti, 2006]. Despite variable effectiveness, the mesalamine derivatives 
may be better tolerated than sulfasalazine, particularly at higher doses. Thus, a trial of 
sulfasalazine or an oral mesalamine derivative is reasonable as initial therapy in 
patients with mild to moderate active CD with ileal, ileocolonic, or colonic involvement 
[Kornbluth & Sachar, 2004]. 
 
Steroids are frequently used for the treatment of active CD, particularly with more 
moderate to severe presentations, or in those patients unresponsive to 
aminosalicylates. Budesonide is a viable first-line option for patients with mild to 
moderate ileal or right-sided (ascending colonic) disease [Hofer, 2003; Otley & 
Steinhart, 2005; AGAI, 2006]. Budesonide is inferior to traditional systemic steroids for 
severe disease, although it carries a lower risk of adverse effects, and does not reach 
areas distal to the ascending colon. Oral systemic steroids are effective in inducing 
remission in up to 70% of patients and should be reserved for patients with moderate to 
severe disease who have failed aminosalicylates or budesonide [AGAI, 2006; 
Gionchetti, 2006]. Hospitalized patients with severe or fulminant disease, or those who 
are unable to tolerate oral therapy, are candidates for administration of parenteral 
steroids [Hofer, 2003; AGAI, 2006].  
 
Metronidazole (given orally up to 20 mg/kg per day in divided doses) has demonstrated 
variable efficacy, but may possibly be useful in some patients with CD, particularly in 
patients with colonic or ileocolonic involvement, or in those patients with perineal 
disease [Sandborn, 2003; AGA, 2003; Guslandi, 2005; Gionchetti, 2006]. For these 
patients, metronidazole is added to a mesalamine product or steroids as adjunctive 
therapy, where satisfactory control of CD is not gained with first-line agents, or in 
attempts to reduce steroid dosage [Lawson, Thomas & Akobeng, 2006]. Ciprofloxacin 
has gained attention as an alternative to metronidazole [Sandborn, 2003; Gionchetti, 
2006]. The combination of metronidazole and ciprofloxacin appears to be efficacious in 
some patients with perianal disease [AGA, 2003; Guslandi, 2005]. 
 
The immunosuppressive agents are effective, but are generally limited to use in 
patients who are not achieving adequate response to standard medical therapy, or to 
reduce steroid doses when high steroid doses are required [Sandborn et al., 2000; 
Derijks, Gilissen, Hooymans & Hommes, 2006; AGAI, 2006; Gionchetti, 2006]. 
Azathioprine and mercaptopurine have both demonstrated long-term benefits in 
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patients with CD [Derijks et al., 2006; Holtmann et al., 2006]. The usual dose of 
azathioprine is 2 to 3 mg/kg per day; the usual dose of mercaptopurine is 1 to 1.5 
mg/kg per day [AGAI, 2006]. Starting doses are typically 50 mg/day and increased at 2-
week intervals; complete blood counts with differential should be monitored every 2 
weeks while doses are being titrated [AGAI, 2006]. The onset of therapeutic effects is 
delayed and a minimum of 3 to 4 months is often required to see clinical benefits 
[AGAI, 2006; Gionchetti, 2006].  
 
Although mostly used in the setting of maintenance therapy, methotrexate is another 
option for use as induction therapy [Gionchetti, 2006]. Use of a weekly intramuscular 
injection of 25 mg has demonstrated efficacy for induction of remission in CD, and has 
also demonstrated corticosteroid-sparing effects [Alfadhli, McDonald & Feagan, 2004; 
AGAI, 2006; Gionchetti, 2006]. Although there are risks of bone marrow suppression, 
hepatotoxicity, and pulmonary toxicity, use of low-dose methotrexate appears relatively 
safe when continued as maintenance therapy if proper monitoring is implemented 
[AGAI, 2006]. 
 
Infliximab is used for treating moderate to severe active CD in patients failing 
immunosuppressive therapy, in those who are corticosteroid dependent, and for 
treatment of fistulizing disease [Rutgeerts, Van Assche & Vermeire, 2006; AGAI, 2006; 
Kamm, 2006]. Patients who receive infliximab often develop antibodies to infliximab, 
which can result in increases in the occurrence of serious infusion reactions and loss of 
response to the drug. Strategies to reduce formation of antibodies to infliximab include 
administration of a second dose within 8 weeks of the first dose, concurrent 
administration of steroids (hydrocortisone 200 mg intravenously on the day of the 
infusion or oral prednisone the day prior), and use of concomitant immunosuppressive 
agents [Rutgeerts et al., 2006; AGAI, 2006; Kamm, 2006]. Induction of tolerance using 
a dose escalation technique was also effective in administering infliximab to patients 
with previous severe infusion reactions [Duburque et al., 2006]. Treatment with 
adalimumab is recommended in patients with moderately to severe active CD, without 
effective response to infliximab. In these cases, the patients have demonstrated up to a 
54% complete response [Konstantinos et al., 2005; Hanauer et al., 2006; Sandborn et 
al., 2007]. 
 
Cyclosporine is typically not recommended for treatment of CD, except for acute 
management of patients with severe fistulizing disease [McDonald et al., 2005; AGAI, 
2006; Bressler & Sands, 2006]. Up to 83% of patients with refractory fistulas responded 
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to intravenous (IV) cyclosporine within a mean of 7.9 days [Gionchetti, 2006]. The dose 
of cyclosporine is important in determining efficacy. An oral dose of 5 mg/kg per day is 
ineffective, whereas 7.6 mg/kg per day has demonstrated effectiveness in some trials 
[McDonald et al., 2005; AGAI, 2006]. However, toxic effects limit the routine use of this 
higher dosage. At present, the therapeutic blood or plasma concentration range for 
cyclosporine has not been established for CD, but whole-blood trough concentrations 
of 300 to 500 ng/ml for IV therapy or 200 to 400 ng/ml for oral therapy are reasonable 
goals [AGAI, 2006; Gionchetti, 2006]. When using cyclosporine clinicians should 
recognize the accompanying long-term risk of renal toxicity and infection, as well as the 
potential for drug interactions [AGAI, 2006].  
4.2. TREATMENT PROTOCOL FOR ULCERATIVE COLITIS 
Prior to initiating therapy for UC, a patient must be evaluated for extent and severity of 
disease. Thenceforth, the management of UC can be applied (FIGURE 6). In general, if 
disease is distal to the splenic flexure, topical therapy such as suppositories and 
enemas may be the first choice. For more extensive disease, oral agents or a 
combination of oral and topical agents are indicated [Mahadevan, 2004]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 6. Treatment algorithm of management of UC [adapted of Dipiro et al., 2008]. 
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Most patients with active UC have mild to moderate disease and do not require 
parenteral medications. The first line of drug therapy for patients with extensive disease 
is oral sulfasalazine or an oral mesalamine derivative [Kornbluth & Sachar, 2004]. Oral 
mesalamine derivatives are reasonable alternatives to sulfasalazine for treatment of 
UC. Oral mesalamine products are used for patients with extensive disease, while 
topical agents, such as enemas and suppositories, are used for distal disease. 
Mesalamine is not more effective than sulfasalazine for extensive disease [Hanauer, 
2006a; Sutherland & MacDonald, 2006]. Topical mesalamine is more effective than 
oral mesalamine or topical steroids for distal disease [Kornbluth & Sachar, 2004]. 
Mesalamine preparations are typically better tolerated, and the majority of patients 
intolerant to sulfasalazine or topical steroids should tolerate one of the other oral 
mesalamine derivatives [Kornbluth & Sachar, 2004; Collins & Rhodes, 2006]. When 
used topically, mesalamine suppositories will only reach to approximately 10 to 20 cm 
and thus should be reserved for patients with proctitis. Because enema formulations 
reach to the splenic flexure, they can be used for distal disease [Regueiro, 2004; 
Kornbluth & Sachar, 2004]. Olsalazine is another 5-ASA that is given orally and is 
effective for treatment of mild to moderate UC. However, of patients taking olsalazine, 
15% to 25% experience severe diarrhea, often necessitating discontinuation of the 
drug. This results from a direct osmotic effect of the drug to induce small-bowel fluid 
secretion. For this reason, it is not the drug of first choice [Kornbluth & Sachar, 2004].  
 
Steroids have a place in the treatment of moderate to severe active UC regardless of 
disease location, or in those patients who are unresponsive to maximal doses of oral or 
topical mesalamine derivatives and/or sulfasalazine [Pruitt et al., 2002; Kornbluth & 
Sachar, 2004]. Overall, steroids and sulfasalazine appear to be equally efficacious; 
however, the response to steroids may be evident sooner. Oral steroids should not be 
used as initial therapy for mild to moderate UC, mainly because of the known risks of 
steroid use. If steroids are used to attain remission, tapered drug withdrawal should be 
accomplished to minimize long-term steroid exposure [Kornbluth & Sachar, 2004]. 
Rectally administered steroids given as suppositories, enemas, or foams can be used 
as initial therapy for patients with ulcerative proctitis, distal colitis or tenesmus. With 
these agents, local actions are believed to be responsible for drug effects. However, 
rectal mesalamine is more effective than rectal steroids for inducing remission 
[Regueiro, 2004; Kornbluth & Sachar, 2004; Sandborn, 2006; Gionchetto, 2006; AGAI, 
2006]. 
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Infliximab is another viable option for patients with moderate to severe active UC who 
are unresponsive to steroids or other immunosuppressive agents [Rutgeerts et al., 
2006; Sandborn, 2006; AGAI, 2006; Lawson et al., 2006]. Outpatients with moderately 
active UC have response rates of up to 69% at 8 weeks following initial doses of 5 
mg/kg [Rutgeerts et al., 2005]. Hospitalized patients have mixed results, with some 
demonstrating reduced rates of colectomy for patients receiving infliximab [Janerot et 
al., 2005; Lawson et al., 2006; Regueiro, Curtis & Plevy, 2006]. 
 
Nicotine has been proposed as a treatment for UC (but not as a treatment for CD) 
based on the observation of the onset of a flare of UC after smoking cessation in some 
individuals. While less effective than aminosalicylates, transdermal nicotine in daily 
doses of 15 to 25 mg may improve symptoms in patients with mild to moderate active 
UC and can be considered as an adjunctive therapy [Kornbluth & Sachar, 2004; 
McGrath, McDonald & MacDonald, 2004].  
 
Patients with uncontrolled severe colitis or who have incapacitating symptoms require 
hospitalization for effective management. Under these conditions, patients generally 
receive nothing by mouth to put the bowel at rest. Most medication is administered by 
parenteral route. Sulfasalazine or mesalamine derivatives are not beneficial for 
treatment of severe colitis because of rapid elimination of these agents from the colon 
with diarrhea, thereby not allowing sufficient time for gut bacteria to cleave the 
molecules. Overall it is difficult to evaluate drugs in this setting, because patients with 
severe disease almost always receive additional medications including steroids 
[Kornbluth & Sachar, 2004]. 
 
Steroids have been valuable in the treatment of severe disease, because may allow 
some patients to avoid colectomy. Methylprednisolone is typically preferred, because of 
its lesser mineralocorticoid effects. A trial of steroids is warranted in most patients 
before proceeding to colectomy, unless the condition is severe or rapidly deteriorating. 
The length of the medical trial before consideration of surgery is open to debate. 
Steroids increase surgical risk, particularly infectious risk, if an operation is required 
later. After a colectomy is performed, steroids should no longer be required for the 
disease; however, they must be withdrawn gradually to avoid hypoadrenal crisis 
because of adrenal suppression [Kornbluth & Sachar, 2004; AGAI, 2006]. 
   
Patients who are unresponsive to parenteral corticosteroids after 7 to 10 days should 
receive cyclosporine by IV infusion [Durai & Hawthorne, 2005]. Continuous IV infusion 
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of cyclosporine is typically effective in steroid-resistant acute severe UC and may 
reduce the need for emergent colectomy [Durai & Hawthorne, 2005; Shibolet, 
Regushevskaya, Brezis & Soares-Weiser, 2005]. Patients who are controlled on IV 
cyclosporine can then be switched to an oral cyclosporine taper regimen with 
subsequent transition to azathioprine or 6-mercaptopurine [AGAI, 2006]. Infliximab is 
also an alternative to cyclosporine, and may also deter the need for colectomy in 
patients with severe disease not responsive to steroids [Rutgeerts et al., 2005; Janerot 
et al., 2005; AGAI, 2006; Lawson et al., 2006]. 
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5. PROGNOSTIC OF INFLAMMATORY BOWEL DISEASE 
The clinical course of IBD is relapsing and remitting; it can occur spontaneously or in 
response to concomitant illnesses or changes in treatment [Kornbluth & Sachar, 2010]. 
The symptoms can last for days, weeks, or months and then go into remission for 
months, years, or sometimes decades [Thoreson & Cullen, 2007]. The severity of 
disease varies but most patients have mild to moderate disease and will remain in 
remission for extended periods of time with maintenance medical therapy. However, at 
some time during the course of the disease, up to 15% of patients will develop a severe 
flare and up to 40% of patients will have a colectomy [Doherty & Cheifetz, 2009]. 
The natural history of IBD differs between adults and children. Pancolitis, proximal 
extension [Ponsky et al., 2007], and steroid dependency are more common in children 
[Levine, 2009]. Growth failure, which can occur in children with IBD, can negatively 
affect psychosocial development and self-image. Poor nutrition, inflammation of the 
gut, disruption of the growth hormone/insulin-like growth factor axis, and corticosteroid 
therapy may be contributing factors to the development of growth failure in these 
patients [Beattie, Croft, Fell, Afzal & Heuschkel, 2006]. 
 
The patients with IBD are also exposed to a risk of colorectal cancer, depending on the 
extent of disease and duration [Kornbluth & Sachar, 2010]. A meta-analysis found that 
colorectal cancer risk for any patient with UC was 2% at 10 years, 8% at 20 years, and 
18% after 30 years of disease. This translates to a 5- to 10-fold increase in the relative 
risk for colorectal cancer compared with age-matched controls [Mpofu, Watson & 
Rhodes, 2004]. Nevertheless, UC that is limited to the rectum or rectosigmoid does not 
increase the risk [Itzkowitz & Present, 2005]. The relative lifetime risk of developing 
colon cancer for patients with either pancolitis or left-sided UC is much higher than in 
the general population [Eaden, Abrams & Mayberry, 2001]. However, a case-control 
study found that the risk was reduced by 75% with the regular use of aminosalicylate 
drugs (sulfasalazine and mesalamine) [Eaden, Abrams, Ekbom, Jackson & Mayberry, 
2000]. 
 
Regarding mortality rate, a meta-analysis of 10 studies including 10,443 patients found 
that the overall risk of death was not significantly different between patients with IBD 
and the general population [Jess, Gamborg, Munkholm & Sorensen, 2007]. Due to 
more aggressive treatment and monitoring, mortality from acute severe disease has 
decreased by 25% [Doherty & Cheifetz, 2009]. 
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While the introduction of biologic inflammatory mediators such as TNF-α inhibitors has 
improved the IBD therapeutic landscape, there remains considerable unmet medical 
need particularly in patients with severe or complicated clinical manifestations and in 
pediatric populations [Yang, Alex & Catto-Smith, 2012a; Assaa et al., 2013; Mehta, 
Silver & Lindsay, 2013]. This need continues to drive IBD research efforts at 
universities, research foundations, and biotechnology and pharmaceutical companies 
spanning the spectrum from basic science to translational medicine. A common thread 
in most of these research efforts is the need for appropriate animal models. Animal 
models provide means of characterizing physiologic interactions when our 
understanding of such processes is insufficient to allow replacement with in vitro 
systems [Voss & Diehl, 2014]. 
 
Medical knowledge, treatment, and research that are involved in understanding the 
etiopathology of IBD have used laboratory animals for decades. The number of animal 
models used for preclinical studies and to understand the mechanisms of 
gastrointestinal inflammation is continually expanding. Currently, many animal models 
are being developed to focus on understanding the genetics and immunology of IBD. 
Many of these animal models are based on experimental needs; however, the positive 
impact of these animal models in advancing the medical knowledge of IBD cannot be 
underestimated [Murphy, 2006]. 
 
 It is apparent that animal models do not entirely resemble human IBD, and also that 
one IBD patient does not entirely resemble another very well. Thus, the diversity of 
responses we observe in animal models is no different than what we observe in 
humans. Experience has been that even homogenously bred animals tend to respond 
differently to certain stimuli and treatments [Murphy, 2006].  Furthermore, although 
these models do not represent the complexity of human disease and do not replace 
studies with patient material, they are valuable tools for studying many important 
disease aspects that are difficult to address in humans, such as the pathophysiological 
mechanisms in early phases of colitis and the effect of emerging therapeutic strategies 
[Wirtz & Neurath, 2007; Szczepanik et al., 2012]. Indeed, animal models play pivotal 
role in the development of novel therapeutic drug to cure IBD and dissect the possible 
mechanism of action of a particular drug [Randhawa, Singh, Singh & Jaggi, 2014]. 
PHARMACOLOGICAL MODULATION OF INFLAMMATION ASSOCIATED WITH INFLAMMATORY BOWEL DISEASE 
CHAPTER 2 – ANIMAL MODELS OF INFLAMMATORY BOWEL DISEASE                                                                                                                                 32 
Clinically, there are several types of animal models of IBD (TABLE 6), who makes it 
difficult for the researcher to choose the most suitable animal model for its own study 
[Qin et al., 2011]. In general, these models can be divided into four major groups based 
upon how the disease is produced. These models include those that express intestinal 
inflammation spontaneously or naturally in their native or confined environment. The 
second category of model includes those models in which intestinal inflammation can 
be induced by specific immunological or chemical agents that physically induce an 
immune response and mucosal damage in the local bacterial environment in relation to 
the damaging agent used. The third category includes those models that are 
genetically engineered by gene knockout, gene knockin or transgenic methods, so that 
the genetic factors related to the disease could be well defined and drugs that target a 
specific gene or cytokine can be tested. The last category includes “adoptive transfer 
models” in which experimental inflammation is induced by transferring certain T cell 
populations into an immune-compromised host lacking lymphoid tissue. Thus, there is 
an assortment of animal models of inflammation available for pharmacological testing 
of anti-inflammatory agents specific to IBD [Murphy, 2006; Wirtz & Neurath, 2007; 
Randhawa et al., 2014]. 
 
Since so many experimental animal models are now available, investigators must take 
into consideration the species, strains, substrains, the microenvironment in which they 
live and the mediators involved in each of these models, for application to preclinical 
testing [Murphy, 2006]. The spontaneous models are not often used, because the 
sporadic nature of the appearance of the disease, self-limiting inflammation, expense in 
procuring some of these animals and their husbandry contribute to their limited use in 
preclinical trials [Murphy, 2006]. On the other hand, the use of genetically engineered 
models of IBD pretends to identify the genetic factors underlying experimental models 
of mucosal inflammation, followed by a candidate gene approach in humans, testing 
the relevance of the identified mouse gene to human IBD [Borm & Bouma, 2004]. 
However, these animal models are not appropriate for a preclinical efficacy testing. 
Genetically engineered models work with an inbred population, with total control of the 
environment and only one specific gene is modified, so all of these parameters don’t 
mimetics the human IBD [Borm & Bouma, 2004]. Regarding immunological models, it 
requires a much more complex and labor-intensive protocol than many other IBD 
models, due to the extraction, isolation, purification, and injection of adoptive T cells, as 
well as the number and viability of T cells transferred and the presence of B cells in the 
recipient animals largely modified the obtained results [Ostanin et al., 2009]. 
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Amongst the various models, chemically induced models are extensively used, as they 
offer reproducibility and ease of development [Randhawa et al., 2014]. Furthermore, 
one of the main goals of animal model use in IBD research is for preclinical efficacy 
testing. This is of considerable importance to pharmaceutical and biotechnology 
companies, and results of preclinical efficacy studies frequently serve as gating criteria 
that determine whether a therapeutic candidate will advance in the drug development 
pipeline. Preclinical efficacy studies most commonly utilize well-established chemically 
induced models of intestinal inflammation [Voss & Diehl, 2014].  
 
Beyond the most suitable animal model, the animal specie used in the study is also 
important. Colitis models have been developed in rats, mice, pigs, rabbits, nonhuman 
primates, and dogs [Mansfield et al., 2001; Murthy, 2006; Holst, Kleinschmidt, Nolte & 
Hewicker-Trautwein, 2012; Wadie et al., 2012]. However, the use of mouse models 
enables relative ease in incorporating animals with specific genetic modifications, use 
of larger cohort sizes, and decreases the quantity of therapeutic reagents required 
[Voss & Diehl, 2014]. 
 
In sum, ideally, a disease model should closely parallel the human disease in clinical 
manifestations, pathophysiology, and response to existing therapeutic reagents. 
However, this is rarely possible with complex human diseases such as IBD where 
multiple genetic and environmental influences determine disease onset and clinical 
course. This creates ongoing challenges for scientists involved in IBD model 
development and analysis. Planning for success in IBD animal model development 
may require that we consider Voltaire’s comment that ‘‘the perfect is the enemy of the 
good’’ (Voltaire, 1772) and focus our efforts on identifying the specific features we need 
to model rather than trying to recapitulate the entirety of human disease in an 
experimental animal [Voss & Diehl, 2014]. 
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1.  CHEMICALLY INDUCED COLITIS MODELS 
Chemically induced models to study IBD are the models studied in greatest detail so 
far and involve induction of colitis by administration of an exogenous colitogenic 
substance. In general, these models require the co-administration of a substance that 
temporarily disrupts the mucosal integrity, allowing the colitogenic components to gain 
access to the mucosal immune system [Borm & Bouma, 2004]. In one of the early 
models of IBD, rabbits were sensitized with ovalbumin. Then, the colonic epithelial 
barrier was disrupted by rectal administration of formalin, followed by re-administration 
of the antigen, leading to a transient inflammation with many similarities to UC [Kraft, 
Fitch & Kirsner, 1963]. An important conclusion from these and subsequent studies 
was that the perpetuating inflammation in IBD results from a break in ‘tolerance’ to 
antigens in the normal mucosal microflora [Borm & Bouma, 2004]. 
 
Among the various chemically induced colitis models, dextran sulfate sodium (DSS)-
induced colitis and trinitrobenzene sulfonic acid (TNBS)-induced colitis models are the 
most widely used to induce IBD. These models symptomatically, morphologically and 
histopathologically resemble human IBD. These colitis models are appropriated to 
developing and testing novel therapeutic strategies for the treatment of IBD. Moreover, 
the plausible mechanism of action of a particular drug can be illustrated using a 
suitable colitis model [Randhawa et al., 2014]. Moreover, chemically induced models of 
colitis, such as DSS and TNBS, induce acute damage to the epithelium. These models 
are useful to explore pathways or therapeutics that are thought to protect intestinal 
epithelial cells from damage or stress response as well as pathways that maintain gut 
integrity in the presence of a biological insult [Voss & Diehl, 2014].  
 
Differences between models may reflect the different subgroups of patients with IBD 
[Jurjus, Khoury & Reimund, 2004]. The scientific evidence suggests that TNBS-induced 
colitis model promotes a Th1 response, resembling CD in humans [Hibi, Ogata & 
Sakuraba, 2002]. In turn, DSS-induced colitis model promotes a Th2 response, 
resembling UC in humans [Randhawa et al., 2014]. In practice, this pattern of T-cell 
differentiation is associated with distinct functional activities: Th1 T cells are the key 
players in delayed-type hypersensitivity reactions, whereas Th2 T cells are potent 
inducers of antibody-mediated immunologic reactions [Abbas, Murphy & Sher, 1996]. 
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1.1. INDUCTION BY DEXTRAN SULFATE SODIUM 
In 1985, Ohkusa reported for the first time the animal model of colitis with DSS 
[Ohkusa, 1985]. Today, it is one of the most commonly used inducers of colitis in 
animal models, thanks largely to the ease of use and potentially short turnaround times 
for obtaining results [Bramhall, Flórez-Vargas, Stevens, Brass & Cruickshank, 2015]. 
The commonly used protocol for DSS-induced colitis in rats or mice is to add DSS to 
drinking water [Ohkusa, 1985; Okayasu et al., 1990; Bramhall et al., 2015]. DSS-
induced colitis is a reproducible model that morphologically and symptomatically 
resembles UC in humans [Wirtz, Neufert, Weigmann & Neurath, 2007; Bramhall et al., 
2015]. In the DSS model, the Th response may switch from Th1 response in the acute 
phase to mixed Th1/Th2 response in the chronic phase of disease, mediated by IL-5 
and IL-13 [Fiocchi, 1998; Dielemann et al., 1998]. 
 
DSS is commonly administered in a dose range of 2-10% for 5-10 days to induce an 
acute inflammation, after a single continuous exposure. By prolonging the DSS 
administration, acute colitis may be extrapolated to chronic colitis by repeated 
exposure administering in three to five cycles (e.g., 7 days DSS, 14 days water) 
punctuated with recovery periods [Wirtz & Neurath, 2007; Tran, Katsikeros & 
Abimosleh, 2012; Bramhall et al., 2015].  
 
The severity of DSS-induced colitis model depends on dose, duration of administration 
and animal strain (C3H/HeJ and BALB/c mice strains are more susceptible) [Ohkusa, 
1985; Okayasu et al., 1990; Bramhall et al., 2015]. Other factors that can influence the 
severity and susceptibility of exposure to DSS are the manufacturer and molecular 
weight of DSS (5kDa for mild and 40kDa for severe colitis), gender (male mice are 
more susceptible), and whether animals are raised in germ-free or specific pathogen-
free environments [Perse & Cerar, 2012; Low, Nguyen & Mizoguchi, 2013]. Depending 
of these factors, DSS causes erosions with complete loss of surface epithelium 
because of its direct toxic effect on epithelial cells. It causes deformity in the epithelial 
integrity, thereby increases the colonic mucosal permeability allowing permeation of 
large molecules such as DSS with molecular weight upto 50,000 Da [Dharmani, Leung 
& Chadee, 2011; Dai et al., 2013]. 
DSS is a synthetic sulfated polysaccharide composed of dextran and sulfated anhydro-
glucose unit [Tran et al., 2012]. The exact mechanism by which DSS induces colonic 
damage is beginning to emerge. Its primary mode of action seems to chemically 
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interfere with gut mucosa barrier integrity, allowing luminal antigens access to the 
lamina propria and the proinflammatory cells within [Low et al., 2013]. Moreover, since 
colonic bacteria can dissociate sulfate from DSS, the free sulfate present in the 
intestine could act as a substrate to produce hydrogen sulfide, which could significantly 
interfere with cellular metabolism to induce a toxic effect on the epithelium. Other 
possible mechanisms include alterations in luminal bacterial ecology and the activation 
of monocytes, macrophages and mast cells [Murthy, 2006; Wirtz & Neurath, 2007]. In 
the course of colonic inflammation, colonic mucosa shows increased expression of 
proinflammatory cytokines, such as TNF-α, IL-1β, IL-6, IL-8 and some adhesion 
molecules genes (ICAM-1) [Jurjus et al., 2004].  
This model is one of the widely used models as it can be easily developed owing to the 
wide availability. It has been shown to be suitable to study epithelial repair mechanisms 
and the contribution of innate immune mechanisms of colitis [Williams et al., 2001]. 
Furthermore, it has been highly applicable for understanding the multistep neoplastic 
process involved in colitis-associated colon cancer and to test investigational drugs that 
are chemopreventive or therapeutic to combat colon cancer in high-risk IBD patients 
[Murphy, 2006]. 
 
The advantage of this model also resides in the ease of producing both “acute” and 
“chronic” disease by simple modification of the DSS feeding protocol. The disease is 
highly reproducible. Chronic inflammation in this model lasts for a longer period, 
permitting the evaluation of the efficacy of compounds without any inherent risk of self-
healing. The functional end points are easy to measure, but labor intensive. However, 
the disadvantage of the model is that DSS is very expensive. Batch to batch variations 
in disease severity could occur due to small molecular weight DSS impurities in the 
DSS preparation. Furthermore, the disease is characterized by progressive crypt 
dropout, suggesting a direct effect of DSS on the epithelial cells as opposed to lamina 
propria cells as suggested in human IBD [Murphy, 2006]. 
1.2. INDUCTION BY TRINITROBENZENE SULFONIC ACID  
Since Morris first described it in 1989, TNBS model has been very popular [Murphy, 
2006]. Its popularity is well founded because a single application of TNBS in rats, mice, 
guinea pigs, dogs and rabbits produce rapid, reliable and reproducible disease. This 
animal model is an efficient method, since can mimic the pattern of inflammation with 
human IBD [Hibi et al., 2002; Linden, Chen, Gershon, Sharkey & Mawe, 2003; 
Randhawa et al., 2014]. Indeed, since TNBS is associated with predominant activation 
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of Th1-mediated immune response, this model promotes chronic transmural colitis with 
severe diarrhea, weight loss, and rectal prolapse, an illness that mimics some 
characteristics of CD in humans [Morris et al., 1989; Elson, Sartor, Tennyson & Riddell, 
1995; Neurath, Fuss, Kelsall, Stuber & Strober, 1995; Boirivant, Fuss, Chu, Strober, 
1998; Yu et al., 2013].  
 
The induction of colitis by TNBS is simple, requiring an introduction of 20–80 mg TNBS 
dissolved in 30–50% ethanol as an enema in the animal colon [Murphy, 2006]. Ethanol 
not only serves as a solvent or carrier, but also aids in inducing gut inflammation by 
breaking the mucosal barrier [Neurath et al., 1995; Ikeda et al., 2008]. The degree of 
disease and time required to produce the injury may vary between laboratories 
[Murphy, 2006]. In general, the acute transmural damage became maximal from 3 days 
to 1 week after instillation, which gradually progresses into chronic inflammation lasting 
for about 8 weeks [Morris et al., 1989; Linden et al., 2005; Lamb, Zhong, Gebhart & 
Bielefeldt, 2006; Murphy, 2006; Qin et al., 2011]. Concretly, TNBS presents an 
infiltration of inflammatory cells within 2 hrs after administration, but typical signs of 
chronic inflammation can develop after 48 hrs [Cheon, Cui, Yeon, Kwon & Park, 2012]. 
 
Protocols of the TNBS-induced colitis model are not standardized, such as the dose of 
TNBS, the depth of TNBS administration, the animal strain, and the time point for 
model evaluation [Wirtz et al., 2007; Qin et al., 2011]. Particularly, TNBS administered 
to rats at different doses gave an indication that TNBS induces acute inflammation and 
damage in a dose dependent manner with the highest doses being more effective. On 
varying alcohol concentration between 25% and 50% alcoholic concentration, it was 
found that the pathological score, like inflammation and visceral hypergelsia was more 
significant in TNBS-50% ethanol treated rats. Curiously, there are studies where 
instillation of a certain dose of TNBS at a depth of 4 cm or 8 cm produced similar 
pattern and severity of colonic inflammation [Qin et al., 2011]. In mice, TNBS colitis 
was initially described in SJL/J mice, which is a mouse strain with high susceptibility for 
the induction of colitis. But now-a-days, various other mouse strains are also frequently 
used for development of colitis, such as BALB/C and C57BL/6. Generally, it involves 
rectal application of low dose of TNBS for induction of colitis [Randhawa et al., 2014].  
 
TNBS can induce colitis by intrarectal instillation of the haptenating substance 
dissolved in ethanol [Morris et al., 1989]. Regarding its mechanism of action (FIGURE 7), 
TNBS is a haptenating agent that couples trinitrophenyl groups to cell surface proteins 
(colonic autologous or microbiota proteins) more or less indiscriminately. Then, altered 
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self-proteins are presented to CD4+ T cells by antigen presenting cells throughout the 
colonic lamina propria (dendritic cells or macrophages), stimulating a local immunologic 
response. Consequently, CD4+ T cell immune response and cytokine production is 
induced, rendering them immunogenic to the host immune system [Allgayer, 
Deschryver & Stenson, 1989; Morris et al., 1989; Neurath et al., 1995; Cavani, Hackett, 
Wilson, Rothbard & Katz, 1995; Murphy, 2006; Wirtz et al., 2007; Qin et al., 2011]. In 
the absence of adequate counter-regulatory mechanisms, excessive secretion of IL-12 
and, subsequent, induction of an unbalanced Th1 T-cell response is produced, usually 
called a delayed hypersensitivity reaction with dense infiltration of 
lymphocytes/macrophages and thickening of the colon wall. Finally, the Th1 cytokines, 
particularly IFN-γ, act on macrophages to induce the production of additional 
proinflammatory cytokines, such as TNF-α, IL-1β, and IL-6, which then serve as the 
immediate causes of the inflammation. These findings probably indicate that a poorly 
regulated Th1 T-cell response is the key mechanism underlying the pathogenesis of 
TNBS-induced colitis [Strober, Ludviksson & Fuss, 1998]. Furthermore, in TNBS-
induced colitis, the injury is also associated with a substantial increase in 
myeloperoxidase (MPO) levels, suggesting that neutrophils play a significant role in the 
production of acute injury. 
 
FIGURE 7. Mechanism of colitis induction and tolerance in the TNBS-induced colitis model 
[adapted of Strober et al., 1998]. 
Legend: TNBS - Trinitrobenzene sulfonic acid; APC – Antigen presenting cells;  
MAC - Membrane attack complex; TNF-α - Tumor necrosis factor α.   
 
Over the last decade, this is by far one of the most popular models used for the 
preclinical evaluation of drugs that have been published. The success of these 
therapies provides valuable comparisons for future drugs to be tested [Murphy, 2006]. 
It is a very useful model and is frequently used in studying many aspects of gut 
PHARMACOLOGICAL MODULATION OF INFLAMMATION ASSOCIATED WITH INFLAMMATORY BOWEL DISEASE 
CHAPTER 2 – ANIMAL MODELS OF INFLAMMATORY BOWEL DISEASE               42 
inflammation including cytokine secretion pattern, cell adhesion and immunotherapy 
[Wirtz & Neurath, 2007; Randhawa et al., 2014].  
 
The advantages of this model are the simplicity and relative low cost of producing 
colitis. On the other hand, TNBS model of colitis suffers from some disadvantages, like 
its reproducibility, which is dependent of many factors as previously described [Murphy, 
2006]. This handicap can be overcome with the padronization and validation of the 
animal model before the preclinical study is applied. Furthermore, the absence of 
spontaneous relapse which is the hallmark of human UC, as do many other methods 
[Stevenson, Marshall & Morgan, 2006]. However, recurrent UC model can also be 
induced by instilling TNBS into the colon through a cannula, but is followed by a 
second instillation with a lower dose of TNBS into the colon 14 days after the first 
induction of colitis leading to generation of recurrent model of UC [Yang et al., 2012b]. 
Recurrent colitis can be achieved by repeated enemas of TNBS, but never by oral 
feeding of TNBS, since will promote significant oral tolerance [Elson et al., 1996]. 
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CHAPTER 3 – NEW PHARMACEUTICAL APPROACHES IN 
INFLAMMATORY BOWEL DISEASE 
 
IBD are chronic relapsing inflammatory conditions of the intestine with a multifactorial 
pathogenesis that includes genetic susceptibility, impaired barrier function, altered gut 
flora and a dysregulated immune response [Neurath, 2014a]. In most cases, it is often 
required to treat patients over years and to adapt the therapy repeatedly with respect to 
flares, complications, personal circumstances or loss of effect of previous medication. 
This can be a quite challenging task but recent advances in understanding the nature 
of IBD have helped and will help to develop new and future therapies, which will enable 
us to improve our strategies regarding these needs. Collectively, our current 
therapeutic concepts for IBD will progressively evolve to become broader in general 
options but though more targeted and individualized in single patients [Zundler & 
Neurath, 2015]. 
Following the breakthrough of TNF-α blockade by neutralizing antibodies in IBD a 
magnitude of therapeutic agents inhibiting the activity of pro-inflammatory cytokines or 
supporting the action of anti-inflammatory cytokines was evaluated for IBD treatment. 
Unfortunately, many of them failed in clinical studies or had beneficial effects in 
subgroups of patients only [Neurath, 2014a], which under scores the notion that 
cytokine networks in human IBD are more complex than assumed before and may vary 
between different patients. This poses the question how further and profound progress 
can be made on the field of targeting cytokines in IBD. A possible answer is to aim at 
several cytokines at the same time, either through combination of different targeted 
antibodies, through interfering with overlapping intracellular signaling pathways or 
through additional enhancement of anti-inflammatory cytokines [Zundler & Neurath, 
2015]. 
Hereupon, the therapy of IBD has recently been enriched by the successful launch of 
the anti-cytokine biologicals, such as Etanercept (TNF receptor-p75 Fc fusion protein), 
Infliximab (chimeric anti-human TNF-α monoclonal antibody) and Adalimumab 
(recombinant human anti-human TNF-α monoclonal antibody). The success of these 
novel treatments has impressively demonstrated the clinical benefit that can be gained 
from therapeutic intervention in cytokine signalling, highlighting the central role of 
proinflammatory cytokine systems like IL-1β and TNF-α to be validated targets. 
However, all of the anti-cytokine biologicals available to date are proteins, and 
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therefore suffering to a varying degree from the general disadvantages associated with 
protein drugs. Therefore, small molecular, orally active anti-cytokine agents, which 
target specific pathways of proinflammatory cytokines, would offer an attractive 
alternative to anti-cytokine biologicals [Peifer, Wagner & Laufer, 2006]. 
Ultimately, the therapeutic dogma in IBD has shifted away from the administration of 
nonspecific immunosuppressives toward a pathway-based approach. Availability of 
such diverse treatment modalities with specific pathway-based targets will increase the 
therapeutic options for patients with IBD [Bamias, Pizarro & Cominelli, 2016]. In the 
coming years, this trend is expected to continue. Yet, many challenges are still ahead. 
A strong collaborative effort by experts from different fields is encouraged and 
necessary to maximize our success in IBD drug targeting [Wolk, Epstein, Ioffe-Dahan, 
Ben-Shabat & Dahan, 2013]. 
 
In general terms, the aim of our work is to evaluate the influence of a set of drugs in the 
IBD. These drugs, such as erythropoietin (EPO), thiadiazolidinone-8 (TDZD)-8 and 
hemin, can modulate some important metabolic pathways in the establishment and 
development of inflammation. Indeed, they may inhibit or stimulate molecular 
pathways, contributing to facilitate a more effective and selective treatment than the 
currently known.  
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1.  ERYTHROPOIETIN 
More than a century ago, a plasmatic humoral factor was assumed to be essential for 
red blood cell production and was called hemopoietin. Hemopoietin was the initial 
name for EPO, which was later identified and described as a 34-kDa glycoprotein of 
165 amino acids that plays the role of a hormone, cytokine and growth factor. The 
peritubular interstitial cells of the kidney are believed to be the main producers of EPO 
[Koury, Bondurant & Koury, 1988; Fisher, Koury, Ducey & Mendel, 1996]. Recently, 
EPO producing kidney cells were not clearly identified as reported in various 
publications [Suzuki, Obara & Yamamoto, 2007]. Indeed, the latest study from Frede et 
al., suggested a potential fibroblast-like/neuronal origin for the EPO-producing cells in 
the kidney [Frede, Freitag, Geuting, Konietzny & Fandrey, 2011]. The incontestable 
fact is that EPO gene is mainly expressed in the fetal liver, whereas it is expressed in 
the kidney after birth, and the kidney then becomes the predominant site of EPO 
production. Therefore, the liver is a secondary site of EPO production in the adult 
[Zanjani, Poster, Burlington, Mann & Wasserman, 1977; Lacombe et al., 1988; Koury, 
Bondurant, Koury & Semenza, 1991]. 
EPO is a multi-functional glycoprotein essential for hematopoietic system, regulating 
the bone marrow erythrocyte production by differentiation and inhibition of the 
apoptosis of erythroid progenitor cells [Chateauvieux, Grigorakaki, Morceau, Dicato & 
Diederich, 2011; Nairz et al., 2011]. Currently, EPO is commercialized to be used in the 
treatment of anemia related to chronic renal failure in dialysis patients, with an initial 
dose of 50 to 100 IU/kg IV or subcutaneous (SC) 3 times weekly, to increase the 
production of autologous blood in normal subjects or to reduce the duration of anemia 
in patients treated with chemotherapy [Willis, Cheung & Slifer, 2012; Jelkmann, 2012]. 
The induction of EPO expression is tightly dependent on the physiological conditions 
that control its production in the kidney. Hypoxia or anemias are the main events that 
are able to induce EPO gene expression [Chateauvieux et al., 2011]. Hypoxia inducible 
factors (HIF) are a family of transcription factors (FIGURE 8) that control the cellular 
response to hypoxia. In the presence of normoxia, HIFα is rapidly destroyed by a 
collaborative effect of oxygen, prolyl hydroxylase domain-containing enzymes and the 
von Hippel-Lindau tumor suppressor protein (VHL). Hydroxylated HIFα can bind to 
VHL, and the HIFα–VHL complex facilitates ubiquitin-mediated proteasomal 
degradation of HIFα. Under conditions of tissue hypoxia, the proteasomal degradation 
of HIFα is slowed, resulting in its cytoplasmic accumulation and subsequent 
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translocation to the nucleus, where it dimerizes with HIFβ and enhances the 
transcription of the EPO gene [Chateauvieux et al., 2011]. 
 
 
 
 
 
 
FIGURE 8. Intracellular oxygen sensing and erythropoietin production  
[adapted of Patnaik & Tefferi, 2009]. 
Legend: HIF - Hypoxia inducible factors; VHL - Von Hippel-Lindau tumor suppressor protein; EPO – Erythropoietin. 
 
After induction of EPO expression, interaction between EPO and its homodimeric 
receptor (EPOR) function as the primary mediators of a general protective response to 
tissue hypoxia by acting to maintain adequate tissue oxygenation through adjustments 
of circulating red-cell mass by using a hormonal feedback control system involving the 
kidney and the bone marrow [Masuda, Nagao & Sasaki, 1999]. EPO physically 
interacts with EPOR that are expressed on the erythroid cell surface [Nairz et al., 
2011], triggering conformational changes in the extracellular domain of the receptor 
with, subsequently, receptor homodimerization and activation of the EPOR-associated 
Janus Kinase (JAK)-2 by autophosphorylation (FIGURE 9) [Patnaik & Tefferi, 2009; Nairz 
et al., 2011].  
 
 
 
 
 
 
FIGURE 9. Scheme of the conformational changes in the EPO homodimeric receptor  
[adapted of Patnaik & Tefferi, 2009]. 
Legend: JAK - Janus Kinase; EPO - Erythropoietin; STAT 5 - Signal transducer and activator of transcription protein. 
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Activated JAK-2 in turn mediates the phosphorylation of key tyrosine residues on the 
distal cytoplasmic region of EPOR, which then serve as docking sites for downstream 
effectors, initiating various signaling pathways responsible for antiapoptotic effects 
(FIGURE 10) [Patnaik & Tefferi, 2009; Nairz et al., 2011]. First, activated signal transducer 
and activator of transcription protein 5 (STAT5) homodimerizes and translocates to the 
nucleus to affect gene transcription, including Bcl-XL [Silva et al., 1999]. Second, 
phosphatidylinositol 3 kinase (PI3K) phosphorylates and activates protein kinase B 
(PKB)/Akt [Kashii et al., 2000]. Akt will phosphorylate and inactivate proapoptotic 
molecules, such as caspase 9, Bad or glycogen synthase kinase (GSK)-3β. It also 
phosphorylates IκB, which activates the transcription factor NF-kB, and induces 
cytoplasmic retention of FOXO transcription factors through their phosphorylation. 
FOXO proteins activate genes encoding proapoptotic molecules, such as Fas ligand or 
Bim. Third, EPO induces the phosphorylation of IκB (inhibitor of NF-κB) and, thus, 
activate the NF-κB in erythroid cells, which in turn enhances the transcriptional activity 
of target genes encoding antiapoptotic molecules, such as XIAP and c-IAP2 
[Digicaylioglu & Lipton, 2001]. Fourth, EPO induces heat shock protein 70 (Hsp70), 
promoting antiapoptotic effects by inhibition of apoptosis protease-activating factor-1 
and of apoptosis-inducing factor [Yang et al., 2003]. All these pathways play a crucial 
role in the regulation of erythro-specific genes to stimulate erythropoiesis by the control 
of cell proliferation, differentiation and apoptosis [Nairz et al., 2011].  
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 10. Schematic representation of the signaling pathways of EPO  
[adapted of Rossert & Eckardt, 2005]. 
Legend: (A) Phosphorylation of the STAT5 transcription factor; (B) Phosphorylation of PI3-K/Akt;  
(C) Phosphorylation of IκB; (D) Activation of Hsp70. 
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Interestingly, EPO also has non-hematopoietic properties through EPOR interaction 
that are expressed on various nonerythroid tissues [Brines & Cerami, 2005; Jelkmann, 
2007], where it plays a role in the reduction in oxidative stress, apoptosis and 
inflammation due to hypoxia, toxicity or injury [Calo, Bertipaglia & Pagnin, 2006; 
Chateauvieux et al., 2011; Nairz, Sonnweber, Schroll, Theurl & Weiss, 2012; Stoyanoff, 
Todaro, Aguirre, Zimmermann & Brandan, 2014]. The presence of mRNA encoding the 
EPOR has been detected in brain, retina, heart, skeletal muscle, kidney and 
endothelial cells [Rossert & Eckardt, 2005]. The protective activity of EPO may be due, 
in some tissues, to the presence of a tissue-protective receptor that is a heterodimeric 
receptor composed of EPOR subunits disulfide linked with beta common receptors 
(βcR) (FIGURE 11) [Brines et al., 2004].  
 
 
 
 
 
 
 
 
 
 
 
FIGURE 11. Erythropoietin signals via two distinct receptor isoforms [adapted of Cerami, 2011]. 
Legend: EPO - Erythropoietin; EPOR - Erythropoietin receptor; βcR - Beta common receptors. 
 
The affinity of EPO for the EPOR/βcR receptor is low, but once it interacts with its 
ligand, the presence of the ligand is no longer required for bioactivity [Cerami, 2011; 
Hand & Brines, 2011]. So, the tissue-protective properties of EPO are reached with 
higher dosage than needed for its circulating hormonal effects and, concurrently, high 
doses of EPO are associated with side effects and abnormally increased 
erythropoiesis. To circumvent the side effects while preventing the cytoprotective 
activities of EPO, different non-erythropoietic EPO derivatives have been developed 
either by chemically modifying or mutating EPO [Chateauvieux et al., 2011]. 
 
Currently, there are several erythropoiesis-stimulating agents (ESA) available in the 
European Union, namely epoetin alfa, epoetin beta, epoetin zeta, epoetin theta, 
darbepoetin alfa, and continuous EPOR activator [Locatelli & Del Vecchio, 2011]. 
Epoetins alfa and beta are widely used and have relative short half-lives (6–8 hours IV 
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and 19–24 hours SC), and their optimal administration schedule is two or three times 
weekly IV or SC Epoetins zeta and theta are biosimilars of epoetin alfa, which are 
similar but not identical to their reference product, because their chemical 
characteristics directly depend on the manufacturing process, which cannot be 
precisely duplicated. The last two ESA have much longer half-lives than others of 25-
48 hours or 130 hours, respectively, promoting an administration less frequent 
[Locatelli & Del Vecchio, 2011; Bernieh et al., 2014]. In general, all ESA are effective in 
correcting renal anemia and increasing hemoglobin levels, but the choice of which to 
use should also take into account their pharmacokinetics and pharmacodynamics, their 
administration route, and economic issues [Locatelli & Del Vecchio, 2011]. However, 
the expert opinion is that the likelihood of differences in clinical outcomes among ESA 
brands is low, although there is no robust evidence supporting this assumption [Willis 
et al., 2012]. 
Carbamylated EPO is a modified EPO with tecidual protective action 
devoid of erythropoietic activity, binds to these heterodimeric receptors and exerts 
tissue protective effects, while it does not bind to the classical EPOR and does not 
stimulate erythropoiesis [Brines et al., 2004; Leist et al., 2004; Fiordaliso et al., 2005]. 
This is the first evidence suggesting that EPOR expressed in different tissues are not 
identical [Rossert & Eckardt, 2005].  
In fact, EPO benefits have been studied in several nonerythroid tissues, such as brain, 
heart and kidney injuries [Sakanaka et al., 1998; Parsa et al., 2003; Yang et al., 2003]. 
In 1998, Sasaki’s group [Sakanaka et al., 1998] reported that intraventricular infusion of 
EPO might protect neurons against ischaemic injury. Following this pioneer work, 
experimental data have shown that systemic injections of large doses of EPO can 
decrease brain or spinal cord damage in various experimental models. EPO also has 
protective effects in experimental models of multiple sclerosis or status epilepticus 
[Brines et al., 2000; Agnello, 2002] and it can prevent or partially reverse experimental 
diabetic neuropathy [Bianchi et al., 2004]. These neuroprotective effects are associated 
with a strong inhibition of apoptosis [Siren et al., 2001; Celik et al., 2002; Junk et al., 
2002] and with neurotrophic activity of EPO [Siren et al., 2001].  
Regarding cardiovascular injuries, consistent with data from knockout mice, which 
show that the heart expresses functional EPOR, injections of large doses of EPO can 
protect against the consequences of transient or permanent coronary artery occlusion 
[Parsa et al., 2003; Moon et al., 2003; Calvillo et al., 2003; Wright et al., 2004]. After 
the initial phase, animals treated with EPO exhibited a reduction in myocardial damage, 
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as assessed by histological analyses and by measurement of haemodynamic 
parameters. These improvements were associated with decreased apoptotic cell death 
[Parsa et al., 2003; Moon et al., 2003; Calvillo et al., 2003].  
In kidney injuries, since 2003, different groups have shown that pretreatment of 
animals with EPO can protect the kidney against ischaemia–reperfusion injury [Yang et 
al., 2003; Patel et al., 2004; Sharples et al., 2004; Gong et al., 2004; Vesey et al., 
2004]. In these studies, injection of EPO at a dose ranging from 300 to 5000 IU/kg 
provided effective protection against renal dysfunction and reduced morphological 
damage. These protective effects were associated with a decrease in apoptotic cell 
death and in caspase activity, but not with increased cell proliferation [Yang et al., 
2003; Sharples et al., 2004]. Furthermore, many studies have also been developed to 
evaluate the influence of EPO in other organ injuries, resulting in positive benefits for 
some diseases, such as liver, pancreatic, retinal and lung injuries [Sepodes et al., 
2006; Ucan et al., 2009; Olgun 2013; Rocha et al., 2015].   
In colon injuries, it has been studied the influence of EPO in experimental models of 
IBD with rodents and, in fact, there are several potential explanations for the protective 
effect of EPO requiring more research (FIGURE 12). 
The inflammation and apoptosis are two distinct phenomena that contribute to the 
tissue deterioration and its regulation by EPO borrows a common part of the signaling 
pathway [Chateauvieux et al., 2011]. As already mentioned, primary investigations on 
the signaling pathways involved EPO demonstrated the phosphorylation and activation 
of JAK1/2, STAT3, STAT5a and PI3K [Chatagner et al., 2010]. Regarding antiapoptotic 
properties of EPO, Akt is able to induce the production of endothelial nitric oxide 
synthase (eNOS), NO, and Bcl2 [Dodd et al., 2000]; inhibition of caspase 3 and 
caspase 8 [Kim et al., 2000]; and is activated by EPOR through PI3K [Beleslin-Cokic et 
al., 2004]. EPO inhibits apoptosis through the activation of Akt, as well as the 
phosphorylation of GSK-3β to its inactive form [Fu & Arcasoy, 2007]. GSK-3β is known 
to be involved in the apoptosis by inhibiting Bcl2 and activating the proapoptotic protein 
BAX. In fact, the implication of Akt in tissue protection, angiogenese, inhibition of 
apoptosis and inflammation triggered by EPO appear to be involved in various 
signaling pathways [Chateauvieux et al., 2011]. 
 
The first studies linking EPO and inflammation showed an inhibition of inflammation by 
the induction of PI3K, activator protein 1 (AP-1) and eNOS via Akt activation [Rui et al., 
2005], as well as the inhibition of the expression of IL-6, TNF-α, and IL-1β via STAT3/5 
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signaling [Li et al., 2006a]. Furthermore, pro-inflammatory protein COX-2 was also 
studied in the regulation of inflammation by EPO. On the one hand, the inhibition of 
COX-2 expression is coupled with the activation of the extracellular signal-regulated 
kinase (ERK)1/2 and is independent of Akt and STAT5 modulation [Li et al., 2006b]. On 
the other hand, EPO induces the expression and activity of COX-2 and subsequently 
the production of its products, such as PGE2 and PGF2α [Liu et al., 2006b]. Another 
study also reported the induction of IL-10 and the inhibition of NF-κB by EPO [Liu et al., 
2006a]. NF-κB plays a key role in the pathophysiology of clinically important diseases 
in most organ systems, namely in the gut [Spehlmann & Eckmann, 2009]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 12. Overview of molecules and pathways implicated in tissues protection 
[adapted of Chateauvieux et al., 2011]. 
Legend: Solid lines - Established relationship; Dashed lines - Direct relationships not proved; Arrow - Positive regulation;       
Bar - Inhibition; Green proteins - Reperfusion injury salvage kinases; Blue proteins - Cytokines. 
Inflammation 
Ischemia 
Angiogenesis 
Apoptosis 
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NF-κB is a key regulator of inducible expression of many genes involved in immune 
and inflammatory response (FIGURE 13) [Spehlmann & Eckmann, 2009]. The NF-κB 
family of proteins consists of five members in mammals, c-Rel, RelA (p65), RelB, NF-
κB1 and NF-κB2 (p100), which all share a conserved Rel-homology domain 
responsible for DNA-binding activity, protein dimerization, and nuclear translocation. 
These subunits form homodimers or heterodimers, which constitute the 
transcriptionally active or suppressive forms of NF-κB. Inactive NF-κB is located in the 
cytosol complexed with an inhibitory protein, IκB. Ligand binding to particular 
membrane or cytosolic receptors leads to activation of the key enzyme, IκB kinase 
(IKK) [Spehlmann & Eckmann, 2009]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 13. Regulation of NF-κB expression [adapted of Viennois, Chen & Merlin, 2012]. 
Legend: TNF-α - Tumor necrosis factor α; IL - Interleukin; LPS - Lipopolysaccharide; IκB - Inhibitory κB;  
IKK - IκB kinase; NF-κB - Nuclear transcription factor kappa B. 
 
Pro-inflammatory cytokines and bacterial pathogens activate NF-κB, mostly through 
IKK-dependent phosphorylation and degradation of IκB proteins. NF-κB induced 
cytokines contribute to the stimulation, activation and differentiation of immune cells, 
thus perpetuating inflammation [Neurath, Pettersson, Meyer zum Buschenfelde & 
Strober, 1996].  
 
Recent findings in gene-targeted mice indicate that NF-κB has more diverse functions 
than initially anticipated, governing both protective and destructive responses (FIGURE 
14), which depend on the cell types involved and the specific pathophysiological 
condition. NF-κB predominantly acts in epithelial protection in homeostasis and certain 
acute inflammatory events by inducing the transcription of antimicrobial and 
antiapoptotic products. However, the cytokine-inducing and anti-apoptotic functions of 
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NF-κB in macrophages and T cells are predominant under chronic inflammatory 
conditions [Spehlmann & Eckmann, 2009].   
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 14. Intestinal protection and destruction induced by NF-κB  
[adapted of Spehlmann & Eckmann, 2009]. 
Legend: Hsp70 - Heat shock protein 70; IL - Interleukin; IFN-γ - Interferon-γ;  
STAT - Signal transducer and activator of transcription protein; NF-κB - Nuclear transcription factor kappa B. 
 
Mucosal inflammation in patients with IBD and in experimental models of intestinal 
inflammation is accompanied by elevated levels of activated NF-κB [Spehlmann & 
Eckmann, 2009]. In parallel, expression of prototypic NF-κB target genes, including IL-
1β, IL-6, TNF-α, and IL-12 p40 is increased [Sanchez-Munoz, Dominguez-Lopez & 
Yamamoto-Furusho, 2008]. Given that many of these gene products promote 
inflammation, it has been reasoned that inflammation in IBD and other conditions can 
be attenuated through inhibition of NF-κB activity [Spehlmann & Eckmann, 2009]. 
So, many established drugs are known to mediate, at least in part, anti-inflammatory 
effects of inflammation score via inhibition of NF-κB activity. NF-κB has been shown to 
be critically important in chronic inflammatory diseases, suggesting an anti-
inflammatory strategy in IBD [Neurath et al., 1996]. Novel approaches that protect and 
salvage injured colon tissue would constitute important advances in the therapy of IBD 
[Cuzzocrea et al., 2004]. In this sense, EPO can be a possible new strategy of IBD 
[Cuzzocrea et al., 2004] and some studies have been developed to evaluate its efficacy 
(TABLE 7). 
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TABLE 7. Experimental studies with EPO in chemically induced colitis models. 
CHEMICALLY 
INDUCED 
COLITIS 
RODENT 
EPO 
DOSE 
TREATMENT EVALUATED PARAMETERS REFERENCE 
DSS Mice 5000 IU/Kg SC 
Daily starting 
day 1 
(12 days) 
Body weight, histology, 
IFN-γ, TNF-α, e-selectin 
Nakamura  
et al., 2015 
DNBS Rats 1000 IU/Kg SC 
Daily starting 
day 2           
(4 days) 
CD4+, CD8+,  
caspase-3, histology 
Tasdemir  
et al., 2013 
TNBS 
(associated 
infection) 
Mice 5000 IU/Kg IP 
Daily starting 
day 2                  
(5 days) 
Body weight , nitrite,  
TNF-α, IL-6, luciferase, 
NF-κB, histology,  
NO, IL-23 
Nairz  
et al., 2011 
DNBS Mice 1000 IU/Kg IP 
Daily starting 
day 2                    
(4 days) 
Body and colon weight, 
MPO, TNF-α, IL-1β,  
PAR, ICAM-1,  
nitrotirosine, histology 
Cuzzocrea  
et al., 2004 
 
Legend: DSS - Dextran sulfate sodium; DNBS - Dinitrobenzene sulfonic acid; TNBS - Trinitrobenzene sulfonic acid; SC – Subcutaneous; 
IP – Intraperitoneal; IFN-γ - Interferon-γ; TNF-α - Tumor necrosis factor α; IL – Interleukin; NF-κB - Nuclear transcription factor kappa B; 
NO - Nitric oxide; MPO – Myeloperoxidase; PAR - Proteinase-activated receptors; ICAM-1 - Intercellular Adhesion Molecule 1. 
 
Encouraged by the substantial body of evidence demonstrating the sizable beneficial 
effects of EPO in models of nervous system injury and ischemia/reperfusion, 
Cuzzocrea and colleagues (2004) designed a study to evaluate the possible beneficial 
effects of EPO treatment in rodent model of dinitrobenzene sulfonic acid (DNBS)-
induced colitis. For the first time, demonstrated that EPO is protective to colon injuries 
and that inhibition of TNF-α formation (among other MPO effects that include inhibition 
of neutrophils infiltration) in the colon probably accounts for its beneficial effects. Since 
then, there were published two studies, evaluating the anti-inflammatory EPO effect on 
the experimental colitis. In fact, EPO inhibits the induction of pro-inflammatory genes 
including TNF-α and inducible NO synthase in activated macrophages, which is 
mechanistically attributable to blockage of NF-κB p65 activation [Cuzzocrea et al., 
2004; Nairz et al., 2011]. Particularly, there is only one published study, where the 
influence of EPO in TNBS-induced colitis is evaluated, but mice are under an intestinal 
infection framework [Nairz et al., 2011]. So, future studies are needed to clarify the anti-
inflammatory property of EPO treatment [Cuzzocrea et al., 2004].  
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2.  THIADIAZOLIDINONE-8 
The somehow chemical structure-related derivatives to TDZD, and already approved 
by FDA are the thiazolidinediones (TDZ), such as rosiglitazone, pioglitazone, and 
troglitazone, are known as agonists of the peroxisome proliferator-activated receptor 
(PPAR)γ [Lehmann et al., 1995; Willson, Brown, Sternbach & Henke, 2000]. PPAR are 
members of the nuclear hormone receptor superfamily of ligand-activated transcription 
factors (FIGURE 15), which includes retinoid, steroid, and thyroid hormone receptors that 
regulate transcription of distint genes through heterodimerization with the retinoid X 
receptors [Schoonjans, Staels & Auwerx, 1996]. Currently, TDZ are used as anti-
diabetic agents and have been authorized in the European Union for combination with 
a glucose-lowering sulphonylurea (for patients in whom metformin is ineffective or 
poorly tolerated) or with metformin (for obese patients) [Krentz & Bailey, 2005]. The 
PPARγ receptor subtype seems to play a pivotal role in the regulation of cellular 
proliferation, differentiation, and inflammation. Furthermore, PPARγ agonists have 
demonstrated to have anti-inflammatory effects on astrocytes and microglial cells, 
inhibiting the production of proinflammatory and neurotoxic products. It has been 
recently shown that PPARγ ligands, including thiazolidinediones, have potent anti-
inflammatory effects, such as the suppression of TNF-α and IL-1β, inducible nitric-
oxide synthase (iNOS), and COX-2 [Jiang, Ting & Seed, 1998; Ricote, Huang, Welch & 
Glass, 1999; Maggi et al., 2000; Bernardo, Levi & Minghetti, 2000; Marx et al., 2000; 
Han et al., 2000; Subbaramaiah, Lin, Hart & Dannenberg, 2001].  
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 15. Regulation of PPARγ pathway by thiazolidinediones [adapted of Heuvel, 2009]. 
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Many studies have been performed in order to study the influence of structural 
modifications in these molecules on its biological activity [Castro et al., 2008]. Thus, 
TDZD are small heterocyclic molecules, which were synthesized following a pathway 
that is based on the reactivity of N-alkyl-S-(N´-(chlorocarbonyl)amino) isothiocarbamoyl 
chlorides with isocyanates [Ottman & Hooks, 1966]. The inhibitory kinase activity of 
these compounds, considering as secondary products in the obstention of potassium 
channel openers [Martinez, Castro, Cardelus, Llenas & Palacios, 1997], muscarinic 
agonist [Martinez et al., 1999], or acetylcholinesterase inhibitors [Martinez et al., 2000], 
was discovered in a GSK-3 directed screening program initiated two years ago 
[Martinez et al., 2002b]. Currently, their structural key features have been established. 
Preliminary structure–activity relationship studies point out to the size and the nature of 
the substituents attached to both nitrogen atoms of the TDZD as crucial features for 
GSK-3 inhibition. Additionally, carbonyl or thiocarbonyl moieties in a 1,3-disposition on 
the heterocyclic framework may be critical for binding. Moreover, a hypothetical GSK-3 
binding mode has been proposed in where the TDZD derivatives may bind to the 
primed phosphate substrate-binding site of the kinase. Interactions of TDZD with the 
main amino acids involved in this recognition site (Arg 96, Lys 205, Tyr 216) of GSK-3 
explain the structure–activity relationships found in this family of compounds until now 
[Martinez et al., 2002b].  
 
In 2002, Martinez and his group described the synthesis, structure-activity relationship 
and a hypothetical binding mode of new TDZD heterocyclic non-ATP competitive GSK-
3β inhibitors [Martinez et al., 2002a; Dugo et al., 2007]. Of these, the 4-benzyl-2-
methyl-1,2,4-thiadiazolidine-3,5-dione (TDZD-8) was considered the most effective 
(FIGURE 16) [Martinez et al., 2002a]. It is a small molecule with favorable pharmacokinetic 
properties, such as good oral bioavailability and blood-brain barrier penetration [Alonso 
et al., 2004]. The capacity of TDZD to suppress the expression of inflammatory 
cytokines and present tissue protective action by GSK-3β inhibiton suggests that this 
agent may be effective in the treatment of several inflammatory diseases [Luna-Medina 
et al., 2005].  
 
 
 
 
 
 
FIGURE 16. Chemical structure of TDZD [adapted of Martinez et al., 2002b]. 
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Currently, there are several GSK-3β inhibitors, some already used for the treatment of 
various diseases, namely lithium, valproic acid, insulin and some purines derivatives 
(like SB216763 and SB415286) [Martinez et al., 2002b; Dugo et al., 2007]. However, 
the toxicity, associated side-effects and concerns regarding the absorption, distribution, 
metabolism and excretion of these inhibitors affect their clinical potential [Meijer, 
Flajolet & Greengard, 2004]. Generally, these GSK-3β inhibitors have some possible 
obstacles, since the chronic suppression of this kinase may lead to cardiac 
complications and increase the propensity for developing certain cancers. Furthermore, 
these compounds are ATP competitive, and therefore, block the phosphorylation of 
every substrate [Martinez et al., 2002b]. However, the discovery of the way in which 
‘‘primed’’ substrates dock with GSK-3 might have opened a new opportunity to develop 
compounds that target only the site that binds the ‘‘priming phosphate’’ of substrates 
[Martinez et al., 2002b]. So, TDZD compounds, the only non ATP-competitve GSK-3 
inhibitors known until the moment, might be less likely to be oncogenic in contrast to 
ATP competitive inhibitors. Clearly, the clinical utility of these drugs awaits animal and 
human trials [Martinez et al., 2002b]. 
GSK-3 is a serine/threonine protein kinase highly abundant in brain, involved in the 
regulation of glycogen by insulin [Martinez et al., 2002b]. In 1980, Embi and colleagues 
identified GSK-3 as one of the protein kinases able to phosphorylate glycogen 
synthase [Embi, Rylatt & Cohen, 1980]. The signalling pathway by which insulin inhibits 
GSK-3 and contributes to the stimulation of glycogen and protein synthesis is a fact 
well established now-a-days (FIGURE 17) [Martinez et al., 2002b]. The binding of insulin to 
its receptor activates the intrinsic protein tyrosine kinase activity of the receptor, 
allowing it to phosphorylate itself at several sites. One phosphotyrosine residue 
interacts with the phosphotyrosine-binding domain of the insulin receptor substrate 
proteins (IRS1 and IRS2), recruiting them to the plasma membrane, where they 
undergo phosphorylation by the insulin receptor. As a result, they interact with the Src-
homology-2 domains of the p85 subunit of PI3K. This recruits PI3K to the plasma 
membrane, enabling the p110 catalytic subunit to catalyse the formation of 
phosphatidylinositol-3,4,5-trisphosphate (PtdIns(3,4,5)P3) from PtdIns(4,5)P2. 
PtdIns(3,4,5)P3 binds to the pleckstrin homology domains of both PDK1 and PKB/Akt, 
co-localizing them at the membrane and allowing PDK1 to activate PKB/Akt. PKB/Akt, 
in turn, phosphorylates and inhibits GSK-3, resulting in the dephosphorylation of 
substrates of GSK-3, including glycogen synthase and eIF2B. This contributes to the 
insulin-induced stimulation of glycogen and protein synthesis [Cohen, 2001]. 
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FIGURE 17. GSK-3 signalling pathway by insulin receptors [adapted of Cohen, 2001]. 
Legend: pY – phosphotyrosine residue; PDK1 - 3-Phosphoinositide-dependent protein kinase 1;  
PKB/Akt - Protein kinase B; eIF2B - Eukaryotic initiation factor 2B. 
 
Initially, the functions of GSK-3 were thought to be limited to glycogen metabolism; 
however, 20 years after its discovery, we know that this kinase also has a major role in 
Wnt and Hedgehog signaling pathways and is involved in the regulation of many cell 
functions, including the specification of cell fate during embryonic development, cell 
division and apoptosis, and signaling by insulin, growth factors and nutrients (FIGURE 18) 
[Frame & Cohen, 2001; Meijer et al., 2004; Whittle et al., 2006]. Today, it is known that 
GSK-3 phosphorylates, and thereby, regulates the functions of many metabolic, 
signaling and structural proteins. Notable among the signaling proteins regulated by 
GSK-3 are many transcription factors, including AP-1, cyclic AMP response element 
binding protein, nuclear factor of activated T cells, heat shock factor-1, β-catenin and 
NF-κB [Martinez et al., 2002b]. More specifically, a proportion of GSK3 in cells is 
present in a multiprotein complex together with axin, the adenomatous polyposis coli 
protein and β-catenin. In the absence of secreted glycoproteins, called WNTs, the 
GSK3 in this complex is active and phosphorylates axin, adenomatous polyposis coli 
and beta-catenin. Axin is stabilized by phosphorylation, but phosphorylation of β-
catenin targets it for ubiquitylation and subsequent proteolytic destruction. The role of 
adenomatous polyposis coli phosphorylation is less clear, but it seems to enhance its 
interaction with beta-catenin. After the binding of WNTs to their receptors, a signal-
transduction pathway is triggered that has yet to be fully elucidated, but which seems to 
involve a protein, termed dishevelled (DVL), which, together with FRAT (frequently 
rearranged in advanced T-cell lymphomas), results in the displacement of axin (and 
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hence adenomatous polyposis coli and β-catenin). This leads to the dephosphorylation 
of axin, adenomatous polyposis coli and β-catenin. The dephosphorylation of β-catenin 
leads to its accumulation in cells and translocation to the nucleus, where it binds to 
members of the T-cell factor (TCF) family of transcription factors (also called LEF, for 
lymphoid-enhancer factor), and stimulates the transcription of genes that are required 
for embryogenesis. The same pathway is likely to be involved in regulating the 
expression of other genes in adult tissues. 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 18. GSK-3 signalling pathway by insulin receptors [adapted of Cohen & Frame, 2001]. 
Legend: APC - adenomatous polyposis coli; GSK - Glycogen synthase kinase; TCF - T-cell factor;  
FRAT - Frequently rearranged in advanced T-cell lymphomas; DVL - Termed disheveled. 
 
GSK-3 has two isoforms, GSK-3α and GSK-3β, encoded by distinct genes and the 
most common regulatory mechanism is inhibition by phosphorylation of Ser21 in GSK-
3α or Ser9 in GSK-3β [Beurel, Michalek & Jope, 2009]. These isoforms are 
ubiquitously expressed, highly homologous and usually have equivalent actions. 
However, they can have distinct biological roles in some specific pathways. Currently, it 
is known that GSK-3β plays a fundamental role in the regulation of the activity of NF-κB 
and, for this reason, it has been investigated the effects of this protein kinase in the 
regulation of inflammatory process [Ali, Hoeflich & Woodgett, 2001; Frame & Cohen, 
2001; Dugo et al., 2007]. NF-κB is a known key transcription factor for the genes 
involved in the production of pro-inflammatory mediators [Karin, Yamamoto & Wang, 
2004]. This concept was first base on the findings that GSK-3β gene-deleted mice 
exhibit a phenotype comparable to that of mice in which the gene for NF-κB subunit 
p65, or the IKK 2 involved in the activation of NF-κB, had been deleted [Hoeflich et al., 
2000]. Deletion of the GSK-3β gene had no effect on TNF-α-induced IκB-α 
degradation, but did prevent the activation of NF-κB [Hoeflich et al., 2000]. The few 
PHARMACOLOGICAL MODULATION OF INFLAMMATION ASSOCIATED WITH INFLAMMATORY BOWEL DISEASE 
CHAPTER 3 – NEW PHARMACEUTICAL APPROACHES OF INFLAMMATORY BOWEL DISEASE            60 
findings suggest that the inhibition of GSK-3β promotes a reduction of activation of NF-
κB. Probably, GSK-3β is able to affect NF-κB activity at different sites (FIGURE 19), 
namely the phosphorylation of IκB-α, the translocation of p50/p65 to the nucleus, its 
binding to DNA and/or phosphorylation of p65 [Schwabe & Brenner, 2002; Sanchez et 
al., 2003; Takada, Fang, Jamaluddin, Boyd & Aggarwal, 2004]. 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 19. Possible sites for GSK-3β activity on NF-κB regulation  
[adapted of Dugo et al., 2007]. 
Legend: TNF-α - Tumor necrosis factor α; IκB - Inhibitory κB; GSK - Glycogen synthase kinase;  
IKK - IκB kinase; LPS – Lipopolysaccharide. 
  
Furthermore, the inactivation of GSK-3β is also mediated by Akt (one of the most 
important physiological mediators of the PI3K survival pathway). Both studies in vitro 
and in vivo have demonstrated that the activation of PI3K-Akt pathway promotes the 
inactivation of GSK-3β by phosphorylation of Ser9, thereby providing an anti-apoptotic 
effect [Cross, Alessi, Cohen, Andjelkovich & Hemmings, 1995; Hurel et al., 1996; 
Moule et al., 1997; Dugo 2007].  
 
Many recent studies suggest GSK-3β has become a novel and important therapeutic 
target in inflammatory and autoimmune diseases and, consequently, several 
pharmacological inhibitors of this kinase have been developed and studied in vitro and 
in preclinical studies in vivo [Cohen & Goedert, 2004; Beurel et al., 2009]. The inhibition 
of GSK-3β activity can be useful in several diseases, including the treatment of 
neurodegenerative diseases, diabetes type II, bipolar disorders, stroke, sepsis, cancer 
and chronic inflammatory disease [Martinez et al., 2002a; Meijer et al., 2004]. In the 
last few years, several potent and specific inhibitors of GSK-3β have been developed 
by the pharmaceutical industry and academic centers due to their therapeutical ability 
and, hence, their potential to be of benefit in a vast number of diseases [Martinez et al., 
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2002b; Cohen & Goedert, 2004]. Althought previous studies in animal models have 
suggested that some GSK-3β inhibitors have anti-inflammatory effect in vivo, the full 
pharmacological profile and selectivity of these agents awaits further evaluation [Dugo 
et al., 2005; Whittle et al., 2006]. 
 
Briefly, many drugs are known to promote anti-inflammatory effects through inhibition 
of GSK-3β with consequently suppression of NF-κB signaling pathway, via reduction of 
phosphorylation of IκB-α [Buss et al., 2004; Takada et al., 2004; Puangpraphant et al., 
2013]. In fact, GSK-3β inhibition has been shown to be critically important in chronic 
inflammatory diseases, suggesting an anti-inflammatory strategy in IBD [Whittle et al., 
2006]. Since novel approaches in the management of injured colon tissue would 
constitute important advances in the therapy of IBD [Cuzzocrea et al., 2004], some 
studies have been developed to evaluate the efficacy of GSK-3β inhibitors in this 
disease (TABLE 8).  
 
TABLE 8. Experimental studies with GSK-3β inhibitors in chemically induced colitis models. 
CHEMICALLY 
INDUCED 
COLITIS 
RODENT 
DRUG 
USED 
TREATMENT 
EVALUATED 
PARAMETERS 
REFERENCE 
TNBS Rats Geraniol  Daily                   (11 days) 
Body weight, MPO,                   
caspase-3, NO, IL-1β, 
ICAM-1, NF-κB, MAPK, 
PGE2, PPARγ, MDA 
Soubh et al.,   
2015 
DSS Mice Carbon 
monoxide 
Single 
inhalation  
at day 6 
Body weight ,  
colon lenght, iNOS,  
IL-10, TNF-α,  
GSK-3β, histology 
Udin et al.,  
2013 
DNBS Rats Yerba 
mate tea 
Daily 
(8 days) 
Body weight, colon 
length, histology,  
NF-κB, GSK-3β, IκB-α, 
iNOS, COX-2 
Puangpraphant 
et al., 2013 
TNBS Rats 
TDZD-8 
0.1; 0.33; 1 
mg/Kg SC 
Twice a day 
(3 days) 
Body and colon weight, 
TNF-α, MPO, NF-κB, 
protein levels, 
macroscopic score,  
% area inflamatory 
Whittle et al.,  
2006 
 
Legend: TNBS - Trinitrobenzene sulfonic acid; DSS - Dextran sulfate sodium; DNBS - Dinitrobenzene sulfonic acid;  
TDZD-8 - Thiadiazolidinone-8; MPO – Myeloperoxidase; NO - Nitric oxide; IL – Interleukin; MDA – Malondialdehyde;  
ICAM-1 - Intercellular adhesion molecule-1; NF-κB - Nuclear transcription factor kappa B; MAPK - Mitogen-activated protein kinases;  
PG – Prostaglandin; PPARγ - Peroxisome proliferator-activated receptor γ; iNOS - Inducible nitric-oxide synthase;  
TNF-α - Tumor necrosis factor α; GSK-3β - Glycogen synthase kinase 3β; IκB - Inhibitory κB; COX-2 – Cyclooxygenase-2. 
 
Since TDZD-8 can be a possible new strategy of IBD, it is crucial to implement 
preclinical studies to evaluate the real efficacy of this compound in IBD [Whittle et al., 
2006]. Curiously, the assessment of TDZD-8 effect in experimental colitis was tested 
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for the first time in 2006. Since that this was the unique study where the TDZD-8 effect 
was explored in IBD until nowadays. The findings of Whittle and colleagues revealed 
that the administration of TDZD-8 promotes a reduction of the colonic inflammation, of 
tissue injury and a reduced decline in body weight [Whittle et al., 2006]. Furthermore, 
the observed increase in the levels of the proinflammatory cytokine TNF-α in the 
inflamed colon was significantly reduced by TDZD-8. The mechanisms underlying this 
anti-inflammatory action may be related to downregulation of NF-κB activity (by GSK-
3β inhibition), involved in the generation of proinflammatory mediators. Additionally, it 
was found the existence of multiple beneficial effects of TDZD-8, but lacks potential 
explanations of its mechanism of action [Whittle et al., 2006]. So, more studies are 
needed to evaluate the anti-inflammatory effect of TDZD-8 in IBD. 
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3. HEMIN 
Hemin is an enzyme inhibitor that is derived from processed red blood cells and was 
formerly known as hematin. The term hematin describes the chemical reaction of 
hemin and sodium carbonate solution. Hemin, or ferriprotoporphyrin IX chloride, is an 
iron-containing metalloporphyrin and hematin is prepared from outdated HBAg 
negative human blood [Abbott Laboratories, 1997]. In 1971, hemin became the 
rationale for treatment of acute porphyria [Bonkowsky et al., 1971]. Given the rarity of 
acute attacks of porphyria, safety and efficacy information built slowly, case-by-case. 
By the late 1980s, however, a consensus existed, and a commercial formulation was 
developed (Panhematin®). It was the first therapeutic approved under the U.S. Orphan 
Drug Act of 1983 [Bissell & Wang, 2015]. Currently, hemin is used in the treatment of 
acute attacks of inducible porphyria (acute intermittent porphyria, variegate porphyria 
and hereditary coproporphyria). It is also used for the amelioration of recurrent attacks 
of acute intermittent porphyria that are temporally related to the menstrual cycle [Abbott 
Laboratories, 1997]. The clinical features of an acute attack include abdominal pain, 
mental symptoms, and a subacute polyneuropathy [Bosch, Pierach & Bossenmaier, 
1977; Walsh, 1977; Lamon & Tschudy, 1978; Anon, 1978; Pierach, 1982].  
 
The porphyria attack is accompanied by an induction of gamma-aminolevulinic acid 
synthetase, which is the rate limiting enzyme in heme biosynthesis. This induction is 
caused by the excessive production in the liver of porphyrin precursers alanine (delta-
aminolevulinic acid - ALA) and porphobilinogen (PBG). The fundamental defect in 
acute intermittent porphyria is a decrease in uroporphyrinogen I synthetase which 
leads to a partial deficiency of heme production. This deficiency in heme inhibits the 
negative feedback cycle on gamma-aminolevulinic acid synthetase, which accounts for 
the acute attack. IV infusion of hemin decreases the concentration of PBG and ALA in 
the blood of an anuric patient with acute porphyria [Bonkowsky et al., 1971]. 
 
The regular pathway of heme synthesis consists in combine the building blocks of 
heme, like succinyl CoA and glycine, to form ALA, the first committed intermediate of 
the pathway (FIGURE 20). ALA synthase is encoded by two distinct genes: ALAS2 in the 
bone marrow and ALAS1 elsewhere, including the liver. The second step involves 
condensation of two molecules of ALA to form PBG, the pyrrole subunit of the heme 
ring. Four PBG are linked initially in a linear tetrapyrrole, hydroxymethylbilane, which 
cyclizes to form the initial porphyrin of the pathway, uroporphyrinogen. The sequential 
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conversion of uroporphyrinogen to coproporphyrinogen and finally to 
protoporphyrinogen involves successive removal of peripheral carboxyl groups. Heme 
is the end-product and exerts feedback regulation on the formation of ALA, the initial 
committed intermediate [Bissell & Wang, 2015]. 
 
 
 
 
 
 
 
 
 
 
FIGURE 20. The pathway of heme synthesis and the enzymes mediating specific steps 
[adapted of Bissell & Wang, 2015]. 
Legend: ALA - Delta-aminolevulinic acid; PBG - Porphobilinogen; UROgen - Uroporphyrinogen;  
COPROgen - Coproporphyrinogen; PROTO – Protoporphyrin; PROTOgen – Protoporphyrinogen; CO – Carbon monoxide; Fe – Iron. 
 
Hemin is also well known as an inducer of heme oxygenase (HO) [Guan et al., 2009; 
Hualin et al., 2012]. Many studies have reported the protective effect of hemin via HO-1 
induction in various animal models [Guan et al., 2009; Hualin et al., 2012]. A wide 
variety of compounds with therapeutic properties have been recognized as inducers of 
HO-1. The induction of this enzyme, or its catalytic activity by either natural or synthetic 
compounds, may represent an effective strategy to intervene in several pathologic 
conditions [Ferrándiz & Devesa, 2008]. With few exceptions, the response to HO-1 
inducers depends largely on transcriptional activation of the HO-1 gene and the 
synthesis of mRNA, regardless of cell type or inducing chemical [Ryter, Alam & Choi, 
2006]. Several studies with HO-1 inducers have been confirmed its beneficial effects in 
many diseases, such as hippocampal injury, renal fibrosis, cardiac 
ischemia/reperfusion, lung injury and sepsis [Guan et al., 2009; Naito et al., 2011; 
Hualin et al., 2012]. Thus, targeting HO-1 to achieve pharmacologic and therapeutic 
benefits is becoming widely accepted [Ferrándiz & Devesa, 2008]. 
 
HO is the rate-limiting enzyme in heme catabolism, a process that leads to the 
generation of equimolar amounts of biliverdin, free iron and CO [Maines, 1997]. Three 
mammalian HO isozymes have been identified, namely HO-1, HO-2 and HO-3. HO-1 is 
a stress-responsive protein induced by various oxidative agents [Naito et al., 2011]. 
HO-1 occurs at a high level of expression in the spleen and other tissues that degrade 
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senescent red blood cells, including specialized reticuloendothelial cells of the liver and 
bone marrow. In most other tissues not directly involved in erythrocyte or hemoglobin 
metabolism, HO-1 typically occurs at low to undetectable levels under basal conditions 
but responds to rapid transcriptional activation by diverse chemical and physical stimuli 
[Ryter et al., 2006]. HO-2 is a constitutively expressed isozyme and is found 
abundantly and ubiquitously in several systemic tissues including, but not limited to, the 
brain and central nervous system, vasculature, liver, kidney, and gut [Ryter et al., 2006; 
Naito et al., 2011]. HO-3 is a newly identified isoform, which is constitutively expressed 
in the liver, spleen, brain and kidney in rats, but its biological role requires further 
elucidation [Naito, Takagi & Yoshikawa, 2004]. Although both HO-1 and HO-2 catalyze 
the identical biochemical reaction, there are some fundamental differences between 
the two in genetic origin, primary structure and molecular weight. HO-1, once 
expressed under various pathological conditions, has an ability to metabolize high 
amounts free heme to produce high concentrations of its enzymatic by-products that 
can influence various biological events, and has recently been the focus of 
considerable medical interest [Abraham & Kappas, 2008].  
 
Indeed, HO-1 is highly inducible by a vast array of stimuli, including oxidative stress, 
heat shock, ultraviolet radiation, ischemia-reperfusion, heavy metals, bacterial 
lipopolysaccharide (LPS), cytokines, NO and elevated levels of its natural substrate, 
heme [Shibahara, 1988]. Accumulating evidence indicates that these inducers of HO-1 
activate protein phosphorylation-dependent signaling cascades that ultimately 
converge on the transcription factors that regulate the HO-1 gene (FIGURE 21) [Ryter et 
al., 2006]. Recent studies have implicated a major role for the mitogen-activated 
protein kinases (MAPK) in HO-1 activation, though other kinases, including tyrosine 
kinases, PI3K and protein kinases A, G, and C have also emerged as potential 
contributing mechanisms [Salinas et al., 2004; Ryter et al., 2006; Lin, Chiang & Chau, 
2008]. Particularly, increases of intracellular reactive oxygen species (ROS) lead to 
perturbation of intracellular thiol equilibrium, leading to reduction of glutathione/oxidized 
glutathione (GSH/GSSG) ratio, and redox regulation of Keap1. On the other hand, 
treatment with heavy metals and/or heme promotes NF-E2 related factor-2 (Nrf2) 
nuclear translocation and nuclear export of the transcriptional repressor Bach-1. 
Finally, activation of mitogen-activated protein kinase activities (MAPK) by 
environmental stresses and cytokines has also been implicated in HO-1 activation. The 
link between redox regulation and MAPK activation is not completely clear. Other 
nuclear factors involved in certain models include activation of Hif-1 (by hypoxia) and 
AP-1 (by hypoxia, and LPS) [Ryter et al., 2006; Naito et al., 2011].  
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FIGURE 21. Signaling pathways leading to HO-1 activation [adapted of Ryter et al., 2006]. 
Legend: GSH - Reduced glutathione; GSSG - Oxidized glutathione; MAPK - Mitogen-activated protein kinase;  
Nrf2 - NF-E2 related factor-2; Hif-1 - Hypoxia inducible factor; AP-1 - Activator protein-1;  
Bach-1 - HO-1 transcriptional repressor; ROS - Reactive oxygen species; NAC - N-acetyl-L-cysteine;  
DFO - Desferrioxamine; HO-1 - Heme oxygenase-1. 
 
The HO system, along with its catabolism products, is involved in a variety of crucial 
physiological functions, including cytoprotection, anti-inflammation, anti-oxidative 
effects, apoptosis, neuro-modulation, immune-modulation, angiogenesis and vascular 
regulation [Pittala, Salerno, Romeo, Modica & Siracusa, 2013]. Their beneficial 
properties may be probably attributed not only its own action, but also to other actions 
of three by-products of HO-1 activity (FIGURE 22). The degradation of the pro-oxidant 
heme by HO-1 itself, the signaling action of CO, the antioxidant properties of 
biliverdin/bilirubin and the sequestration of free iron by ferritin could all concertedly 
contribute to the anti-inflammatory effects observed with HO-1 [Naito et al., 2011].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 22. Mechanism underlying the biological actions of heme oxygenase  
[adapted of Naito et al., 2004]. 
Legend: ROS - Reactive oxygen species; CO - Carbon monoxide; MAPK - Mitogen-activated protein kinases. 
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The pharmacological application of CO mimics the HO-1 dependent cytoprotection and 
anti-inflammation in many injury models (FIGURE 23) [Naito et al., 2011]. CO is known to 
be an activator of soluble guanylate cyclase, akin to its classical regulator NO, 
promoting the increase of cGMP production and, consequently, smooth muscle 
relaxation by direct effects on the contractile machinery as well as by altering calcium 
homeostasis and voltage-gated ion channel activity [Carvajal, Germain, Huidobro-Toro 
& Weiner, 2000]. CO can also modulate MAPK, including the p38 MAPK, ERK, and c-
Jun N-terminal kinases (JNK) pathways [Ryter et al., 2006]. Thus, CO is able to inhibit 
the production of proinflammatory cytokines, such as TNF-α, IL-1β, and macrophage 
inflammatory protein-1 [Otterbein et al., 2000; Ryter et al., 2006]. The heat shock factor 
1 and Hsp70 may act as potential intermediates in this pathway [Ryter et al., 2006]. CO 
also inhibited the expression of other proinflammatory enzymes, such as iNOS and 
COX-2 via the regulation of NF-κB activation [Suh, Jin, Yi, Wang & Choi, 2006]. 
Furthermore, it has also been reported its anti-apoptotic potential due to inhibition of 
TNF-α in fibroblasts and endothelial cells by MAPK and NF-κB pathways [Petrache, 
Otterbein, Alam, Wiegand & Choi, 2000; Brovard et al., 2000; Zhang, 2003; Brovard et 
al., 2002]. Briefly, the potential physiological effects of CO include tissue specific 
protection throught its anti-inflammatory, anti-apoptotic, anti-proliferative, and anti-
thrombotic properties [Ryter et al., 2006]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 23. Potential signaling pathways activated by CO leading to tissue protection 
 [adapted of Ryter et al., 2006]. 
Legend: CO - Carbon monoxide; MAPK - Mitogen-activated protein kinases; JNK - c-Jun N-terminal kinases;  
ERK - Extracellular signal-regulated kinase; Hsp70 - Heat shock protein 70; IL – Interleukin; TNF-α - Tumor necrosis factor α. 
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Biliverdin, the first product of HO-catalyzed heme cleavage, is a soluble greenish 
pigment. Its enzymatic reduction by biliverdin reductase (BVR) produces bilirubin, a 
hydrophobic yellowish pigment that partitions to the lipid phase. Like CO, bilirubin is 
formally considered as a metabolic waste product with potentially harmful effects. 
Under normal physiological conditions, biliverdin and bilirubin are processed for rapid 
elimination. Whether during the course of their elimination these substances provide 
intrinsic benefit to an organism remains controversial and has provided fuel for recent 
debate. Potential antioxidative effects of bilirubin were first noted as early as 1976 
[Ryter 2006]. In normal physiological condition of oxidative stress, BVR catalyzes 
biliverdin to bilirubin and induces HO, which further provides more biliverdin from heme 
(FIGURE 24). And the resulting bilirubin may turn back to biliverdin partially by oxidants. 
This bicyclic nature of bilirubin system provides the efficient physiological antioxidative 
capacity. But in harsh conditions of high oxidative stress, BVR is catalytically 
inactivated and is blocked for nuclear translocation, which inhibits the induction of HO, 
resulting in inhibition of catalytic turnover of heme to biliverdin and also biliverdin to 
bilirubin, leading to oxidative damages of the biomolecules and finally to tissue injury 
[Kim & Park, 2012]. 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 24. Physiological network of the bicyclic bilirubin system in tissue injury  
[adapted of Kim & Park, 2012]. 
Legend: HO – Heme oxygenase; BVR - Biliverdin reductase; ROS - Reactive oxygen species. 
 
In fact, both molecules act as antioxidants in vitro and in vivo and their increased local 
concentrations after HO induction may be beneficial in protecting several types of cells 
from injury [Naito et al., 2011]. Bilirubin can scavenge peroxyl radicals in vitro as 
effectively as α-tocopherol, which is regarded as the most potent antioxidant against 
lipid peroxidation [Stocker, Yamamoto, McDonagh, Glazer & Ames, 1987]. Several 
Tissue injury 
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epidemiological studies indicate that mild to moderately elevated serum bilirubin levels 
are associated with a better outcome in diseases involving oxidative stress [Djousse, 
Rothman, Cupples, Levy & Ellison, 2003; Sedlak & Snyder, 2004]. Bilirubin also acts as 
an efficient scavenger of hypochlorous acid, a macrophage-derived oxidant [Stocker & 
Peterhans, 1989]. Finally, biliverdin and bilirubin also display in vitro reactivity toward 
various forms of reactive nitrogen species, including NO gas, NO donor compounds, 
and S-nitrosothiols, peroxynitrite, or nitroxyl anion, which is prevented by thiol 
antioxidants [Kaur et al., 2003; Mancuso, Bonsignore, Di Stasio, Mordente & Motterlini, 
2003]. These findings suggest that biliverdin and bilirubin can promote antioxidative 
and antinitrosative effects [Ryter et al., 2006].   
 
The iron released from heme by HO activity potentially enters such a pool of “labile” or 
“chelatable” iron, where it may be available for cellular processes that depend on iron 
[Ryter & Tyrrell, 2000]. One hypothesis states that the iron released from HO activity is 
transiently available for the promotion of intracellular ROS production. The potential 
reactions in which iron may play a catalytic role include but are not limited to the 
multiplication of lipid peroxidation chain reactions, the NO-dependent nitrosylation of 
thiols, and the Haber-Weiss reaction, which generates the reactive oxidant hydroxyl 
radical from the metal catalyzed decomposition of hydrogen peroxide [Halliwell & 
Gutteridge, 1999]. However, HO activity seems to have an antioxidative protection with 
respect to iron metabolism, facilitating further coupling with proteins that either promote 
the sequestration or export of the liberated iron. Cells that realize an excess of 
intracellular iron utilize these mechanisms to reduce intracellular iron levels [Eisenstein 
& Munro, 1990; Kuhn, 1998]. The enhancement of ferritin synthesis by high iron levels 
increases the iron storage capacity of the cell. Furthermore, ferritin synthesized as a 
consequence of HO activity has been proposed as a contributory mechanism 
underlying HO-dependent cytoprotection [Vile, Basu-Modak, Waltner & Tyrrell, 1994]. 
 
Indeed, HO-1 has clearly emerged as a therapeutic target that offers protection against 
several diseases. HO-1 induction using gene therapy or pharmacological modulation 
has shown promising results both in vitro and in vivo [Ferrándiz & Devesa, 2008]. Thus, 
a better understanding of the heme-HO system may result in novel therapeutic 
strategies for some important pathological disorders and in the development of novel 
inducers of HO-1. In the management of colitis, novel approaches would constitute 
important advances in the therapy of IBD [Cuzzocrea et al., 2004]. Some studies have 
been developed to evaluate the efficacy of HO-1 inducers in this disease (TABLE 9).  
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TABLE 9. Experimental studies with HO-1 inducers in chemically induced colitis models  
[adapted of Naito et al., 2011; Takagi et al., 2010]. 
CHEMICALLY 
INDUCED 
COLITIS 
RODENT DRUG USED TREATMENT 
EVALUATED 
PARAMETERS 
REFERENCE 
DSS Mice Hemin 
Once a day 
(at day 0, day 
1 and day 6) 
Treg, IL-17, 
HO-1 
Zhong et al.,  
2010 
DSS Mice Tranilast 
Once a day 
(at day 0, day 
2 and day 4) 
Body weight, 
colon lengh, 
TNF-α, IFN-γ, 
IL-17, IL-6, 
IL-10, HO-1, 
histology 
Sun et al.,  
2010 
DSS Mice CoPP 
Once a day 
(at day 1 and 
day 3) 
MPO, HO-1, 
histology 
Paul et al.,  
2005 
DSS Mice CoPP 3 times a day Body weight, HO-1 
Berberat  
et al., 2005 
TNBS Rats 5-ASA Once daily (3 days) 
MPO, TNF-α, 
HO-1 
Horváth  
et al., 2008 
TNBS Rats 
Heme 
ZnPP 
SnPP 
Cadmium chloride 
Once daily 
(10 days) HO-1, MPO 
Varga et al.,  
2007 
TNBS Mice Chalcone 
Once a day 
(at day -1, day 
3 and day 6) 
Body weight, 
colonic 
damage, 
ICAM-1, IL-1β, 
TNF-α, 
histology 
Lee et al.,  
2007 
TNBS Rats Glutamine Once a day (18 days) 
MDA, GSH, 
caspase-3, 
HO-1, NF-κB 
Giriş et al.,  
2007 
TNBS Rats Octreotide 
Once a day 
starting day -5                  
(20 days) 
MDA, GSH, 
HO-1, NF-κB 
Erbil et al.,  
2007 
TNBS Mice Gliotoxin 
Once a day 
(at day -1, day 
3 and day 6) 
Body weight, 
HO-1, MPO, 
NF-κB, IL-1β, 
TNF-α, IL-12, 
IL-8, I-κB, 
histology 
Jun et al.,  
2006 
TNBS Mice Bolinaquinone Petrosaspongiolide 
Once a day 
(4 days) 
Colonic length 
and weight , 
MPO, PGE2, 
IL-1β, NO,  
NF-κB 
Busserolles 
et al., 2005 
TNBS Rats Hemin SnMP 
Single 
administration 
HO-1, MPO, 
iNOS  
Wang et al.,  
2001 
 
Lengend: CoPP - Cobalt-protoporphyrin; 5-ASA - 5-Aminosalicylic acid; MDA – Malondialdehyde; GSH – Glutathione;  
SnMP - Tin mesoporphyrin IX chloride;  TNBS - Trinitrobenzene sulfonic acid; DSS - Dextran sulfate sodium; HO – Heme oxygenase; 
MPO – Myeloperoxidase; NO - Nitric oxide; IL – Interleukin; GSH – Glutathione; ICAM-1 - Intercellular adhesion molecule-1;  
NF-κB - Nuclear transcription factor kappa B; PG – Prostaglandin; iNOS - Inducible nitric-oxide synthase;  
TNF-α - Tumor necrosis factor α; IκB - Inhibitory κB; IFN-γ - Interferon-γ. 
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Briefly, HO-1 expression can confer cytoprotective, antiapoptotic and anti-inflammatory 
properties, suggesting thus that HO-1 can be a possible therapeutic target in several 
kinds of gastrointestinal diseases [Naito et al., 2011]. About IBD, Wang and colleagues 
used a rat model of colitis induced by TNBS to investigate whether the expression of 
HO-1 is an endogenous mechanism responsible for host defense against inflammatory 
injury in colonic tissue. They demonstrated that HO activity and HO-1 gene expression 
increased markedly after TNBS induction, and that administration of tin mesoporphyrin, 
an HO inhibitor, potentiated the colonic damage as well as decreased HO-1 activity. 
These results indicate that HO-1 plays a protective role in the colonic damage induced 
by TNBS enema [Wang et al., 2001]. Since then, some studies have been developed in 
DSS and TNBS colitis models to evaluate the effect of HO-1 inducers on the 
management of IBD. However, the biological significance of HO-1 up-regulation in 
gastrointestinal inflammation remains to be fully elucidated as well as the mechanisms 
underlying HO-1 activity on gene expression [Naito et al., 2011]. 
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AIM 
 
The main objective of the study is to test a set of drugs that modulate some important 
metabolic pathways in the establishment and development of inflammation in IBD, 
through an experimental model of IBD in rodents. These drugs may inhibit or stimulate 
the expression of these pathways, contributing to facilitate a more effective and 
selective treatment than the currently known. Thus, the specific objectives are:  
- Development of animal model of TNBS-induced colitis; 
- Evaluation of the influence of EPO in the IBD; 
- Evaluation of the influence of TDZD-8 in the IBD; 
- Evaluation of the influence of hemin in the IBD. 
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CHAPTER 4 - MATERIALS AND METHODS 
 
 
CHEMICALS / MATERIALS 
2,4,6-Trinitrobenzene sulfonic acid (TNBS 5%), 4-benzyl-2-methyl-1,2,4-
thiadiazolidine-3,5-dione (TDZD-8), ferriprotoporphyrin IX chloride (Hemin), dimethyl 
sulfoxide (DMSO) and sodium hydroxide (NaOH) were purchased from Sigma 
Chemical Co. Erythropoietin (Eprex® 10000 IU/ml) was purchased from Janssen-Cilag 
Farmacêutica. Ketamine (Imalgene® 1000) was purchased from Merial. Xilazine 
(Rompun® 2%) was purchased from Bayer. ADVIA® kit was purchased from Siemens 
Healthcare Diagnostics. ELISA assay kits for TNF-α, IL-1β and MPO measurements 
were obtained from Hycult Biotechnology. 
 
ANIMALS 
Male CD-1 mice, 30-40 g in weight and 6-10 weeks of age, obtained from Charles 
River. Animals were housed in standard polypropylene cages with ad libitum access to 
food and water, under uniform and controlled temperature, humidity and lighting 
conditions. Animal care was in strict accordance with the Declaration of Helsinki, EEC 
Directive of 24th November 1986 (nº 86/609/EEC), the relevant Portuguese laws D.R. 
nº 31/92, D.R. 153 I-A 67/92, and all subsequent legislation.  
 
INDUCTION OF EXPERIMENTAL COLITIS 
TNBS was instilled intracolonic single dose as previously described by Morris et al. 
[Morris et al., 1989]. Briefly, mice were left unfed during 24h. In the induction day (day 
0), mice were anesthetized with around 40µl of ketamine 100mg/Kg + xilazine 10mg/Kg 
by intraperitoneal injection (IP). Then, 100µl of TNBS solution was administered 
through a catheter carefully inserted until 4 cm into the colon. Mice were kept for 1 min 
in a Tredelenburg position to avoid reflux [Mazzon et al., 2005; Wirtz et al., 2007]. 
On day 4 and 6, depending the experimental group, mice were anesthetized and blood 
samples were collected by cardiac puncture. Then, the mice were euthanized by 
cervical dislocation and necropsied. The abdomen was opened by a midline incision. 
The small intestine and colon were removed, freed from surrounding tissues and 
washed with phosphate buffered saline.   
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EXPERIMENTAL GROUPS  
Groups were categorized based on the main objectives of this study, namely the 
development of the TNBS-induced colitis model and the evaluation of the influence of a 
set of drugs, as EPO, TDZD-8 and hemin in the IBD (FIGURE 25). Thus, the experimental 
groups were: 
 
A. DEVELOPMENT OF ANIMAL MODEL OF TNBS-INDUCED COLITIS 
The TNBS day 4 group (n = 35) and the TNBS day 6 group (n = 35) received both 100 
µl intrarectal of 2.5% TNBS in 50% ethanol and its necropsy was made on day 4 and 6, 
respectively. The ethanol group (n = 20) received 100µl intrarectal of 50% ethanol 
(TNBS vehicle). The sham group (n = 20) received 100µl intrarectal of saline solution. 
After data analysis, the TNBS day 4 group came to be called TNBS group. So, the 
TNBS, ethanol and sham groups were then used as a reference groups to compare 
and evaluate the influence of EPO, TDZD-8 and hemin in the treatment of IBD. 
 
B. EVALUATION OF THE INFLUENCE OF ERYTHROPOIETIN IN THE IBD 
The TNBS+EPO500 group (n = 35) and TNBS+EPO1000 group (n = 35) were a TNBS-
induced colitis models treated daily with 500 IU/kg and 1000 IU/kg IP of EPO 
(dissolved in saline solution) since the induction day, respectively. As a control, the 
EPO1000 group (n = 20) only received 1000 IU/kg IP of EPO daily since the induction 
day.  
 
C. EVALUATION OF THE INFLUENCE OF TDZD-8 IN THE IBD 
The TNBS+TDZD-8 group (n = 35) was a TNBS-induced colitis model treated daily with 
5 mg/kg IP of TDZD-8 (dissolved in DMSO) since the induction day. The 
TNBS+Vehicle group (n = 20) was a TNBS-induced colitis model treated daily with the 
TDZD-8 vehicle (10% IP of DMSO saline solution) since the induction day. As a 
control, the TDZD-8 group (n = 20) only received 5 mg/kg IP of TDZD-8 daily since the 
induction day.  
 
D. EVALUATION OF THE INFLUENCE OF HEMIN IN THE IBD 
The TNBS+Hemin5 group (n = 35) and the TNBS+Hemin10 group (n = 35) were a 
TNBS-induced colitis models treated daily with 5 mg/kg and 10 mg/Kg IP of hemin 
(dissolved in NaOH and PBS) since the induction day, respectively. The TNBS+Vehicle 
group (n = 20) was a TNBS-induced colitis model treated daily with the hemin vehicle 
(10 mg/Kg IP of NaOH aqueous solution) daily since the induction day. As a control, 
the Hemin10 group (n = 20) only received 10 mg/kg IP of hemin daily since the 
induction day.  
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FIGURE 25. Scheme of study design with the involved experimental groups.  
 
MONITORING OF CLINICAL SYMPTOMS/SIGNS 
After induction, the animals were observed daily, monitoring body weight, morbidity, 
stool consistency and anus appearance. 
 
BIOCHEMICAL MARKERS 
The serum from collected blood samples was separated by centrifugation at 3600 rpm 
for 15 min and sent to a reference laboratory. Serum samples were analyzed by an 
automated clinical chemistry analyzer (ADVIA® Chemistry XPT).  
Biochemical markers were evaluated to determine the severity of colitis, namely: 
. Colon length, as a marker of tissue integrity, determined using a measuring scale; 
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. Fecal hemoglobin, as an index of hemorrhagic focus, measured using a quantitative 
method by immunoturbidimetry (Kroma Systems); 
. Alkaline phosphatase (ALP) was determined as a marker of intestinal homeostasis. 
ALP in the sample catalyzes the hydrolysis of colorless p-nitrophenyl phosphate to give 
p-nitrophenol and inorganic phosphate. At the pH of the assay (10.3 e 10.4), the p-
nitrophenol is in the yellow phenoxide form. The rate of absorbance increase at 
410/478 nm is directly proportional to the ALP activity in the sample. Optimized 
concentrations of zinc and magnesium ions are present to activate the ALP in the 
sample; 
. Urea was determined as a marker of renal function. Urea is hydrolyzed in the 
presence of water and urease to produce ammonia and carbon dioxide. The ammonia 
reacts with 2-oxoglutarate in the presence of glutamate dehydrogenase and reduced 
nicotinamide adenine dinucleotide. The oxidation of nicotinamide adenine dinucleotide 
to oxidized nicotinamide adenine dinucleotide is measured as an inverse rate reaction 
at 340/410 nm;  
. Creatinine was determined as a marker of renal function. Creatinine reacts with picric 
acid in an alkaline medium to produce a red-colored creatinine-picrate complex. The 
rate of complex formation is measured at 505/571 nm and is proportional to the 
creatinine concentration; 
. Alanine aminotransferase (ALT) was determined as a marker of hepatic function. The 
reaction is initiated by the addition of α-ketoglutarate. The concentration of reduced 
nicotinamide adenine dinucleotide is measured by its absorbance at 340/410 nm and 
the rate of absorbance decrease is proportional to the ALT activity; 
. Hematocrit was determined in the experimental groups from EPO treatment, in order 
to evaluate the chance to promote cardiovascular adverse effects. It was used a 
hematologic autoanalyzer (ADVIA® 2120 – SIEMENS®). 
 
MYELOPEROXIDASE ACTIVITY 
Neutrophil infiltration to the inflamed colon was indirectly quantitated using an MPO 
assay and it was expressed in ng/ml. The colon was weighed, homogenized (Ultra-
turrax T25, 13.500rev/min, twice for 30s) in phosphate buffer and then centrifuged (at 
15.000rpm for 15min at 4ºC). An aliquot of the supernatant was incubated in microtiter 
wells coated with biotinylated tracer antibody, recognizing mouse MPO. Streptavidin-
peroxidase conjugate was added to bind the biotinylated tracer antibody and then was 
mixed with tetramethylbenzidine substrate. The reaction is stopped by the addition of 
oxalic acid and assayed spectrophotometrically at 450nm (ELISA 1kit HK210, Hycult 
Biotech).  
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MEASUREMENT OF CYTOKINES 
The TNF-α and IL-1β (pro-inflammatory cytokines) and IL-10 (anti-inflammatory 
cytokine) were measured and expressed as pg/ml. The colonic tissue samples were 
weighed and homogenized (Ultra-turrax T25, 13.500rev/min, twice for 30s) in 
phosphate buffer and then centrifuged (at 15.000rpm for 15min at 4ºC). The aliquots of 
the supernatant were stored at -20ªC until use. The cytokine levels were measured 
spectrophotometrically at 450 nm (ELISA kit Quantikine, Hycult Biotechnology).   
 
HISTOPATHOLOGICAL ANALYSIS 
The intestine samples were fixed in 10% phosphate-buffered formalin, processed 
routinely for paraffin embedding, sectioned at 5 µm, and stained with hematoxylin and 
eosin. The morphological features of small intestine and colon were evaluated by the 
same evaluated criteria. However, in the small intestine were analyzed several sections 
along this intestinal portion due to its length and because no macroscopic lesions were 
identified. In the colon, there were an identified macroscopic lesions, so it was 
analyzed several sections of this specific location.  
 
MICROSCOPIC ASSESSMENT OF COLITIS SEVERITY 
Two blinded independent histopathologists to treatment groups from Faculty of 
Veterinary Medicine (FMV-ULHT) and Institute of Molecular Medicine (IMM) carried out 
the histopathological studies. Sections of distal colon were evaluated based on 
adapted criteria of Corazza and colleagues (1999) and Seamons and colleagues 
(2013) (TABLE 10). The histopathological score of lesions were partially scored (0–4 
increasing severity) with some parameters, namely: (1) presence of tissue 
loss/necrosis, (2) severity of mucosal epithelial lesion, (3) inflammation, (4) extent 1 - 
the percentage of intestine affected in any manner and (5) extent 2 - the percentage of 
intestine affected by the most severe lesion. The colitis severity was calculated by 
summing the individual lesions and the extent scores, promoting a final colitis score 
(max score=20). 
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TABLE 10. Scoring system for histopathologic evaluation of TNBS-induced colitis. 
POINTS TISSUE LOSS EPITHELIAL LESION INFLAMMATION EXTENT 
0 None None  None None 
1 Mucosa < 50% Mild mucous cell depletion Mild – mucosa only < 5% 
2 Mucosa > 50% Moderate mucous cell depletion Moderate – mural 6-30% 
3 Mural*  Severe with aberhant crypts*** Transmural 31-60% 
4 Transmural** Severe with crypt loss Extension to the mesentery > 61% 
 
Legend: * Mural - Involves mucosa and submucosa; ** Transmural - Involves mucosa, submucosa,  
muscle layer and subserosa; *** Aberhant crypts - Corresponds to dilated crypts. 
 
The colonic lesions in the TNBS-induced colitis can be illustrated in some histological 
images that exemplify the observed lesional characteristics, corresponding to a 
progressive increase of injury severity from 0 (1st picture) to 20 (last picture) (FIGURE 26). 
Thus, the histological images can be characterized in: 
A. In normalcy, the wall of the colon is composed of four layers: mucosa, submucosa, 
muscularis (or muscularis propria), and adventitia (or serosa). The mucosa is the 
innermost layer formed by glandular epithelium, lamina propria, and muscularis 
mucosae. The glandular epithelium forms cylindrical structures, called crypts. The 
lamina propria, which supports the epithelium, is a layer of reticular connective 
tissue with elastin, reticulin, and collagen fibers, lymphocytes, plasma cells, and 
eosinophilic granulocytes, as well as lymphatics and capillaries. The muscularis 
mucosae consist of a thin layer of smooth muscle at the boundary of the mucosa 
and submucosa. The submucosa, between the muscularis mucosae and the 
muscularis propria, is a fibrous connective tissue layer that contains fibroblasts, 
mast cells, blood and lymphatic vessels, and a nerve fiber plexus. The muscularis 
propria, mainly responsible for contractility, consists of two layers of smooth muscle: 
an inner circular coat and an outer longitudinal coat arranged in a helicoidal pattern. 
The serosa is the outermost layer of connective tissue, covered by a single layer of 
mesothelial cells; 
B. Initial stages of the TNBS-induced colitis are characterized by mucous cell depletion, 
with loss of the large mucus-laden vacuoles within the epithelial cells of the mucosa, 
accompanied by mild inflammatory cell infiltration extending to the submucosa; 
C. The inflammation then progresses in extent (involving the muscularis propria) and 
severity (with more cells and more severe edema); 
D. Then the crypts become dilated and the epithelium eroded, to which follows mucosal 
loss (disappearance of the top of the crypts) and ulceration (disappearance of the 
whole crypt/epithelium); 
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E-F. In the most severe stages the necrosis extends firstly to the submucosa and 
muscle layer (E), and then to the serosa, often associated with peritonitis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 26. Characterization of the colonic lesions in TNBS-induced colitis. 
 
STATISTICAL ANALYSIS 
All results were expressed as mean ± SEM of N observations, where n represents the 
number of animals studied. Data analysis was performed by using GraphPad Prism 5.0 
software (GraphPad, San Diego, CA, USA). The results were analyzed by one-way 
ANOVA to determine statistical significance between the experimental and control 
groups followed by Tukey’s post hoc test for multiple comparisons or chi-square test 
depending on the variables under study. A p-value of less than 0.05 was considered 
significant. 
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CHAPTER 5 – DEVELOPMENT OF A TNBS-INDUCED COLITIS MODEL 
 
The protocols of the TNBS-induced colitis model are not standardized, since the acute 
transmural damage became maximal from three days to one week after instillation [Qin 
et al., 2011]. Thus, two independent groups of TNBS-induced colitis were developed 
and monitored under the same specific conditions, however one group of mice were 
sacrificed on day 4 (TNBS day 4 group) and the other one on day 6 (TNBS day 6 
group), after instillation. The main objective is to identify the maximal acute damage 
with the induction method used on this study.     
 
1. RESULTS 
MONITORING OF CLINICAL SYMPTOMS/SIGNS  
During six days, the mice were observed daily for morbidity, stool consistency and 
anus appearance. On day 4, all mice presented an alteration of intestinal motility 
characterized by diarrhea or soft stools, severe edema of the anus and moderate 
morbidity. But, on day 6, the mice presented an apparently recover, revealing the same 
clinical signs, but more lightly. In the control groups, namely ethanol and sham groups, 
were not identified any alteration, keeping these observed clinical symptoms/signs 
during all experimental period. Regarding body weight, both TNBS groups 
demonstrated a very similar curve in the register of body weight each day (FIGURE 27). 
For example, on day 4, the TNBS day 4 group revealed a weight loss of around -12 ± 
1.4% of its initial weight, whereas the TNBS day 6 group lost -9.9 ± 3.3% of its initial 
weight. After day 4, the mice body weight began to increase gradually day by day until 
day 6, where the mice just had -7.6 ± 3.4% of its initial weight. On the other hand, the 
ethanol and sham groups presented a considerable increase in body weight, especially 
from day 0 to day 1, around 20 to 30% at day 1. At the end of experimental period, the 
ethanol and sham groups gained 15.2 ± 1.1% and 31.2 ± 1.6% (p<0.0001, compared 
with TNBS day 4 group) of its initial weight, respectively.  
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FIGURE 27. Change of body weight during the development of TNBS-induced colitis. 
 
BIOCHEMICAL MARKER 
The colon length was determined at the end of the treatment period, using a measuring 
scale (FIGURE 28 AND 29). Four days after intra-colonic administration of TNBS, the colon 
appeared flaccid and filled with liquid stool. Furthermore, the TNBS-induced colitis had 
an influence on colon length comparing with control groups, especially on day 4. More 
specifically, the TNBS day 4 group presented around 10.1 ± 0.2 cm of colon and, after 
two days, the TNBS day 6 group revealed a significantly increase of colon length with 
11.1 ± 0.3 cm (p<0.01). On day 4, the colon length of TNBS group was considerably 
lower than control groups, as ethanol and sham groups, which presented 11.5 ± 0.4 cm 
and 11.5 ± 0.2 cm of colon, respectively (p<0.001). 
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FIGURE 28. Effect of TNBS-induced colitis on colon length in the IBD.  
Legend: One-way ANOVA and Tukey’s post hoc test; ** p<0.01; *** p<0.001 compared with sham group or between groups. 
 
 
 
 
 
 
 
 
 
FIGURE 29. Appearance and length of colon in the TNBS and sham groups. 
Legend: (A) Sham group; (B) TNBS day 4 group. 
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The fecal hemoglobin allows evaluating the intensity of hemorrhagic focus (FIGURE 30). 
Thus, the TNBS-induced colitis significantly increased the fecal hemoglobin 
concentration comparing with sham group (p<0.001). On day 4, the mice with colitis 
had 12.5 ± 0.3 µmol Hg/g feces and, passed 2 days, the fecal hemoglobin considerably 
decreased to 6.6 ± 0.6 µmol Hg/g feces (p<0.001). The control groups presented very 
low concentrations of fecal hemoglobin with 1.1 ± 0.1 µmol Hg/g feces on ethanol 
group and 0.7 ± 0.1 µmol Hg/g feces on sham group.  
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FIGURE 30. Effect of TNBS-induced colitis on fecal hemoglobin in the IBD. 
Legend: One-way ANOVA and Tukey’s post hoc test; *** p<0.001 compared with sham group or between groups. 
 
It was evaluated the ALP concentration on blood, due to ALP plays an essential role in 
some systems, like intestinal homeostasis (FIGURE 31). The TNBS day 4 group presented 
the highest values with around 72.7 ± 2.3 IU/L of ALP (p<0.001, compared with the 
sham group). On day 6, the ALP significantly decreased to 51.6 ± 1.5 IU/L of ALP 
(p<0.001, compared with the TNBS day 4 group).  Ethanol and sham groups presented 
lower concentrations of ALP with around 38.5 ± 0.6 IU/L and 19.2 ± 1.8 IU/L, 
respectively.  
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FIGURE 31. Effect of TNBS-induced colitis on serum total ALP concentration in the IBD. 
Legend: One-way ANOVA and Tukey’s post hoc test; *** p<0.001 compared with sham group or between groups. 
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The renal damage was assessed based on urea and creatinine concentrations (FIGURE 
32 AND 33). The TNBS day 4 group revealed an increase in urea level compared with 
sham group (62.4 ± 1.5 vs 49.3 ± 0.9 mg/dl, p<0.001), as well as the creatinine level 
compared with sham group (0.27 ± 0.01 vs 0.20 ± 0.02 mg/dl, p<0.001). The TNBS day 
6 group presented a significant decrease of urea with around 54 ± 1.5 mg/dl, which is 
quite similar with sham group (p<0.001, compared with TNBS day 4 group). With 
respect to creatinine at day 6, the concentration slightly decreased to 0.24 ± 0.01 mg/dl 
(p<0.05, compared with sham group). There are no statistically significant differences 
in urea and creatinine levels between the control groups. Thus, the ethanol group 
presented 41.4 ± 0.5 mg/dl of urea and 0.21 ± 0.01 mg/dl of creatinine.  
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FIGURE 32. Effect of TNBS-induced colitis on serum urea concentration in the IBD. 
Legend: One-way ANOVA and Tukey’s post hoc test; *** p<0.001 compared with sham group or between groups. 
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FIGURE 33. Effect of TNBS-induced colitis on serum creatinine concentration in the IBD. 
Legend: One-way ANOVA and Tukey’s post hoc test; * p<0.05; *** p<0.001 compared with sham group. 
 
The hepatic function was evaluated according serum ALT concentration (FIGURE 34). The 
ALT concentration was significantly higher in the TNBS day 4 group compared with the 
sham group (38.7 ± 1.2 vs 17.5 ± 0.8 IU/L, p<0.001). On day 6, the ALT decreased to 
31.7 ± 0.6 IU/L compared to TNBS day 4 group (p<0.001), but yet for higher values 
than sham group (p<0.001). The ALT concentration on ethanol group (32.3 ± 1.2 IU/L) 
was higher than the sham group (p<0.001). 
*** 
*** 
*** 
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FIGURE 34. Effect of TNBS-induced colitis on serum ALT concentration in the IBD. 
Legend: One-way ANOVA and Tukey’s post hoc test; *** p<0.001 compared with sham group or between groups. 
 
MYELOPEROXIDASE ACTIVITY 
The MPO was evaluated in the development of the experimental colitis as inflammation 
marker (FIGURE 35). The TNBS-induced colitis was characterized by an increase in MPO 
comparing with sham group (p<0.001). The mice with colitis showed 42 ± 2.8 ng/ml of 
MPO, 4 days TNBS after instillation. Thenceforth, the MPO tends to decrease, 
presenting 30.5 ± 2.3 ng/ml of MPO (p<0.01, compared with TNBS day 4 group). The 
control groups, as ethanol and sham groups revealed 5.8 ± 0.9 ng/ml and 2.3 ± 0.4 
ng/ml of MPO, respectively. 
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FIGURE 35. Effect of TNBS-induced colitis on MPO activity in the IBD. 
Legend: One-way ANOVA and Tukey’s post hoc test; ** p<0.01; *** p<0.001 compared with sham group or between groups. 
 
MEASUREMENT OF CYTOKINES 
The TNBS-induced colitis showed a significant production of pro-inflammatory 
cytokines, as TNF-α and IL-1β, after four days of TNBS administration (FIGURE 36 AND 37). 
However, these pro-inflammatory cytokines were significantly reduced on day 6 
(p<0.001, compared with TNBS day 4 group). The TNBS day 4 group presented 253.2 
± 31.4 pg/ml of TNF-α and 263.9 ± 25 pg/ml of IL-1β, whereas the TNBS day 6 group 
presented 121.8 ± 8.54 pg/ml of TNF-α and 165.2 ± 13.2 pg/ml of IL-1β, passed only 
two days. Both TNBS groups presented higher levels of pro-inflammatory cytokines 
than sham group (p<0.001). Even, the ethanol and sham groups had very similar 
*** 
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concentrations of pro-inflammatory cytokines, without statistically significant 
differences. The ethanol group presented 14.9 ± 2 pg/ml of TNF-α and 16.2 ± 1.6 pg/ml 
of IL-1β and the sham group presented 11.2 ± 0.2 pg/ml of TNF-α and 12.7 ± 0.1 pg/ml 
of IL-1β. 
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FIGURE 36. Effect of TNBS-induced colitis on TNF-α concentration in the IBD. 
Legend: One-way ANOVA and Tukey’s post hoc test; *** p<0.001 compared with sham group or between groups. 
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FIGURE 37. Effect of TNBS-induced colitis on IL-1β concentration in the IBD. 
Legend: One-way ANOVA and Tukey’s post hoc test; *** p<0.001 compared with sham group or between groups. 
 
Cytokines can also become dysregulated under in inflammation conditions with anti-
inflammatory effect as IL-10 (FIGURE 38). Usually the IL-10 decrease when the TNF-α and 
IL-1β concentrations increase under inflammatory conditions. Curiously, these results 
of IL-10 did not confirm the obtained results in the TNF-α and IL-1β measurements. 
The TNBS day 4 group presented the highest concentrations of IL-10 with 31.4 ± 3.3 
pg/ml (p<0.001, compared with sham group). However, the TNBS day 6 group 
presented a decrease of IL-10 concentration of around 25.5 ± 2.2 pg/ml, contrary to our 
expectations (p<0.05, compared with sham group). The control groups, as ethanol and 
sham groups, had similar results with 17.3 ± 1.2 pg/ml and 15.7 ± 0.1 pg/ml of IL-10, 
respectively. 
*** 
*** 
*** 
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FIGURE 38. Effect of TNBS-induced colitis on IL-10 concentration in the IBD. 
Legend: One-way ANOVA and Tukey’s post hoc test; * p<0.05; *** p<0.001 compared with sham group. 
 
ASSESSMENT OF SMALL INTESTINE LESIONS 
Since colitis induction can eventually promote tissue injury in the small intestine 
[Murthy 2006], it was analyzed and showed similar histological results among 
evaluated groups and the number of days after induction. Apparently, no macroscopic 
lesions were observed, but microscopically, a slight lymphoplasmacytic infiltrate in the 
lamina propria was identified and it was similar to all studied groups independently of 
the day after induction (FIGURE 39). 
 
 
 
 
 
 
 
 
FIGURE 39. Histopathological features of small intestine sections. 
Legend: Each image corresponding to a different experimental group,  
namely (A) TNBS group, (B) Ethanol group, and (C) Sham group. 
 
ASSESSMENT OF COLITIS SEVERITY 
Regarding macroscopic evaluation of colon, there were observed several hemorrhagic 
focus and generalized edema, whereas no macroscopic alterations were observed in 
the control groups. Microscopically, the colon was analyzed and it showed different 
histological results, depending the evaluated experimental group. In relation to 
development of this animal model, the TNBS group presented severe lesions at day 4 
and no substantial morphological changes were detected at day 6 compared with day 
4. Furthermore, all biochemical markers and the concentrations of pro- and anti-
inflammatory cytokines, under evaluation, corroborate that the damage became 
maximal at day 4 after the induction. For all these reasons, it will be used only the 
A B C 
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obtained results of TNBS day 4 group to validate and compare this animal model of 
TNBS-induced colitis with the control groups, as ethanol and sham groups.  
 
The histopathological score was calculated based on the presence of tissue 
loss/necrosis, severity of mucosal epithelial lesion, inflammation and extension of the 
lesions (TABLE 11). At day 4, the mice with TNBS-induced colitis revealed a significantly 
higher score in all evaluated parameters of severity and extension comparatively to the 
ethanol and sham groups. The control groups presented residual scores in all 
parameter under evaluation. The partial histopathological scores of the ethanol group 
were slightly higher than sham group. 
 
TABLE 11. Average (± SEM) of partial histopathological score of TNBS-induced colitis.  
  
TNBS DAY 4 ETHANOL SHAM 
MUCOSAL LOSS 3.3 ± 0.2 0.2 ± 0.1 0 ± 0 
EPITHELIAL LESIONS 3.4 ± 0.2 0.9 ± 0.5 0 ± 0 
INFLAMMATION 3.8 ± 0.1 1.1 ± 0.2 0.1 ± 0.1 
EXTENT 1* 3.7 ± 0.1 1.3 ± 0.3 0.1 ± 0.1 
EXTENT 2** 3 ± 0.2 1 ± 0.2 0.1 ± 0.1 
 
Legend: * Extent 1 - Percentage of intestine affected in any manner;  
** Extent 2 - Percentage of intestine affected by the most severe lesion. 
 
The final histopathological score ranges between 0 and 20 (FIGURE 40). With regard to 
mice with TNBS-induced colitis, the TNBS group had a final score of around 17 ± 0.6, 
presenting a score substantially higher than the sham group (p<0.001). The control 
groups, as the sham group, revealed a residual histopathological score with around 0.2 
± 0.2 of final score. However, the histopathological score of the ethanol group was 
slightly higher with 4.5 ± 1.2 (p<0.01 compared with sham group). These results are 
consistent with the histopathological images.  
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FIGURE 40. Effect of TNBS-induced colitis on histophatological score. 
Legend: One-way ANOVA and Tukey’s post hoc test; ** p<0.01; *** p<0.001 compared with TNBS group or between groups. 
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Representative images translating the histopatological score for the experimental 
groups analyzed are showed herein (FIGURE 41). The histopathology analysis of mice 
with TNBS-induced colitis displays diffuse transmural necrosis with severe 
hemorrhaging, involving the mucosa, submucosa, muscle layer and serosa, and often 
associated with peritonitis. The ethanol group showed only mild epithelial erosion, and 
no lesions were observed in the sham groups. 
 
 
 
FIGURE 41. Effect of TNBS-induced colitis on histopathologic changes. 
Legend: Each column corresponding with a different experimental group,  
namely (A) TNBS group, (B) Ethanol group, and (C) Sham group. 
 
2. DISCUSSION OF RESULTS 
IBD is a common gastro-intestinal disorder marked with chronic inflammation of 
intestinal epithelium, damaging mucosal tissue and manifests into several intestinal 
and extra-intestinal symptoms, mainly related to oxidative stress, inflammation and 
autoimmune type [Mowat et al., 2011; Pawar et al., 2011]. Animal models mimic the 
characteristics of disease in real life and play an important role in studies of action 
mechanisms. There are several chemical agent-induced colitis models and all of them 
couldn’t fully reflect the complexity of the disease present in human and each method 
has its own disadvantages [Wirtz & Neurath, 2007]. However, between the TNBS-
induced colitis and the human disease exist a similar pathogenesis of IBD [Pawar et 
al., 2011], and this is the reason why so many research groups are now using this 
model to investigate novel approaches for the treatment of IBD. Furthermore, the major 
advantages of this model include proposing a simple process and reproducible colonic 
damage, short duration of the experiment, long-lasting damage accompanied by 
inflammatory cell infiltration and ulcers [Zheng, Gao & Wang, 2000]. In addition, this 
model can mimic both acute and chronic phases of human colitis [Dohi & Fujihashi, 
2006]. The TNBS can induce colitis by intrarectal instillation of the haptenating 
substance dissolved in ethanol, resulting in a dysregulation of the mucosal immune 
system [Morris et al., 1989; Li et al., 2005; Menozzi et al., 2006]. Therefore, the aim of 
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this study is to develop an acute experimental colitis model, by induction with TNBS, in 
order to evaluate the influence of EPO, TDZD-8 and hemin in the IBD.  
The first step on this study was to develop and validate the TNBS-induced colitis 
model, since the protocols of this animal model are not standardized, such as the 
dosage of TNBS, the depth of TNBS administration, and the time point for model 
evaluation [Qin et al., 2011]. The TNBS-induced colitis model was applied in 1989 for 
the first time by Morris et al. and since that the acute transmural damage became 
maximal from 3 days to 1 week after instillation, and resolved within 2 weeks [Morris et 
al., 1989; Linden et al., 2005; Lamb et al., 2006; Liang et al., 2007; Qin et al., 2011]. 
Therefore, it was implemented a protocol to development of TNBS-induced colitis 
model based on Morris et al. procedure [Morris et al., 1989]. Briefly, two independent 
groups of TNBS-induced colitis were developed and monitored under the same specific 
conditions, however one group of mice were sacrificed on day 4 and the other one on 
day 6, after induction. During these 6 days, there were evaluated several parameters, 
like clinical symptoms/signs, biochemical markers, histopathological analysis and 
cytokines concentration. The main objective was to identify the day where the maximal 
acute damage was achieved by the induction method used on this study.     
Regarding monitoring of clinical symptoms/signs, TNBS group presented an alteration 
of intestinal motility characterized by diarrhea or soft stools, severe edema of the anus 
and moderate morbidity, while ethanol and sham groups remained without any 
alterations. The manifestations became maximal at day 4 after induction and the effect 
began to decline starting that day. These clinical manifestations in the TNBS group 
were expected and compatible with a correct induction of CD [Cuzzocrea et al., 2004; 
Motavallian-Naeini et al., 2012].  
The peak of clinical symptoms/signs was also confirmed by the progressive fall in body 
weight over the 4-day experimental period on TNBS with around -12 ± 1.4% of weight 
loss, consistent with other research groups [Cuzzocrea et al., 2004; Motavallian-Naeini 
et al., 2012; Szczepanik et al., 2012]. After day 4, the body weight of these mice began 
to increase slightly until day 6, presenting a weight recovery on day 6, with a gain of 
2.3% of weight in just 2 days. Although the weight difference between day 4 and day 6 
was not statistically significant, this change represents a weight gain trend. Regarding 
control groups, they presented a considerable increase in body weight with a gain of 
around 20 to 30% of its initial weight, especially from day 0 to day 1. In fact, they were 
fasted for 12 hours since the day before of the induction day. After induction, they woke 
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up from anesthesia, felt healthy and prepared to eat, unlike the other groups with 
experimental colitis, thus justifying the increase.  
The colon length was also measured as a marker of tissue integrity. We found that 
TNBS-induced colitis significantly shortened colon length on day 4 and, passed only 2 
more days, the colon length significantly recovered TNBS effects, suggesting that the 
maximal damage is manifested on day 4. On day 6, the colon length is similar with the 
control groups. In this study, mice without TNBS-induced colitis showed a normal colon 
length with around 11.5 cm, however we verified that TNBS-induced colitis promotes a 
reduction of 1cm in the colon length compared with sham group and, this is consistent 
with the findings from other research groups [Nayak, George & Mishra, 2012; 
Szczepanik et al., 2012]. 
The determination of fecal hemoglobin allows the diagnosis and evaluation of various 
colorectal diseases, as for example identify patients with IBD with active inflammation 
[Hirata et al., 2007; Mooiweer, Fidder, Siersema, Laheij & Oldenburg, 2014]. Thus, 
fecal hemoglobin can be useful in the detection of lesions accompanied by bleeding, 
since it determines the intensity of eventual hemorrhagic focus in the colonic tissue 
[Hirata et al., 2007; Jagtap, Niphadkar & Phadke, 2011]. In this regard, the fecal 
hemoglobin also confirmed the manifestation of maximal damage on day 4, since we 
verified a significantly reduction of around 6 µmol Hg/g feces on day 6, presenting thus 
a recovery of hemorrhagic ulcers. The control groups presented residual 
concentrations of fecal hemoglobin.  
ALP is regularly measured in clinical practice and its changes in serum levels are 
observed in a number of clinical conditions of organs where it can be found like bone, 
liver, bowel, kidney and placenta [Moscandrew, Mahadevan & Kane, 2009; Tinnion & 
Embleton, 2012]. Concretely, the intestinal ALP is expressed on the apical surface of 
enterocytes and it has received increasing attention as a factor responsible for mucosal 
defense, promoting the interaction between toll like receptor (TLR)-4 in the intestinal 
mucosa and LPS derived from the bacterial flora [Malo et al., 2010; Nagalingam, Kao & 
Young, 2011]. Therefore, TNBS group presented the highest values of serum total ALP 
concentration and the peak of maximal damage was also achieved on day 4, since the 
mice revealed a decrease in around 29% of ALP on day 6. Thus, the low 
concentrations of APL in both control groups suggest that the origin of increased APL 
in the TNBS group is due to intestinal lesion inducted in this study. On the other hand, 
the ethanol group presented a slight increase of ALP compared with sham group, 
perhaps due to its ability to induce an intestinal permeability alteration promoting a 
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superficial and mild damage of colonic tissue with subsequently release of intestinal 
ALP to systemic circulation. These our results are consistent with other studies, which 
observed a higher serum ALP activity in the colitic animals comparing with non-colitic 
animals from acute intestinal inflammation model induced by TNBS [Cruz, Gálvez, 
Crespo, Ocete & Zarzuelo, 2001; Luchini et al., 2008].  
MPO activity represents the degree of neutrophil infiltration in a tissue. Under normal 
physiological conditions, MPO is released from azurophillic storage granules [Krawisz, 
Sharon & Stenson, 1984]. When an inflammatory insult leads to the formation of 
reactive species, release of this enzyme increases MPO of colonic mucosa scraping 
which is a manifestation of increased infiltration [Patil, Kandhare & Bhise, 2012]. 
Indeed, neutrophils play a crucial role in the development and full manifestation of 
gastrointestinal inflammation, because they represent a major source of free radicals in 
the inflamed colonic mucosa, promoting the destruction of foreign antigens and in the 
breakdown and remodeling of injured tissue [Grisham, 1994; Cuzzocrea et al., 2001]. 
In this study, the TNBS-induced colitis was characterized by an increase of MPO 
activity, especially on day 4. Since that day, the MPO activity significantly decreased, 
suggesting a reduction of the colon inflammation. The control groups presented a 
residual MPO activity, compatible with the absence of an inflammatory process. These 
findings were fully confirmed by the measurements of pro-inflammatory and anti-
inflammatory cytokine concentrations. Furthermore, these data are consistent with the 
findings of other research groups, since they registered the same MPO activity after 
TNBS-induced colitis [Ukil et al., 2003; Szczepanik et al., 2012].  
Cytokines are crucial for fighting off infections and in other immune responses. 
However, they can become dysregulated and pathological in inflammation, trauma and 
sepsis [Műzes et al., 2012]. TNF-α and IL-1β are pro-inflammatory cytokines, released 
through the activation of white blood cells (including macrophages) via neutrophils 
[Paunovic et al., 2011]. These are clearly involved in the pathogenesis of colitis, since 
they are increased in inflamed colon tissue [Carty, De Branbander, Feakins & 
Rampton, 2000; Nairz et al., 2011]. This current study confirms that the used TNBS-
induced colitis model promotes a significantly increase in the levels of these pro-
inflammatory cytokines in the colon. Specifically, these cytokines registered the 
maximal peak of its concentration on day 4 and, passed only 2 more days, the cytokine 
levels decreased in average 44.6%, indicating an eventual onset of the chronic phase 
of this inflammatory disease.  
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Although the data of TNF-α and IL-1β levels have been enlightening, to confirmation 
the inflammatory process observed in the TNBS-induced colitis, culture supernatants 
were additionally tested for the presence of anti-inflammatory cytokines, as IL-10. The 
obtained data allows concluding that TBNS-induced colitis promotes a decreased 
production of IL-10 by mesenteric lymph nodes, as expected [Coquerelle et al., 2009; 
Yang, Meng, Jiang, Chen & Wu, 2010]. 
In the histopathological analysis of the small intestine, there was a slight lymphocytic 
inflammatory infiltrate in the lamina propria similar with all experimental groups. These 
lesions are consistent with a sub-acute to chronic process, suggesting no relationship 
with this study. Perhaps, the reason is that the mice used in the study are not Specific 
Pathogen Free, even because there are similar for all experimental groups. These 
should therefore be devalued, so no morphological alterations were detected in the 
small intestine.  
Regarding to histopathological analysis of colon, the morphological features in the 
TNBS-induced colitis were evaluated and no substantial morphological changes were 
detected between day 4 and day 6. In general, the histopathological analysis revealed 
a diffuse transmural necrosis with severe hemorrhaging, involving the mucosa, 
submucosa, muscle layer and serosa, and often associated with peritonitis. These 
lesions are consistent with a correct induction of experimental colitis by TNBS [Alex et 
al., 2009; Pawar et al., 2011; Nairz et al., 2011; Motavallian-Naeini et al., 2012]. On the 
other hand, no histological alterations were observed in the control groups, except in 
the ethanol group where it was observed mild epithelial erosion due to its ability to 
induce an intestinal permeability alteration, promoting a superficial and mild damage of 
colonic tissue. 
The prevalence of extraintestinal manifestations in IBD varies from 6% to 46% [Rojas-
Feria, Castro, Suárez, Ampuero & Romero-Gómez, 2013; Corica & Romano, 2015]. 
These manifestations can be divided in to 3 groups: those that are seen in association 
with IBD, those that are due to metabolic and physiologic changes induced by the IBD 
and those that are secondary to the drugs used in the treatment of IBD [Yarur, Czul & 
Levy, 2014]. Regarding our findings, the TNBS-induced colitis presented a significantly 
alteration of renal and hepatic functions comparing with control groups. The peak of 
maximal damage was again detected on day 4, presenting a considerable decline of all 
evaluated parameters since then. This is consistent with the literature, since 
extraintestinal manifestations can involve almost every organ system and some of the 
most frequently involved organs are the liver and kidney [Oikonomou, Kapsoritakis, 
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Eleftheriadis, Stefanidis & Potamianos, 2011; Rojas-Feria et al., 2013; Corica & 
Romano, 2015]. 
Briefly, a TNBS-induced colitis model was monitored during 6 days, since we wanted to 
identify the day where the maximal acute damage was achieved. Indeed, all clinical 
symptoms/signs, biochemical markers, histopathological analysis and concentrations of 
pro- and anti-inflammatory cytokines, under evaluation, corroborate that the damage 
became maximal at day 4 after the induction. Possibly, because some mice died during 
the early days of the study, no resisting to aggravation of the disease in its acute 
phase, while the remaining mice resisted and progressed to chronic phase of the 
disease, showing the same symptoms but more lightly. These data allow concluding 
that TNBS-induced colitis was developed in 4 days, providing an acute intestinal 
inflammation model. This model exhibits many of the pathological, molecular and 
immunological features of human colitis [Boughton-Smith, Wallace & Whittle, 1988; 
Morris et al., 1989; Sun et al., 2001; Whittle, Cavicchi & Lamarque, 2003; Riviera, 
2006]. Furthermore, the validation of this animal model is truly relevant to the scientific 
community, since there is no standard practice in the induction of colitis by TNBS 
[Tomasello et al., 2015].  
Nowadays, no medical cure has been developed for IBD and treatment focuses on 
producing and maintaining remission [Podolsky, 2002; Forbes et al., 2004; Baumaqart 
& Sandborn, 2007]. Conventional pharmacotherapy for both types of IBD is treatment 
with aminosalicylates and corticosteroids [Sands, 2000; Langmead & Rampton, 2006]. 
Moreover, immuno-suppressive agents and biological response modifiers are 
considered as alternative therapies [Braus & Elliott, 2009]. Nonetheless, available 
medicines are not universally effective and result in marked deleterious effects 
[Dubinsky, 2004]. Researchers have shown an increased interest in investigating the 
effect of different drugs used for the treatment of IBD. In order to understand how drugs 
affect the colitis, animal models of colitis are normally applied [Motavallian-Naeini et al., 
2012]. Therefore, this study evaluated the influence of a set of drugs in this 
experimental colitis model, as EPO, TDZD-8 and hemin, which are able to stimulate or 
inhibit some inflammatory pathways involved in IBD. 
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CHAPTER 6 – ERYTHROPOIETIN EFFECT  
IN INFLAMMATORY BOWEL DISEASE 
 
 
1. RESULTS 
 
MONITORING OF CLINICAL SYMPTOMS/SIGNS  
The animals were observed daily for stool consistency, anus appearance, morbidity 
and body weight changes (FIGURE 42). Following experimental induction of colitis, TNBS 
group presented an alteration of intestinal motility characterized by diarrhea or soft 
stools, severe edema of the anus and moderate morbidity. Since day 0, it was found a 
progressive fall in body weight over the 4-day experimental period on TNBS group (-12 
± 1.4%). However, in both doses of EPO treatment, the same clinical signs were found, 
but lighter, like soft stools, moderate edema of the anus and mild morbidity. 
Furthermore, the fall in body weight determined 4 days following induction of 
experimental colitis with TNBS group was attenuated by EPO treatment and the effects 
were statistically significant with the higher dose. At the end of experimental period, the 
TNBS+EPO500 group lost -3.7 ± 3% of its initial weight and TNBS+EPO1000 group 
gained 7.3 ± 3.8% (p<0.0001) of its initial weight. The EPO1000, ethanol and sham 
groups remained without any alterations with respect to morbidity, stool consistency 
and anus appearance during the study. At the end of experimental period, they also 
gained 21 ± 2.7%, 15.2 ± 1.1% and 31.2 ± 1.6% (p<0.0001, compared with TNBS 
group) of its initial weight, respectively.  
 
 
 
FIGURE 42. Change of body weight during EPO treatment in the IBD. 
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BIOCHEMICAL MARKERS 
The observed inflammatory changes of the colon were associated with a reduction in 
the length of the colon (FIGURE 43). TNBS induced colitis (10.1 ± 0.2 cm) reduced 
significantly the colon length relatively with the sham group (11.5 ± 0.2 cm) as a 
comparable tissue (p<0.001). Furthermore, EPO treatment showed an influence on the 
colon length in a dependent dose manner, but without statistical significance. 
TNBS+EPO500 group presented an increase on the colon length with 10.4 ± 0.2 cm, 
as well as in the TNBS+EPO1000 group with 10.9 ± 0.2 cm of colon length. The 
EPO1000, ethanol and sham groups presented similar results between them, like 11.8 
± 0.1 cm, 11.5 ± 0.4 cm, 11.5 ± 0.2 cm, respectively. 
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FIGURE 43. Effect of EPO treatment on colon length in the IBD.  
Legend: One-way ANOVA and Tukey’s post hoc test; *** p<0.001 compared with TNBS group. 
 
The intensity of hemorrhagic focus was evaluated by the fecal hemoglobin 
determination (FIGURE 44). The findings in colons from the TNBS group included severe 
bloody stools compared to the sham group (12.5 ± 0.3 vs 0.7 ± 0.1 µmol Hg/g feces, 
p<0.0001). EPO treatment has an influence in the intensity of hemorrhagic focus, since 
a significant difference in fecal hemoglobin was also observed between the TNBS 
group and both EPO doses, namely TNBS+EPO500 group (6.6 ± 0.1 µmol Hg/g feces, 
p<0.0001) and TNBS+EPO1000 group (2.4 ± 0.3 µmol Hg/g feces, p<0.0001). The 
EPO dose has a positive influence in the intensity of hemorrhagic focus, since the fecal 
hemoglobin decreased when the EPO dose was increased (p<0.0001). Mice from 
EPO1000 (1.6 ± 0.1 µmol Hg/g feces) and ethanol groups (1.1 ± 0.1 µmol Hg/g feces) 
did not display significant changes compared to the sham group (0.7 ± 0.1 µmol Hg/g 
feces).  
*** 
*** 
*** 
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  FIGURE 44. Effect of EPO treatment on fecal hemoglobin in the IBD. 
Legend: One-way ANOVA and Tukey’s post hoc test; **** p<0.0001 compared with TNBS group or between groups. 
 
ALP was identified in all experimental groups (FIGURE 45). The ALP concentration on the 
TNBS group was considerably higher compared with the sham group (72.7 ± 2.3 vs 
19.2 ± 1.8 IU/L, p<0.0001). The EPO treatment was able to decrease the ALP 
concentration on blood at both EPO doses, but it was not achieved a dose dependent 
effect with statistical significance. The TNBS+EPO500 group presented 45 ± 4.8 IU/L, 
whereas the TNBS+EPO1000 group presented 39 ± 0.9 IU/L (p<0.0001, compared 
with TNBS group). The ALP in the EPO1000 group is increased by 53.3 ± 1.1 IU/L 
compared with the remaining control groups, like ethanol (38.5 ± 0.6 IU/L) and sham 
(19.2 ± 1.8 IU/L) groups (p<0.0001 compared with sham group). Even the ethanol 
group presents statistically significant differences with sham group (p<0.0001).     
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FIGURE 45. Effect of EPO treatment on serum total ALP concentration in the IBD. 
Legend: One-way ANOVA and Tukey’s post hoc test; **** p<0.0001 compared with TNBS group. 
 
The EPO treatment can affect the hematocrit level and promote cardiovascular adverse 
effects, so it is important evaluate the range of hematocrit in some experimental groups 
(FIGURE 46). All evaluated experimental groups, like TNBS+EPO500 (46.7 ± 0.9 %), 
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TNBS+EPO1000 (47.2 ± 0.7 %) and EPO1000 (47.1 ± 0.5 %) groups, presented 
similar values of hematocrit with sham group (48.3 ± 0.7 %), without statistically 
significant differences. 
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FIGURE 46. Effect of EPO treatment on hematocrit in the IBD. 
 
 
It were analyzed sera from mice with TNBS induced colitis and mice treated with EPO 
to determine if there were alterations in the values for the renal damage markers, like 
urea and creatinine (FIGURE 47 AND 48). The TNBS group exhibited a significant increase in 
urea compared with sham group (62.4 ± 1.5 vs 49.3 ± 0.9 mg/dl, p<0.01), as well as 
the creatinine compared with sham group (0.27 ± 0.01 vs 0.20 ± 0.02 mg/dl, p<0.0001). 
The mice treated with EPO presented a significant decrease of urea and creatinine 
levels to values quite similar with sham group (p<0.01, compared with TNBS group), 
promoting thus a dose-dependent effect but without statistical significance between 
EPO doses. The renal biochemistries of TNBS+EPO500 group revealed 51 ± 5.3 mg/dl 
of urea and 0.22 ± 0.01 mg/dl creatinine, while the TNBS+EPO1000 group revealed 
44.5 ± 1.1 mg/dl of urea and 0.20 ± 0.01 mg/dl of creatinine. There are no statistically 
significant differences in urea and creatinine levels between the control groups, like 
EPO1000, ethanol and sham. In the control groups, the creatinine concentration in 
EPO1000 group (0.26 ± 0 mg/dl) was the only parameter that was significantly higher 
than sham group (p<0.0001). 
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FIGURE 47. Effect of EPO treatment on serum urea concentration in the IBD. 
Legend: One-way ANOVA and Tukey’s post hoc test; ** p<0.01 compared with sham group. 
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FIGURE 48. Effect of EPO treatment on serum creatinine concentration in the IBD. 
Legend: One-way ANOVA and Tukey’s post hoc test; **** p<0.0001 compared with sham group. 
 
 
The hepatic function was evaluated according serum ALT concentration from mice with 
TNBS induced colitis and mice treated with EPO (FIGURE 49). The ALT concentration in 
blood was significantly higher in the TNBS group compared with the sham group (38.7 
± 1.2 vs 17.5 ± 0.8 IU/L, p<0.0001). The EPO treatment at both doses promoted a 
decreased of ALT levels (27.4 ± 0.7 and 27.1 ± 0.9 IU/L, respectively) relatively to 
TNBS group (p<0.0001), but yet for higher values than sham group (p<0.001). The ALT 
levels on EPO1000 (27.5 ± 0.7 IU/L) and ethanol (32.3 ± 1.2 IU/L) groups were higher 
than the sham group (p<0.0001). 
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FIGURE 49. Effect of EPO treatment on serum ALT concentration in the IBD. 
Legend: One-way ANOVA and Tukey’s post hoc test; *** p<0.001; **** p<0.0001 compared with sham group or between groups. 
 
MYELOPEROXIDASE ACTIVITY 
The MPO activity was measured in all experimental groups as inflammation marker 
(FIGURE 50). The TNBS group presented an increased MPO concentration comparing 
with the sham group (42 ± 2.8 vs 2.3 ± 0.4 ng/ml, p<0.0001). Furthermore, the EPO 
treatment was able to decrease the MPO concentration with both EPO doses. In the 
TNBS+EPO500 group was registered 21.7 ± 4.6 ng/ml of MPO, whereas in the 
TNBS+EPO1000 group was registered 13.5 ± 2.3 ng/ml of MPO (p<0.0001, compared 
with TNBS group). A dose dependent effect was identified in the decrease of MPO 
after EPO treatment, however without statistical significance between doses. The EPO 
and ethanol groups presented a significantly decrease of MPO activity to around 2.4 ± 
0.4 ng/ml and 5.8 ± 0.9 ng/ml of MPO, respectively.  
 
FIGURE 50. Effect of EPO treatment on MPO activity in the IBD. 
Legend: One-way ANOVA and Tukey’s post hoc- test; **** p<0.0001 compared with TNBS group. 
 
MEASUREMENT OF CYTOKINES 
Cytokines can become dysregulated in pathological conditions promoting inflammatory 
effect as TNF-α (FIGURE 51) and IL-1β (FIGURE 52). In this case, the TNBS group revealed a 
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significant increase of TNF-α compared with sham group (253.2 ± 31.4 vs 11.2 ± 0.2 
pg/ml, p<0.0001), as well as IL-1β compared with sham group (263.9 ± 25 vs 12.7 ± 
0.1 pg/ml, p<0.0001). Under treatment with 500 IU/Kg of EPO, the mice had 127.4 ± 
6.6 pg/ml of TNF-α and 126.5 ± 13 pg/ml of IL-1β. When it was administrated 1000 
IU/Kg of EPO, the mice presented 99.1 ± 10.2 pg/ml of TNF-α and 71.9 ± 10.6 pg/ml of 
IL-1β. Indeed, the mice under EPO treatment exhibited a significant decrease of these 
inflammatory cytokines (p<0.0001, compared with TNBS group), with a dose-
dependent effect. In the IL-1β concentration, this effect had a statistical significance 
between EPO doses. The remaining control groups presented values of TNF-α and IL-
1β quite similar with sham group. The EPO1000 group had 11.7 ± 0.5 pg/ml of TNF-α 
and 12.6 ± 0.1 pg/ml of IL-1β. And the ethanol group had 14.9 ± 2 pg/ml of TNF-α and 
16.2 ± 1.6 pg/ml of IL-1β. 
 
FIGURE 51. Effect of EPO treatment on TNF-α concentration in the IBD. 
Legend: One-way ANOVA and Tukey’s post hoc test; **** p<0.0001 compared with TNBS group. 
 
FIGURE 52. Effect of EPO treatment on IL-1β concentration in the IBD. 
Legend: One-way ANOVA and Tukey’s post hoc test; * p<0.05; **** p<0.0001 compared with TNBS group or between groups. 
 
The results of IL-10 measurements, as anti-inflammatory cytokine, confirm the obtained 
results with TNF-α and IL-1β measurements, because usually the IL-10 decrease when 
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the TNF-α and IL-1β increase under inflammatory conditions (FIGURE 53). Therefore, the 
TNBS group presented a low IL-10 concentration of around 31.4 ± 3.3 pg/ml. The EPO 
treatment promoted an increase of IL-10, with a dose-dependent effect and statistical 
significance at the higher dose (p<0.0001, compared with TNBS group). Concretely, 
the TNBS+EPO500 and TNBS+EPO1000 groups had 63.8 ± 5.5 pg/ml and 151.1 ± 
25.3 pg/ml, respectively (p<0.0001). The control groups, like EPO1000, ethanol and 
sham groups, had similar results with 21.6 ± 2.4 pg/ml, 17.3 ± 1.2 pg/ml and 15.7 ± 0.1 
pg/ml of IL-10, respectively. 
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FIGURE 53. Effect of EPO treatment on IL-10 concentration in the IBD. 
Legend: One-way ANOVA and Tukey’s post hoc test; **** p<0.0001 compared with TNBS group or between groups. 
 
ASSESSMENT OF COLITIS SEVERITY 
The macroscopic inspection of cecum, colon, and rectum in the TNBS group showed 
presence of mucosal congestion, hemorrhagic ulcerations and necrosis. After EPO 
treatment, the lesions appeared to have the same severity, but with less extension. No 
macroscopic alterations were observed in the control groups.  
 
The histopathological score was calculated based on the presence of tissue 
loss/necrosis, severity of mucosal epithelial lesion, inflammation and extension of the 
lesions (TABLE 12). The analysis of partial scores allows evaluating the beneficial effect of 
EPO treatment and which parameters are affected. Daily treatment with EPO (500 and 
1000 IU/kg) resulted in a decrease in the severity of colitis in each parameter under 
evaluation, but especially in the decrease of the mucosal loss. This treatment also 
allowed a decrease of extension of colitis, especially with a decrease of the percentage 
of intestine affected by the most severe lesion. The administration of the higher EPO 
dose promoted a slight decrease of inflammation and the percentage of intestine 
affected in any manner and intestine affected by the most severe lesion. On the other 
hand, the control groups revealed partial scores too low in all evaluated parameters. 
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TABLE 12. Average (± SEM) of partial scores of histopathological score  
of TNBS-induced colitis under EPO treatment. 
  
TNBS TNBS+EPO500 
TNBS+EPO
1000 EPO1000 ETHANOL SHAM 
MUCOSAL LOSS 3.3 ± 0.2 1.9 ± 0.5 1.8 ± 0.5 0 ± 0 0.2 ± 0.1 0 ± 0 
EPITHELIAL LESIONS 3.4 ± 0.2 2.7 ± 0.5 2.8 ± 0.4 0 ± 0 0.9 ± 0.5 0 ± 0 
INFLAMMATION 3.8 ± 0.1 2.7 ± 0.4 2.3 ± 0.4 0.5 ± 0.2 1.1 ± 0.2 0.1 ± 0.1 
EXTENT 1* 3.7 ± 0.1 3.2 ± 0.3 2.8 ± 0.3 0.5 ± 0.2 1.3 ± 0.3 0.1 ± 0.1 
EXTENT 2** 3 ± 0.2 1.8 ± 0.3 1.6 ± 0.3 0.5 ± 0.2 1 ± 0.2 0.1 ± 0.1 
 
Legend: * Extent 1 - Percentage of intestine affected in any manner;  
** Extent 2 - Percentage of intestine affected by the most severe lesion. 
 
The histopathological score ranges between 0 and 20 (FIGURE 54). With regard to mice 
with TNBS-induced colitis, the TNBS group had a final score of around 17 ± 0.6, 
presenting a score substantially higher than the sham group (p<0.0001). Under EPO 
treatment, the histopathological score decreased, such that the TNBS+EPO500 and 
TNBS+EPO1000 groups obtained a final score of 12.2 ± 1.6 and 11.3 ± 1.4, 
respectively (p<0.05 and p<0.01, compared with TNBS group). No statistically 
significant differences were found between EPO doses. The control groups revealed a 
residual histopathological score with EPO1000 and sham groups presenting around 1.5 
± 0.6 and 0.2 ± 0.2 of final score, respectively. The ethanol control group was the only 
group with a histopathological score slightly higher with 4.5 ± 1.2, but without 
statistically significant differences with sham group. This result is consistent with the 
histopathological images.  
 
FIGURE 54. Effect of EPO treatment on histopathological score. 
Legend: One-way ANOVA and Tukey’s post hoc test; * p<0.05; ** p<0.01; **** p<0.0001 compared with TNBS group.  
 
Representative images translating the histopatological score for the experimental 
groups analyzed are showed herein (FIGURE 55). Briefly, the TNBS group displays diffuse 
transmural necrosis with severe hemorrhaging, involving the mucosa, submucosa, 
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muscle layer and serosa, and often associated with peritonitis. Under EPO treatment, 
similar lesions are seen, namely the transmural necrosis, but with lesser extent and 
with a multifocal pattern, interspersed with areas in which the mucosal integrity is 
maintained. In these areas there is mild to moderate epithelial erosion and ulceration, 
and severe inflammatory cell infiltration, extending to the submucosa. The increase of 
EPO dose has a minor effect in the histopathological score, with lower extent of the 
lesions, but without statistical significance. The ethanol group showed only mild 
epithelial erosion, and no lesions were observed in the EPO and sham groups.  
 
 
 
 
 
 
 
FIGURE 55. Effect of EPO treatment on histopathologic changes in the IBD. 
Legend: Each column corresponding with a different experimental group, namely (A) TNBS group,  
(B) TNBS+EPO500 group, (C) TNBS+EPO1000 group, (D) EPO group, (E) Ethanol group and (F) Sham group. 
 
MORTALITY RATE  
At the end of the study, it was evaluated the mortality rate in the experimental groups 
as a sign of toxicity (TABLE 13). The TNBS group presented 31.4% of mortality rate 4 
days after induction. The mortality rate decreased, when these mice were treated with 
a daily dose of EPO. The TNBS+EPO500 group presented 28.6%, while the 
TNBS+EPO1000 group presented 25.7% of mortality rate.  Although it have not been 
verified a statistically significant differences between groups, the mortality rate 
decreased with the increase of EPO dose. In the sham group, all mice survived during 
the study. 
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TABLE 13. Effect of EPO treatment on mortality rate in the IBD. 
 TOTAL DEATHS SURVIVORS 
P-VALUE 
n (%) n (%) n (%) 
EXPERIMENTAL 
GROUPS 
TNBS 35 (100%) 11 (31.4%) 24 (68.6%) 
0.353 (ns) 
TNBS + EPO500 35 (100%) 10 (28.6%) 25 (71.4%) 
TNBS + EPO1000 35 (100%) 9 (25.7%) 26 (74.3%) 
Sham 20 (100%) 0 (0%) 20 (100%) 
 
Legend: Chi-square test; ns – no statistical significance. 
 
 
2.  DISCUSSION OF RESULTS 
EPO, the principal hormone promoting the survival and differentiation of erythroid 
progenitor cells, is currently being used in the therapy of patients with chronic renal 
failure suffering from anemia [Cody et al., 2001; Nairz et al., 2011]. However, EPO also 
bears extrahematopoietic properties that are transduced by EPOR expressed on 
various nonerythroid tissues [Brines & Cerami, 2005; Jelkmann, 2007]. In the TNBS-
induced colitis, there is some scientific evidence that EPO-EPOR interaction inhibits 
NF-κB pathway, decreasing the production of NF-κB inducible immune mediators and, 
subsequently, limiting tissue damage and ameliorating disease severity. These 
immune-modulatory effects of EPO may be of therapeutic relevance in inflammatory 
disease [Nairz et al., 2011]. EPO benefits have been studied in cardiovascular, 
neurologic, retinal, auditory, pancreatic, renal and liver injuries [Sanchis-Gomar et al., 
2014; Chatagner et al., 2010; Loeliger et al., 2011; Olgun et al., 2013; Ucan et al., 
2009; Imamura et al., 2007; Sepodes et al., 2006]. Until nowadays, some studies have 
evaluated the influence of EPO on the experimental colitis, but much more research is 
needed to understand and confirm the effect of this drug in IBD. Particularly, mice with 
TNBS-induced colitis (and without any other comorbidity) were never subjected to an 
EPO treatment. The results on this specific colitis model are very relevant, since TNBS-
induced colitis is one of the most used as colitis model and promotes a typically colon 
injury compatible with CD. Thus, we proposed to assess the influence of EPO in the 
TNBS-induced colitis model. Furthermore, EPO doses used in this study will be lower 
than those which have been used in other studies, so are more approached of the 
doses usually used in the clinical practice in humans.   
Mice with TNBS-induced colitis were daily followed, monitoring by some clinical 
symptoms/signs. We observed that EPO treatment was able to attenuate the diarrhea 
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and moderate the edema of the anus in these colitic mice. Furthermore, EPO also 
significantly reduced the percentage of weight loss of mice during the experimental 
period at both administrated doses. Curiously, the mice treated with the higher EPO 
dose presented a weight gain of around 7.3% of its initial weight. This data might 
suggest that similarly to other studies [Cuzzocrea et al., 2004; Nairz et al., 2011] 
Variations in the length of any part of the colon are the developmental origin and may 
lead to variety of acute and chronic pathological conditions [Nayak et al., 2012]. TNBS-
induced colitis is characterized by a shortened colon. EPO treatment was able to 
increase the colon length in a dose dependent manner but without statistical 
significance. This finding suggests a beneficial effect of EPO in this biomarker, 
eventually in a highest dose.   
In regarding to fecal hemoglobin, its determination can be useful in the detection of 
lesions accompanied by bleeding [Hirata et al., 2007; Jagtap et al., 2011], however it 
had never been measured the influence of EPO treatment in this biological marker. 
Thus, we verified that EPO also has an influence in the intensity of hemorrhagic focus, 
since a significant reduction of fecal hemoglobin was observed after EPO treatment in 
a dose dependent manner. In the higher EPO dose, the mice presented fecal 
hemoglobin values similar with the control groups.  
 
The intestinal APL is expressed on the enterocytes and it is responsible for mucosal 
defense [Malo et al., 2010; Nagalingam et al., 2011], so the influence of EPO treatment 
on ALP level must be evaluated. We observed that the elevated level of ALP was 
significantly attenuated by the EPO treatment by virtue of its anti-inflammatory 
potential. This data is consistent with other previous findings, where anti-inflammatory 
drugs are able to decrease ALP level [Kumar et al., 2014]. In both EPO doses, the 
mice presented serum ALP values similar with the EPO1000 and ethanol groups.  
 
EPO treatment significantly reduced the level of MPO in inflamed colon in a dose 
dependent manner. The inhibition of neutrophil infiltration in colonic tissue by EPO is 
also evident in the histopathological observations. Thus, beneficial effect of EPO 
treatment may be due in part to the suppression of inflammatory response via the 
inhibition of leukocyte infiltration [Cuzzocrea et al., 2004; Karatepe et al., 2010].  
To test whether EPO treatment may modulate the inflammatory process through the 
regulation of the secretion of some cytokines, we analyzed the colon levels of pro-
inflammatory cytokines, as TNF-α and IL-1β, in mice treated with EPO. In this sense, 
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we observed that the levels of these cytokines were significantly reduced in the colon 
tissues collected from TNBS-treated mice after EPO administration in a dose 
dependent manner. These findings, therefore, suggest that EPO reduced the activation 
and the subsequent expression of pro-inflammatory cytokines, confirming again its anti-
inflammatory activity, which is mechanistically attributable to blockage of NF-κB 
activation [Sandborn & Hanauer, 1999; Cuzzocrea et al., 2004; Nairz et al., 2011].  
To confirmation the mechanism of observed amelioration of TNBS-induced colitis by 
EPO, culture supernatants were additionally tested for the presence of IL-10. IL-10 
itself functions as an anti-inflammatory cytokine and limits excessive tissue disruption 
caused by inflammation [Coquerelle et al., 2009; Yang et al., 2010]. We observed that 
EPO also promoted a significantly increase of IL-10 levels with a dose dependent 
effect, constituting an important role in controlling inflammatory response in the TNBS-
induced colitis. In the higher EPO dose, the IL-10 concentration increased around 80% 
comparing with TNBS-induced colitis. However, this data is not consistent with other 
studies, since their findings concluded that EPO treatment promoted a decrease of pro-
inflammatory cytokine without affecting the expression of IL-10 [Nairz et al., 2011]. 
The histopatological score was significantly reduced in TNBS-treated mice receiving 
EPO treatment. EPO was able to decrease the severity and the extension of the colon 
injury, suggesting a remarkable recovery of the disease. These beneficial effects are 
coincident with other findings observed previously [Cuzzocrea et al., 2004; Karatepe et 
al., 2010; Nairz et al., 2011; Tasdemir et al., 2013].  
The well-documented extra-intestinal manifestations and complications of IBD, as well 
as the possible renal and hepatic side effects of pharmacotherapy, emphasize the 
need for periodic evaluation of renal and hepatic functions [Larsen, Bendtzen & 
Nielsen, 2010; Oikonomou et al., 2011; Rojas-Feria et al., 2013]. The evaluation of the 
influence of EPO in the extra-intestinal manifestations of IBD is truly relevant, since had 
never been investigated. For the first time, we observed that a single daily dose of EPO 
is able to recover the renal and hepatic functions to normal levels, similarly to sham 
group. Our findings suggest that EPO has a beneficial effect in the extra-intestinal 
manifestations due to metabolic and physiologic changes induced by the IBD. 
Furthermore, we also can conclude that EPO does not promote renal and/or hepatic 
changes as adverse drug reaction, in this experimental colitis model. More studies are 
needed to understand the mechanism beside of the beneficial effect of EPO in the 
extra-intestinal manifestations of IBD. Probably, it is due to the interaction of EPO-
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EPOR expressed on various nonerythroid tissues [Brines & Cerami, 2005; Jelkmann, 
2007]. 
EPO stimulates erythropoiesis which leads to increased production of erythrocytes and, 
subsequently, an increase of hematocrit [Panjeta et al., 2015]. Moreover, some trials 
has raised safety concerns with the drug and suggested that potential benefits may be 
mitigated by prothrombotic effects. However, the small sample sizes produced 
underpowered results [Gao et al., 2012]. In fact, the influence of EPO treatment in the 
appearance of possible cardiovascular adverse events was never evaluated in other 
studies, previously. Therefore, although our acute colitis model has been developed in 
only four days, the hematocrit level was measured at the end of experimental period to 
evaluate the risk of related side effects. All experimental groups registered normal 
hematocrit levels, according to reference levels in CD-1 mice between 43.9 and 53.3%, 
as previously described [Prefontaine, 2013]. These data suggest that EPO does not 
increase the risk of adverse events related with blood viscosity.  
Briefly, EPO treatment had a positive influence in the development of experimental 
colitis in all evaluated parameters, thus reducing its severity and extension. More 
precisely, EPO reduced the percentage of weight loss, fecal hemoglobin, ALP, MPO, 
pro-inflammatory cytokines (TNF-α and IL-1β) and histopathological score. On the 
other hand, EPO also increased colon length and anti-inflammatory cytokine (IL-10) 
and regulated the renal and hepatic functions. Furthermore, the mortality rate reduced 
around 5.7% with the higher EPO dose, as well as the hematocrit remained unchanged 
after EPO treatment. These data indicate that EPO significantly inhibits acute 
inflammatory response in the TNBS-induced colitis model, without adverse events 
related to blood viscosity. All of these findings also support the view that EPO is 
protective in experimental colitis and that inhibition of TNF-α and IL-1β formation 
(among other MPO effects that include inhibition of neutrophils infiltration) in the colon 
probably accounts for its beneficial effects. 
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CHAPTER 7 – THIADIAZOLIDINONE-8 EFFECT  
IN INFLAMMATORY BOWEL DISEASE 
 
 
1. RESULTS 
 
MONITORING OF CLINICAL SYMPTOMS/SIGNS  
During the experimental study, the mice were observed daily for stool consistency, 
anus appearance and morbidity. After the induction of colitis, the TNBS group revealed 
an alteration of intestinal motility characterized by diarrhea or soft stools, severe edema 
of the anus and moderate morbidity. Under TDZD-8 treatment, these mice maintained 
the alterations of intestinal motility, as diarrhea or soft stools, that it was observed in 
the TNBS group. However, the other clinical symptoms/signs showed an improvement 
with moderate edema of the anus and mild morbidity, while the control groups, like 
TDZD-8, ethanol and sham groups, didn’t reveal any alteration in these clinical 
symptoms/signs. The change of body weight was also measured daily since the 
induction day until the end of the study (FIGURE 56). The TNBS group presented a 
progressive fall in body weight over experimental period, reaching a loss of around -12 
± 1.4% of its initial weight. The TNBS+TDZD-8 group also followed the same profile 
with a fall in body weight of -11.5 ± 3%. Curiously, the TNBS+Vehicle group had a 
better profile in the changes of body weight ending with -4.4 ± 9.9% of weight loss 
(p<0.05, compared with TNBS group). However, the control groups presented a 
considerable increase in body weight, especially from day 0 to day 1, around 10 to 30% 
at day 1. At the end of experimental period, the TDZD-8, ethanol and sham groups 
gained 10.6 ± 5.2%, 15.2 ± 1.1% and 31.2 ± 1.6% (p<0.0001, compared with TNBS 
group) of its initial weight, respectively. 
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FIGURE 56. Change of body weight during TDZD-8 treatment in the IBD. 
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BIOCHEMICAL MARKERS 
The colon length was evaluated and compared between all experimental groups, as a 
marker of tissue integrity (FIGURE 57). The mice with TNBS-induced colitis had a 
shortening of colon length (10.1 ± 0.2 cm) relatively to the sham group (11.5 ± 0.2 cm) 
as a comparable normal colonic tissue (p<0.01). However, the TDZD-8 treatment had 
no effect on the colon length, because the TNBS+TDZD-8 (10.3 ± 1.2 cm) and 
TNBS+Vehicle (10.3 ± 0.6 cm) groups presented similar results to TNBS group. The 
other control groups, as the TDZD-8 and ethanol groups, presented an increase of 
colon length coincident to the sham group, like 11.7 ± 0.9 cm and 11.5 ± 0.4 cm, 
respectively, without statistically significance differences between them. 
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FIGURE 57. Effect of TDZD-8 treatment on colon length in the IBD. 
Legend: One-way ANOVA and Tukey’s post hoc test; ** p<0.01; *** p<0.001 compared with TNBS group. 
 
The fecal hemoglobin was measured in all groups and it allowed evaluate the impact of 
TDZD-8 treatment in the experimental colitis (FIGURE 58). The concentration of fecal 
hemoglobin in the TNBS group was increased comparing to the sham group (12.5 ± 
0.3 vs 0.7 ± 0.1 µmol Hg/g feces, p<0.0001). This biochemical marker was also higher 
than the other control groups, like TDZD-8 (1 ± 0 µmol Hg/g feces) and ethanol (1.1 ± 
0.1 µmol Hg/g feces) (p<0.0001, compared with TNBS group). No statistically 
significant changes were found between control groups. The mice with TNBS-induced 
colitis revealed a decreased of fecal hemoglobin after TDZD-8 daily administration, with 
4.4 ± 0.3 µmol Hg/g feces in the TNBS+TDZD-8 group (p<0.0001, compared with 
TNBS group). Curiously, the TNBS+Vehicle group also presented a decrease of fecal 
hemoglobin comparing with TNBS group (9.7 ± 0.2 µmol Hg/g feces, p<0.0001), but 
not so expressive as TNBS+TDZD-8 group.  
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FIGURE 58. Effect of TDZD-8 treatment on fecal hemoglobin in the IBD. 
Legend: One-way ANOVA and Tukey’s post hoc test; **** p<0.0001 compared with TNBS group or between groups. 
 
The APL concentration was evaluated in all experimental groups, due to its protective 
effect on intestinal system (FIGURE 59).  The TNBS group presented 72.7 ± 2.3 IU/L of 
ALP concentration on blood, as well as the TNBS+Vehicle group with 70.3 ± 1.7 IU/L. 
The TDZD-8 treatment had a protective effect with a decrease of ALP concentration to 
44.9 ± 1.3 IU/L (p<0.0001, compared with TNBS group). The TDZD-8 and ethanol 
groups had quite similar results, like 42.3 ± 1 U/L and 38.5 ± 0.6 IU/L, respectively. The 
sham group presented 19.2 ± 1.8 IU/L of APL (p<0.0001, compared with TNBS group).  
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FIGURE 59. Effect of TDZD-8 treatment on serum total ALP concentration in the IBD. 
Legend: One-way ANOVA and Tukey’s post hoc test; **** p<0.0001 compared with TNBS group. 
 
The renal function of mice with TNBS-induced colitis was evaluated based on serum 
urea and creatinine concentrations (FIGURE 60 AND 61).  The TNBS group had 62.4 ± 1.5 
mg/dl of urea concentration comparing to 49.3 ± 0.9 mg/dl in the sham group 
(p<0.0001). The mice under TDZD-8 treatment presented 44.3 ± 0.7 mg/dl of urea 
similar with the control groups, whereas the TNBS+Vehicle group presented 65.5 ± 1.2 
mg/dl similar with TNBS group. The other control groups, like TDZD-8 and ethanol 
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groups, revealed 43 ± 1.1 mg/dl and 41.4 ± 0.5 mg/dl of urea, respectively. The 
creatinine concentration described the same tendency than urea concentrations. The 
TNBS and TNBS+Vehicle groups were those with the highest values, like 0.27 ± 0.01 
mg/dl and 0.28 ± 0.01 mg/dl, respectively (p<0.0001, compared with sham group). The 
TNBS+TDZD-8 group had 0.19 ± 0.01 mg/dl of creatinine comparable with the control 
groups. The TDZD-8, ethanol and sham groups presented coincident results, namely 
0.20 ± 0 mg/dl, 0.21 ± 0.01 mg/dl and 0.20 ± 0.02 mg/dl, respectively.  
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FIGURE 60. Effect of TDZD-8 treatment on serum urea concentration in the IBD. 
Legend: One-way ANOVA and Tukey’s post hoc test; **** p<0.0001 compared with sham group. 
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FIGURE 61. Effect of TDZD-8 treatment on serum creatinine concentration in the IBD. 
Legend: One-way ANOVA and Tukey’s post hoc test; **** p<0.0001 compared with sham group. 
 
The hepatic function was evaluated based on serum ALT concentration (FIGURE 62). The 
TNBS group exhibited an increase in ALT concentration compared with sham group 
(38.7 ± 1.2 vs 17.5 ± 0.8 IU/L, p<0.0001). The mice treated with TDZD-8 presented a 
significant decrease of ALT levels to around 28.3 ± 0.8 IU/L (p<0.0001, compared with 
TNBS group). The hepatic biochemistries of TNBS+Vehicle group revealed 38 ± 1.1 
IU/L of ALT, without statistically significant differences with TNBS group. In the TDZD-8 
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and ethanol groups, the ALT concentration was slightly higher than the sham group 
(29.4 ± 0.8 IU/L and 32.3 ± 1.2 IU/L, respectively, p<0.0001). 
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FIGURE 62. Effect of TDZD-8 treatment on serum ALT concentration in the IBD. 
Legend: One-way ANOVA and Tukey’s post hoc test; **** p<0.0001 compared with sham group or between groups. 
 
MYELOPEROXIDASE ACTIVITY 
The MPO measurements allowed identifying differences in its activity between all 
experimental groups (FIGURE 63). The TNBS group presented an increase of MPO 
concentration comparing with the sham group (42 ± 2.8 vs 2.3 ± 0.4 ng/ml, p<0.001). 
As expected, in the TNBS+Vehicle group (41.5 ± 1.9 ng/ml) was registered a MPO 
activity quite similar with TNBS group. Furthermore, the TDZD-8 treatment was able to 
decrease the MPO activity to 27.6 ± 3.2 ng/ml (p<0.001, compared with TNBS group). 
The TDZD-8 and ethanol groups presented a significantly decrease of MPO activity to 
around 10.8 ± 3.8 ng/ml and 5.8 ± 0.9 ng/ml of MPO, respectively.  
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FIGURE 63. Effect of TDZD-8 treatment on MPO activity in the IBD. 
Legend: One-way ANOVA and Tukey’s post hoc test; *** p<0.001 compared with TNBS group. 
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MEASUREMENT OF CYTOKINES 
The TDZD-8 treatment revealed a significant decrease in the pro-inflammatory 
cytokines production, as TNF-α and IL-1β (FIGURE 64 AND 65). Concretely, the 
TNBS+TDZD-8 presented 153.3 ± 12.1 pg/ml of TNF-α and 129.1 ± 9.9 pg/ml of IL-1β. 
Indeed, the TDZD-8 treatment had a positive influence on the TNBS-induced colitis, 
since the mice from TNBS group presented a considerable increase of pro-
inflammatory cytokines with 253.2 ± 31.4 pg/ml of TNF-α and 263.9 ± 25 pg/ml of IL-1β  
(p<0.01 and p<0.001, respectively, compared with TNBS+TDZD-8 group). The 
TNBS+Vehicle group also registered an increased TNF-α and IL-1β levels with 274.8 ± 
21.9 pg/ml and 271.1 ± 22.6 pg/ml, respectively. However, all control groups presented 
the lowest levels of pro-inflammatory cytokines. The ethanol and sham groups had very 
similar concentrations of pro-inflammatory cytokines. The ethanol group presented 14.9 
± 2 pg/ml of TNF-α and 16.2 ± 1.6 pg/ml of IL-1β and the sham group presented 11.2 ± 
0.2 pg/ml of TNF-α and 12.7 ± 0.1 pg/ml of IL-1β. Nevertheless, the TDZD-8 group was 
the only group with a TNF-α and IL-1β levels slightly higher with 71.2 ± 46.1 pg/ml and 
92 ± 45.8 pg/ml, respectively, but without statistically significant differences with sham 
group. 
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FIGURE 64. Effect of TDZD-8 treatment on TNF-α concentration in the IBD. 
Legend: One-way ANOVA and Tukey’s post hoc test; ** p<0.01; *** p<0.001 compared with TNBS group. 
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FIGURE 65. Effect of TDZD-8 treatment on IL-1β concentration in the IBD. 
Legend: One-way ANOVA and Tukey’s post hoc test; *** p<0.001 compared with TNBS group. 
 
In return, the anti-inflammatory cytokines, as IL-10, are typically decreased in the 
TNBS-induced colitis (FIGURE 66). The assessment of IL-10 concentrations confirms the 
obtained results in the TNF-α and IL-1β measurements. Concretely, the TNBS group 
presented a low IL-10 concentration with 31.4 ± 3.3 pg/ml (p<0.01, compared with 
sham group), as well as the TNBS+Vehicle group with 32.1 ± 1.9 pg/ml of IL-10. 
However, after TDZD-8 treatment, the mice showed a significant increase of IL-10 with 
75.1 ± 4.9 pg/ml (p<0.001, compared with TNBS group). The control groups, as TDZD-
8, ethanol and sham groups, had similar results with 19.8 ± 0.9 pg/ml, 17.3 ± 1.2 pg/ml 
and 15.7 ± 0.1 pg/ml of IL-10, respectively. 
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FIGURE 66. Effect of TDZD-8 treatment on IL-10 concentration in the IBD. 
Legend: One-way ANOVA and Tukey’s post hoc test; * p<0.05; ** p<0.01; *** p<0.001 compared with TNBS group. 
 
ASSESSMENT OF COLITIS SEVERITY 
The macroscopic inspection of cecum, colon, and rectum in the TNBS group showed 
presence of mucosal congestion, hemorrhagic ulcerations and necrosis. After TDZD-8 
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treatment, the macroscopic alterations were the same than were observed in the TNBS 
group. No macroscopic alterations were observed in the control groups. 
 
The histopathological score was calculated based on severity (the presence of tissue 
loss/necrosis, severity of mucosal epithelial lesion and inflammation) and extension of 
the lesions (TABLE 14). The treatment with TDZD-8 has no effect on the severity of colitis 
comparing with TNBS group. However, it is possible to identify a slight decrease of the 
percentage of intestine affected by the most severe lesion from 3 ± 0.2 to 2.3 ± 0.2 
after TDZD-8 treatment. The TNBS+Vehicle group presented results on each 
parameter very similar with the TNBS group. Finally, the control groups revealed partial 
scores too low in all evaluated parameters, except the ethanol group with a slight 
increase in values, consistent with the histopathological images. 
 
TABLE 14. Average (± SEM) of partials scores of histopathological score  
of TNBS-induced colitis under TDZD-8 treatment. 
  
TNBS TNBS + TDZD-8 
TNBS + 
VEHICLE TDZD-8 ETHANOL SHAM 
MUCOSAL LOSS 3.3 ± 0.2 3.9 ± 0.1 3.8 ± 0.5 0 ± 0 0.2 ± 0.1 0 ± 0 
EPITHELIAL LESIONS 3.4 ± 0.2 4 ± 0 4 ± 0 0 ± 0 0.9 ± 0.5 0 ± 0 
INFLAMMATION 3.8 ± 0.1 4 ± 0 4 ± 0 0.4 ± 0.2 1.1 ± 0.2 0.1 ± 0.1 
EXTENT 1* 3.7 ± 0.1 3.8 ± 0.1 3.9 ± 0.1 0.4 ± 0.2 1.3 ± 0.3 0.1 ± 0.1 
EXTENT 2** 3 ± 0.2 2.3 ± 0.2 2.8 ± 0.2 0.4 ± 0.2 1 ± 0.2 0.1 ± 0.1 
 
Legend: * Extent 1 - Percentage of intestine affected in any manner;  
** Extent 2 - Percentage of intestine affected by the most severe lesion. 
 
The histopathological score was evaluated in all experimental groups (FIGURE 67). The 
TNBS group presented a final score of around 17 ± 0.6, substantially higher than the 
sham group (p<0.0001). Curiously, when the mice are treated with TDZD-8, the 
histopathological score keeps unchanged (18 ± 0.2). The results from TNBS+Vehicle 
are quite similar with the TNBS and TNBS+TDZD-8 groups (18.5 ± 0.3). The control 
groups revealed a histopathological score very low, namely 1.3 ± 0.6 for the TDZD-8 
group, 4.5 ± 1.2 for the ethanol group and 0.2 ± 0.2 for the sham group. The ethanol 
control group was the only group with a histopathological score slightly higher.  
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FIGURE 67. Effect of TDZD-8 treatment on histopathological score. 
Legend: One-way ANOVA and Tukey’s post hoc test; **** p<0.0001 compared with TNBS group. 
 
The images reflect the histopatological score for these experimental groups (FIGURE 68). 
The TNBS group displays diffuse transmural necrosis with severe hemorrhaging, 
involving the mucosa, submucosa, muscle layer and serosa, and often associated with 
peritonitis. Under TDZD-8 treatment, similar lesions are seen, without any improvement 
in the severity and/or extension of the lesion. The histopathological images of 
TNBS+Vehicle group present the same lesions than TNBS group. The ethanol group 
showed only mild epithelial erosion, and no lesions were observed in the TDZD-8 and 
sham groups.  
  
 
 
 
 
 
 
 
 
FIGURE 68. Effect of TDZD-8 treatment on histopathologic changes in the IBD.  
Legend: Each column corresponding with a different experimental group, namely (A) TNBS group,  
(B) TNBS+TDZD-8 group, (C) TNBS+Vehicle group, (D) TDZD-8 group, (E) Ethanol group and (F) Sham group. 
 
 
E F B C D A 
**** 
**** 
**** 
 PHARMACOLOGICAL MODULATION OF INFLAMMATION ASSOCIATED WITH INFLAMMATORY BOWEL DISEASE 
CHAPTER 7 – THIADIAZOLIDINONE-8 EFFECT IN INFLAMMATORY BOWEL DISEASE      120 
MORTALITY RATE 
The mortality rate was evaluated as a sign of toxicity (TABLE 15). The TNBS group 
presented 31.4% of mortality rate in the end of the study, but this percentage 
decreased for 25.7% when these mice were treated with a daily dose of TDZD-8. The 
TNBS+Vehicle group presented 20% of mortality rate. Although it have not been 
verified a statistically significant differences between groups, the mortality rate 
decreased after TDZD-8 treatment. In the sham group, all mice survived during the 
study. 
 
TABLE 15. Effect of TDZD-8 treatment on mortality rate in the IBD. 
 TOTAL DEATHS SURVIVORS 
P-VALUE 
n (%) n (%) n (%) 
EXPERIMENTAL 
GROUPS 
TNBS 35 (100%) 11 (31.4%) 24 (68.6%) 
0.499 (ns) 
TNBS + TDZD-8 35 (100%) 9 (25.7%) 26 (74.3%) 
TNBS + Vehicle 20 (100%) 4 (20%) 16 (80%) 
Sham 20 (100%) 0 (0%) 20 (100%) 
 
Legend: Chi-square test; ns – no statistical significance. 
 
 
2. DISCUSSION OF RESULTS 
 
This study also evaluated the influence of TDZD-8 in the TNBS-induced colitis model. 
TDZD-8 is the first non-ATP competitive GSK-3β inhibitors with highly effectiveness 
and selectivity [Martinez et al., 2002a; Dugo et al., 2007]. The few findings suggest that 
the inhibition of GSK-3β promotes a reduction of NF-κB, suggesting the influence of 
this protein kinase in the regulation of inflammatory process [Whittle et al., 2006]. Many 
recent studies suggest GSK-3β has become a novel and important therapeutic target in 
inflammatory and autoimmune diseases [Cohen & Goedert, 2004; Whittle et al., 2006; 
Beurel et al., 2009]. Indeed, GSK-3β emerged in a therapeutic potential for the 
treatment of several diseases, such as cancer, diabetes type II, chronic inflammatory 
processes, stroke, and neurological diseases [Castro & Martinez, 2000; Kim & Kimmel, 
2000; Wagman & Nuss, 2001; Cohen, 2001; Sasaki et al., 2001]. Until nowadays, the 
influence of TDZD-8 on the experimental colitis was not well described, as well as the 
full pharmacological profile and selectivity of this agent awaits further evaluation [Dugo 
et al., 2005]. Only one study was published, describing the data from rats with TNBS-
induced colitis treated with TDZD-8 and, furthermore, some inflammation parameters 
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were not evaluated yet. So, more studies are needed to understand the effect of this 
drug in IBD.  
 
Regarding clinical symptoms/, TDZD-8 treatment showed an improvement with 
moderate edema of the anus and mild morbidity comparing with non-treated mice. In 
body weight, we observed that the fall in body weight determined 4 days following 
challenge with TNBS was not attenuated by TDZD-8 treatment. On the other hand, the 
mice with TNBS-induced colitis treated with DMSO (TDZD-8 vehicle) presented a 
reduction of the percentage of weight lost compared with non-treated mice. These 
findings are not consistent with other studies, where TDZD-8 or other drug is used as 
GSK-3 inhibitor [Whittle et al., 2006; Uddin et al., 2013]. Because TDZD-8 treatment 
usually promotes an increase of body weight and DMSO supposedly has no effect on 
the disease management [Whittle et al., 2006]. One possible explanation can be based 
on some recent studies, which demonstrated that DMSO can present anti-inflammatory 
and anti-oxidant effects, beyond its use as vehicle of several pharmaceuticals [Li et al., 
2015]. However, DMSO is the most recommended vehicle for TDZD-8 and these 
properties only manifested when DMSO is used above of 10% of the administrated 
solution [Whittle et al., 2006; Li et al., 2015]. In our study, DMSO was diluted in the 
proportion of 1:10 in a saline solution, so it means that the dose was below those that 
promote anti-inflammatory and anti-oxidant effects.  
In the evaluation of colon length, this study verified that the shortening of the colon due 
to TNBS-induced colitis was not also influenced by TDZD-8 treatment, as well as with 
DMSO administration. One more time, this finding is not consistent with other studies 
[Whittle et al., 2006]. Apparently, there is no explanation for this data, since the dose of 
TDZD-8 used during the treatment was above than the doses previously used in other 
studies. Curiously, these findings (eg. body weight and colon length) are not also 
consistent with the remaining evaluated parameters, where the TDZD-8 treatment had 
a significant influence in the reduction of inflammation associated to TNBS-induced 
colitis. In sum, data are not coherent among studies, so more research studies are 
needed to evaluate the influence of TDZD-8 treatment in specific parameters, as body 
weight and colon length. 
Bloody diarrhea is the hallmark of IBD, but in mild disease, rectal bleeding may be 
absent [Kornbluth & Sachar, 2010]. Therefore, to assess whether TDZD-8 has 
influence in TNBS-induced colon damage, there was analyzed the fecal hemoglobin 
and quantified the intensity of hemorrhagic damage. Mice with TNBS-induced colitis 
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revealed an elevated concentration of fecal hemoglobin, however TDZD-8 was able to 
significantly attenuate its presence in the feces, after only 4 days of daily treatment. 
These data suggest that TDZD-8 promotes a decrease of intensity of hemorrhagic 
focus. 
Regarding to ALP measurement, we observed that TNBS-induced colitis presented an 
elevated ALP concentration, however TDZD-8 treatment had a protective effect, 
decreasing its serum concentration on blood. This result suggests that TDZD-8 has an 
anti-inflammatory effect by GSK-3 inhibition, since the inhibition of inflammatory 
process promotes a decrease of ALP level [Kumar et al., 2014]. 
Neutrophils have an important involvement in these inflammatory bowel processes, 
therefore the TNBS-induced colitis is always accompanied by a substantial increase in 
the levels of MPO [Ukil et al., 2003; Szczepanik et al., 2012]. The MPO measurements 
revealed that the level of MPO activity in the colonic tissue was substantially increased 
after DMSO administration (TNBS+Vehicle group) following TNBS challenge, 
compared with that from the nonchallenged control group. This result confirms that 
DMSO has no effect on amelioration of colonic inflammation, as previously known 
[Whitlle, 2006]. On the other hand, treatment with TDZD-8 caused a significant 
reduction in the elevated MPO activity, confirming its potent anti-inflammatory effect in 
a TNBS-induced colitis model. 
GSK-3β might be such a potential switch protein and was recently identified as a 
critical regulator in the modulation of TLR-induced inflammatory responses of blood 
monocytes, promoting the production of pro-inflammatory cytokines such as TNF-α and 
IL-1β [Carty et al., 2000; Hofmann, Dunger, Scholmerich, Falk & Obermeier, 2010]. 
Therefore, the effect of TDZD-8, as GSK-3β inhibitor, on the colonic levels of these pro-
inflammatory cytokines was evaluated. In our study, the observed increase in the levels 
of TNF-α and IL-1β in the inflamed colon was significantly reduced by TDZD-8 
treatment, suggesting a beneficial effect on TNBS-induced colitis where inhibition of 
GSK-3β is involved. This finding confirms the obtained data previously with TDZD-8 
[Whittle et al., 2006], as well as with other GSK-3 inhibitors [Uddin et al., 2013; Soubh, 
Abdallah & El-Abhar, 2015]. Thus, the blockade of GSK-3β attenuates TLR-mediated 
excessive pro-inflammatory cytokines and constitutes a promising therapeutic option 
for reducing intestinal immune reactions toward the luminal flora in IBD [Hofmann et al., 
2010].  
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GSK-3β promotes the production of pro-inflammatory cytokines, while simultaneously 
suppressing the secretion of anti-inflammatory cytokines as IL-10 [Carty et al., 2000; 
Hofmann et al., 2010]. In our study, we observed that assessment of IL-10 
concentrations confirms the obtained results in the TNF-α and IL-1β measurements. 
After TDZD-8 treatment, the mice with TNBS-induced colitis showed a significant 
increase of IL-10, suggesting and confirming the mechanism of observed amelioration 
of TNBS-induced colitis by GSK-3β inhibition [Hofmann et al., 2010].  
Regarding to histological score, we observed that colons of TDZD-8 treated mice were 
similar than those of non treated mice, suggesting that TDZD-8 treatment possibly has 
no effect on the severity and/or extension of the intestinal lesion inducted by disease. 
However, the histological features of the lesions allow identifying a slight decrease of 
the percentage of intestine affected by the most severe lesion after TDZD-8 treatment. 
So, these results suggest that TDZD-8 also reduced the extension of colon injury. 
TNBS-induced colitis model presented an increase of renal and hepatic markers, as 
secondary extra-intestinal symptoms to colon injury. However, TDZD-8 treatment 
significantly suppressed the level of these markers, suggesting a beneficial effect in the 
extra-intestinal symptoms due to GSK-3β inhibition. Renal markers were even reduced 
to similar concentrations with sham group. Our findings also suggest that TDZD-8 does 
not promote renal and/or hepatic changes as adverse drug reaction, in this 
experimental colitis model. 
As already mentioned, there is only one published paper relating the TDZD-8 treatment 
with IBD and, therefore, several parameters had never been evaluated in a TNBS-
induced colitis model after TDZD-8 administration, such as IL-1β, IL-10, histological 
features and extra-intestinal symptoms. Thus, this study was innovative, since some 
new parameters were measured for the first time. Briefly, TDZD-8 had also a positive 
influence in the development of experimental colitis, but not in all evaluated 
parameters. This drug promoted a reduction of fecal hemoglobin, ALP, MPO and pro-
inflammatory cytokines (TNF-α and IL-1β). TDZD-8 was also able to increase the anti-
inflammatory cytokine (IL-10) and the renal and hepatic functions were regulated. 
Indeed, TDZD-8 treatment significantly improved several inflammation markers and, 
subsequently, promoted a reduction of severity of this TNBS-induced colitis model, 
suggesting an anti-inflammatory effect of TDZD-8 by GSK-3β inhibition. Furthermore, 
TDZD-8 treatment slightly decreased the extension of colon injury, which was identified 
in the histological images. In sum, these data indicate that TDZD-8 significantly inhibits 
acute inflammatory response in the experimental colitis. 
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CHAPTER 8 – HEMIN EFFECT IN INFLAMMATORY BOWEL DISEASE 
 
 
1. RESULTS 
 
MONITORING OF CLINICAL SYMPTOMS/SIGNS  
The clinical symptoms/signs daily observed during the experimental period were stool 
consistency, anus appearance and morbidity. Following experimental induction of 
colitis, the TNBS group presented an alteration of intestinal motility characterized by 
diarrhea or soft stools, severe edema of the anus and moderate morbidity. Under 
hemin treatment, these mice maintained the alterations of intestinal motility, as diarrhea 
or soft stools, which were observed in the TNBS group. However, the other clinical 
symptoms/signs showed an improvement with moderate edema of the anus and mild 
morbidity. The control groups, as hemin10, ethanol and sham groups, remained 
without any alterations. 
 
The body weight change was other clinical sign under evaluation (FIGURE 69). The TNBS 
group presented a progressive fall in body weight over the 4-day experimental period   
(-12 ± 1.4%). Curiously, the fall in body weight in mice with TNBS-induced colitis was 
attenuated by hemin treatment, but without a dose dependent effect. The 
TNBS+Hemin5 group decreased the body weight to around -5 ± 1.8% (p<0.05, 
compared with TNBS group), whereas the TNBS+Hemin10 group presented a body 
weight change coincident with the TNBS group with -10.2 ± 1.5% of weight loss. At the 
end of experimental period, the TNBS+Vehicle group also lost -10.4 ± 1.3% of its initial 
weight. The hemin10, ethanol and sham groups gained 7.5 ± 1.2%, 15.2 ± 1.1% and 
31.2 ± 1.6% (p<0.0001, compared with TNBS group) of its initial weight, respectively. It 
was observed statistically significant differences between the body weights of the 
control groups. The considerable increase in body weight was observed in the control 
groups, especially from day 0 to day 1, around 7 to 30% at day 1.  
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FIGURE 69. Change of body weight during hemin treatment in the IBD. 
 
BIOCHEMICAL MARKERS 
The colon length, used as an indirect marker of inflammation, was determined at the 
end of the treatment period (FIGURE 70). Briefly, the colon appearance of TNBS group 
was flaccid and filled with liquid stool. Furthermore, the TNBS-induced colitis (10.1 ± 
0.2 cm) reduced significantly the colon length relatively with the sham group (11.5 ± 0.2 
cm) as a comparable tissue (p<0.0001). The hemin treatment showed an influence on 
the colon length at both doses, but without statistical significance. The colon length in 
the TNBS+Hemin5 group was higher (10.9 ± 0.2 cm) than TNBS group, even as the 
TNBS+Hemin10 group with 10.8 ± 0.2 cm of colon length. The TNBS+Vehicle group 
presented intermediate values for colon length between colitis groups with and without 
hemin treatment (10.5 ± 0.2 cm). The hemin10, ethanol and sham groups presented 
similar results between them, like 11.1 ± 0.2 cm, 11.5 ± 0.4 cm, 11.5 ± 0.2 cm, 
respectively. 
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FIGURE 70. Effect of hemin treatment on colon length in the IBD. 
Legend: One-way ANOVA and Tukey’s post hoc test; * p<0.05; **** p<0.0001 compared with TNBS group. 
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The intensity of hemorrhagic focus is evaluated by the fecal hemoglobin concentration 
(FIGURE 71). The fecal hemoglobin concentration in TNBS group was significantly higher 
than the sham group (12.5 ± 0.3 vs 0.7 ± 0.1 µmol Hg/g feces, p<0.0001). In the 
TNBS+Vehicle group, the data were similar with the TNBS group, presenting 13 ± 0.6 
µmol Hg/g feces. Hemin treatment had a positive influence in the intensity of 
hemorrhagic focus, since the fecal hemoglobin concentration decreased when the 
hemin dose was increased, verifying a dose dependent effect (p<0.0001). Concretely, 
the TNBS+Hemin5 group presented 8.1 ± 0.4 µmol Hg/g feces and the 
TNBS+Hemin10 group presented 5.6 ± 0.5 µmol Hg/g feces (p<0.0001, compared with 
TNBS group). Mice from hemin10 (1.6 ± 0.1 µmol Hg/g feces) and ethanol groups (1.1 
± 0.1 µmol Hg/g feces) did not display significant changes compared to the sham group 
(0.7 ± 0.1 µmol Hg/g feces).  
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FIGURE 71. Effect of hemin treatment on fecal hemoglobin in the IBD. 
Legend: One-way ANOVA and Tukey’s post hoc test; **** p<0.0001 compared with TNBS group or between groups. 
 
The ALP plays an essential role on intestinal homeostasis and its concentration was 
measured in all experimental groups (FIGURE 72). The ALP concentration on the TNBS 
group was considerably higher compared with the sham group (72.7 ± 2.3 vs 19.2 ± 1.8 
IU/L, p<0.0001). The TNBS+Vehicle group had 69.7 ± 0.4 IU/L of ALP, quite similar 
with the TNBS group. The hemin treatment was able to decrease the ALP 
concentration on blood at both hemin doses, achieving a dose dependent effect with 
statistical significance (p<0.0001, compared with TNBS group). The TNBS+Hemin5 
group presented 49.7 ± 0.7 IU/L, whereas the TNBS+Hemin10 group presented 36.8 ± 
1 IU/L of ALP (p<0.0001). The ALP in the hemin10 and ethanol groups are increased 
comparing with the sham group, with 41.1 ± 0.6 IU/L and 38.5 ± 0.6 IU/L, respectively.     
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FIGURE 72. Effect of hemin treatment on serum total ALP concentration in the IBD. 
Legend: One-way ANOVA and Tukey’s post hoc test; **** p<0.0001 compared with TNBS group or between groups. 
 
The influence of hemin treatment on the renal function was evaluated by measurement 
of renal markers concentration, like urea and creatinine (FIGURE 73 AND 74). The TNBS 
group exhibited a significant increase in urea compared with sham group (62.4 ± 1.5 vs 
49.3 ± 0.9 mg/dl, p<0.0001), as well as the creatinine compared with sham group (0.27 
± 0.01 vs 0.20 ± 0.02 mg/dl, p<0.0001). The TNBS+Vehicle group had both renal 
markers, like urea (68.8 ± 0.7 mg/dl) and creatinine (0.28 ± 0.01 mg/dl), higher than 
TNBS group. The mice treated with hemin presented a significant decrease of urea and 
creatinine levels to values quite similar with sham group, promoting thus a dose 
dependent effect with statistical significance between hemin doses in the urea levels 
(p<0.0001). The renal biochemistries of TNBS+Hemin5 group revealed 53.8 ± 1.1 
mg/dl of urea and 0.21 ± 0.01 mg/dl of creatinine, while the TNBS+Hemin10 group 
revealed 41.4 ± 0.9 mg/dl of urea and 0.20 ± 0.01 mg/dl of creatinine. In the control 
groups, the urea concentration in the hemin10 and ethanol groups were lower than the 
sham group, with 40.6 ± 1 mg/dl and 41.4 ± 0.5 mg/dl, respectively (p<0.05). There are 
no statistically significant differences in creatinine levels between the control groups, 
like hemin10, ethanol and sham. 
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FIGURE 73. Effect of hemin treatment on serum urea concentration in the IBD. 
Legend: One-way ANOVA and Tukey’s post hoc test; * p<0.05; **** p<0.0001 compared with sham group or between groups. 
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FIGURE 74. Effect of hemin treatment on serum creatinine concentration in the IBD. 
Legend: One-way ANOVA and Tukey’s post hoc test; **** p<0.0001 compared with sham group.  
 
The ALT concentration was measured in mice with colitis induced-TNBS and mice 
treated with hemin to evaluate the hepatic function (FIGURE 75). The ALT concentration in 
blood was significantly higher in the TNBS group compared with the sham group (38.7 
± 1.2 vs 17.5 ± 0.8 IU/L, p<0.0001). The TNBS+Vehicle group presented a slight 
decrease of ALT concentration (32.4 ± 0.6 IU/L) compared with the TNBS group. On 
the other hand, the hemin treatment at both doses promoted a considerable decrease 
of ALT levels, namely to 30.1 ± 0.8 IU/L in the TNBS+Hemin5 group and 25.5 ± 1 IU/L 
in the TNBS+Hemin10 group, comparing with the TNBS group (p<0.0001). However, 
these results are still higher than the sham group (p<0.001). The ALT levels on 
hemin10 (30.4 ± 0.6 IU/L) and ethanol (32.3 ± 1.2 IU/L) groups were higher than the 
sham group (p<0.0001). 
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FIGURE 75. Effect of hemin treatment on serum ALT concentration in the IBD. 
Legend: One-way ANOVA and Tukey’s post hoc test; *** p<0.001; **** p<0.0001 compared with sham group. 
 
MYELOPEROXIDASE ACTIVITY 
The MPO activity was registered in all experimental groups (FIGURE 76). The TNBS group 
presented an increase of MPO concentration comparing with the sham group (42 ± 2.8 
vs 2.3 ± 0.4 ng/ml, p<0.001). The TNBS+Vehicle group also had an elevated level of 
MPO with 39.4 ± 2.3 ng/ml. Furthermore, the mice treated with hemin presented a 
decrease of MPO concentration with both hemin doses. In the TNBS+Hemin5 group 
was registered 36 ± 3.2 ng/ml of MPO, whereas in the TNBS+Hemin10 group was 
registered a lower MPO activity with 16.8 ± 3.8 ng/ml (p<0.001). A dose dependent 
effect was identified in the decrease of MPO after hemin treatment, however a 
statistical significance difference was only identified in the highest dose (p<0.001, 
compared with TNBS group). The hemin10 and ethanol groups presented a 
significantly decrease of MPO activity to around 1.8 ± 0.1 ng/ml and 5.8 ± 0.9 ng/ml of 
MPO, respectively.  
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FIGURE 76. Effect of hemin treatment on MPO activity in the IBD. 
Legend: One-way ANOVA and Tukey’s post hoc test; *** p<0.001 compared with TNBS group or between groups. 
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MEASUREMENT OF CYTOKINES 
The pro-inflammatory cytokines were increased in the TNBS-induced colitis (FIGURE 77 
AND 78). So, the TNBS group revealed a significant increase of TNF-α compared with 
sham group (253.2 ± 31.4 vs 11.2 ± 0.2 pg/ml, p<0.001), as well as IL-1β compared 
with sham group (263.9 ± 25 vs 12.7 ± 0.1 pg/ml, p<0.001). The TNBS+Vehicle group 
also revealed an increased concentration of TNF-α (258.5 ± 14.3 pg/ml) and IL-1β 
(264.8 ± 15.6 pg/ml). After hemin treatment, the mice exhibited a decrease of these 
pro-inflammatory cytokines with a dose-dependent effect (p<0.001, for the highest 
dose compared with TNBS group). In detail, the TNBS+Hemin5 group presented 215.6 
± 17.7 pg/ml of TNF-α and 209 ± 29.1 pg/ml of IL-1β, whereas the TNBS+Hemin10 
group had a decrease of these cytokines with 85.4 ± 14.9 pg/ml of TNF-α and 118.7 ± 
23.5 pg/ml of IL-1β, with statistically significant differences. The remaining control 
groups presented quite similar concentrations of these cytokines with sham group. The 
hemin10 group had 13.7 ± 1 pg/ml of TNF-α and 15 ± 0.8 pg/ml of IL-1β and the 
ethanol group had 14.9 ± 2 pg/ml of TNF-α and 16.2 ± 1.6 pg/ml of IL-1β. 
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FIGURE 77. Effect of hemin treatment on TNF-α concentration in the IBD. 
Legend: One-way ANOVA and Tukey’s post hoc test; *** p<0.001 compared with TNBS group or between groups. 
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FIGURE 78. Effect of hemin treatment on IL-1β concentration in the IBD. 
Legend: One-way ANOVA and Tukey’s post hoc test; * p<0.05; *** p<0.001 compared with TNBS group or between groups. 
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The assessment of IL-10 concentration is crucial to confirm the obtained results with 
TNF-α and IL-1β measurements (FIGURE 79). Concretely, in the TNBS group was 
registered a low IL-10 concentration of around 31.4 ± 3.3 pg/ml, as well as the 
TNBS+Vehicle group with 31.5 ± 0.9 pg/ml. The mice treated with hemin had an 
increase of IL-10 concentration, with a dose-dependent effect (p<0.001, for the highest 
dose compared with TNBS group). The TNBS+Hemin5 and TNBS+Hemin10 groups 
had 33.7 ± 3.3 pg/ml and 58.4 ± 5.3 pg/ml, respectively (p<0.001). The control groups, 
as hemin10, ethanol and sham groups, had similar results with 23.6 ± 2.5 pg/ml, 17.3 ± 
1.2 pg/ml and 15.7 ± 0.1 pg/ml of IL-10, respectively. 
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FIGURE 79. Effect of hemin treatment on IL-10 concentration in the IBD. 
Legend: One-way ANOVA and Tukey’s post hoc test; * p<0.05; ** p<0.01; *** p<0.001 compared with TNBS group or between groups. 
 
ASSESSMENT OF COLITIS SEVERITY 
The macroscopic inspection of cecum, colon and rectum in the TNBS group showed 
presence of mucosal congestion, hemorrhagic ulcerations and necrosis. After hemin 
treatment, the macroscopic alterations were the same than were observed in the TNBS 
group. No macroscopic alterations were observed in the control groups.  
 
The histopathological score was calculated based on the severity and extension of the 
lesions (TABLE 16). The analysis of partial scores allows evaluating the beneficial effect of 
hemin treatment and which parameters are affected. Daily treatment with hemin (5 and 
10 mg/kg) had an influence in the extension of the lesions, promoting a decrease of the 
percentage of intestine affected by the most severe lesion. However, the final 
histopathological score doesn´t allow to identify this influence. Furthermore, the hemin 
had no effect in the severity of colitis, since this drug was not able to promote a 
considerable and consistent decrease of severity parameters under evaluation. The 
partials scores in the TNBS+Vehicle group were quite similar with the TNBS group in 
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all parameters. The control groups revealed partial scores too low in all evaluated 
parameters. 
 
TABLE 16. Average (± SEM) of partials scores of histopathological score  
of TNBS-induced colitis under hemin treatment. 
  
TNBS TNBS + HEMIN5 
TNBS + 
HEMIN10 
TNBS + 
VEHICLE HEMIN10 ETHANOL SHAM 
MUCOSAL LOSS 3.3 ± 0.2 2.9 ± 0.5 3,5 ± 0,3 3.8 ± 0.3 0 ± 0 0.2 ± 0.1 0 ± 0 
EPITHELIAL 
LESIONS 
3.4 ± 0.2 4 ± 0 3,9 ± 0,1 4 ± 0 0 ± 0 0.9 ± 0.5 0 ± 0 
INFLAMMATION 3.8 ± 0.1 3.5 ± 0 4 ± 0 3.8 ± 0.3 0 ± 0 1.1 ± 0.2 0.1 ± 0.1 
EXTENT 1* 3.7 ± 0.1 4 ± 0 4 ± 0 3.8 ± 0.3 0 ± 0 1.3 ± 0.3 0.1 ± 0.1 
EXTENT 2** 3 ± 0.2 2 ± 0.3 2,4 ± 0,2 2.7 ± 0.3 0 ± 0 1 ± 0.2 0.1 ± 0.1 
 
Legend: * Extent 1 - Percentage of intestine affected in any manner;  
** Extent 2 - Percentage of intestine affected by the most severe lesion. 
  
The histopathological score was evaluated in all experimental groups (FIGURE 80). The 
TNBS group presented a final score of around 17 ± 0.6, substantially higher than the 
sham group (p<0.0001). Even after the treatment with hemin, the histopathological 
score remained unchanged at both hemin doses, presenting 16.5 ± 1 and 17.6 ± 0.5 of 
histopathological score with 5 and 10 mg/kg of hemin, respectively. The results from 
TNBS+Vehicle (17.8 ± 1) are quite similar with the TNBS and TNBS+Hemin groups. 
The control groups revealed a histopathological score very low, namely 0 ± 0 for the 
hemin10 group and 0.2 ± 0.2 for the sham group, except the ethanol group with 4.5 ± 
1.2 of final score.  
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FIGURE 80. Effect of hemin treatment on histopathological score. 
Legend: One-way ANOVA and Tukey’s post hoc test; **** p<0.0001 compared with TNBS group. 
 
Representative images of the histopatological score were analyzed for all experimental 
groups (FIGURE 81). Briefly, the TNBS group displays diffuse transmural necrosis with 
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severe hemorrhaging, involving the mucosa, submucosa, muscle layer and serosa, and 
often associated with peritonitis. Under hemin treatment, similar lesions are seen, 
without any improvement in its severity. However, it is perceptible a slight influence in 
the extension of the lesions, but without expression on the histopathological score. The 
increase of hemin dose has no effect in the histophatological images and, 
consequently, in the histopathological score. The histopathological images of 
TNBS+Vehicle group show the same lesions that TNBS group. The ethanol group 
showed only mild epithelial erosion, and no lesions were observed in the hemin10 and 
sham groups. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 81. Effect of hemin treatment on histopathologic changes in the IBD. 
Legend: Each column corresponding with a different experimental group, namely (A) TNBS group, (B) TNBS+Hemin5 group,  
(C) TNBS+Hemin10 group, (D) TNBS+Vehicle group, (E) Hemin10 group (F) Ethanol group and (G) Sham group. 
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MORTALITY RATE 
The mortality rate was evaluated in the experimental groups as a sign of toxicity (TABLE 
17). At the end of the study, the TNBS group presented 31.4% of mortality rate. After 
these mice were treated with a daily dose of hemin, the mortality rate fell completely for 
0%. In this case, the administration of hemin produced a statistically significant 
decrease of mortality rate. Curiously, TNBS+Vehicle group presented 5% of mortality 
rate. In the sham group, all mice survived during the study. 
 
TABLE 17. Effect of hemin treatment on mortality rate in the IBD. 
 TOTAL DEATHS SURVIVORS 
P-VALUE 
n (%) n (%) n (%) 
EXPERIMENTAL 
GROUPS 
TNBS 35 (100%) 11 (31.4%) 24 (68.6%) 
<0.001 
TNBS + Hemin5 35 (100%) 0 (0%) 35 (100%) 
TNBS + Hemin10 35 (100%) 0 (0%) 35 (100%) 
TNBS + Vehicle 20 (100%) 1 (5%) 19 (95%) 
Sham 20 (0%) 0 (0%) 20 (100%) 
 
Legend: Chi-square test; *** p<0.001 compared between groups. 
 
 
2. DISCUSSION OF RESULTS 
 
In this study, we also assessed the influence of hemin in the TNBS-induced colitis 
model. Hemin is well known as an inducer of HO-1 [Guan et al., 2009; Hualin et al., 
2012]. HO-1 is a rate-limiting enzyme for heme metabolism and is capable of producing 
anti-oxidant and anti-inflammatory products, such as biliverdin/bilirubin and CO [Willis, 
Moore & Willoughby, 2000; Maines, 2005; Ryter et al., 2006]. Biliverdin/bilirubin can 
scavenge peroxyl radicals in vitro as effectively as α-tocopherol, which is regarded as 
the most potent antioxidant against lipid peroxidation [Stocker et al., 1987], whereas 
CO can inhibit the production of pro-inflammatory cytokines in macrophages, such as 
TNF-α, IL-1β, and macrophage inflammatory protein-1, through modulation of MAPK 
activation [Otterbein et al., 2000]. Nowadays, hemin is already used in the 
management of porphyria attacks, particularly in acute intermittent porphyyria [Bissell & 
Wang, 2015]. However, many studies have reported the protective effect of hemin via 
HO-1 induction in various animal models, as hippocampal injury, renal fibrosis, cardiac 
ischemia/reperfusion, lung injury [Hangaishi et al., 2000; Guan et al., 2009; Correa-
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Costa et al., 2010; Hualin et al., 2012]. HO-1 expression can confer cytoprotective, 
antiapoptotic and anti-inflammatory properties, suggesting thus that HO-1 can be a 
possible therapeutic target in several kinds of gastrointestinal diseases [Naito et al., 
2011]. Some studies have been developed in DSS and TNBS colitis models to 
evaluate the effect of HO inducers on the management of IBD [Naito et al., 2011]. 
However, there is only one study testing the influence of hemin in the TNBS-induced 
colitis model [Wang et al., 2001]. Thus, the biological significance of HO-1 up-
regulation by hemin in this colitis model remains to be not fully elucidated as well as the 
mechanisms underlying HO-1 activity [Naito et al., 2011].  
Mice received daily IP injection of hemin, promoting an improvement of some clinical 
symptoms/signs such as a moderate edema of the anus and mild morbidity comparing 
with non-treated mice. Their weight change was also monitored and expressed as 
percentage of original body weight. Thus, we observed that hemin treatment 
significantly attenuated the weight loss caused by TNBS-induced colitis, suggesting 
that enhancement of HO-1 functional activity is implicated in controlling intestinal 
inflammation. However, no clear dose-response relationship was observed, since this 
beneficial effect was only observed in the lower hemin dose. The increase of hemin 
dose did not promote a better beneficial effect in the changes of body weight. We have 
not a clear explanation for this finding yet. Nevertheless, the findings from other studies 
do not also allow to compare with our results, since do not evaluate the influence of 
hemin treatment in the changes of body weight.  
In this study, the length of colon was also assessed as a marker of tissue integrity. 
Since the variations in the length of any part of the colon may lead to variety of acute 
and chronic pathological conditions [Nayak et al., 2012], it is truly relevant measuring 
this parameter. Nevertheless, colon length was never evaluated under these 
conditions. Thus, we registered that shortening of the colon due to TNBS-induced 
colitis was influenced by hemin treatment at both administered doses. However, this 
evident tendency did not represent a statistically significant difference. 
The intensity of hemorrhagic focus was evaluated by the fecal hemoglobin 
concentration. We observed that hemin treatment produced a considerable influence in 
the intensity of hemorrhagic focus, since the fecal hemoglobin concentration 
significantly decreased in a dose dependent manner after a daily dose of hemin. This 
finding suggests that hemin-treated mice presented an amelioration of the active 
inflammatory disease identified in mice with TNBS-induced colitis [Hirata et al., 2007; 
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Mooiweer et al., 2014]. The influence of hemin treatment in fecal hemoglobin was 
measured for the first time in this study.  
Regarding ALP concentration, the data were consistent with the other results of the 
evaluated parameters. In this study, we observed that hemin treatment was able to 
decrease the elevated level of ALP on blood in a dose dependent manner, 
demonstrating an anti-inflammatory potential by HO-1 induction. This data is consistent 
with other previous findings, where anti-inflammatory drugs are able to decrease ALP 
level [Kumar et al., 2014]. In both hemin doses, the mice presented serum ALP values 
similar with control groups, like hemin10 and ethanol groups.  
MPO activity was used as an index of quantitative inflammation and neutrophil 
infiltration in tissues [Rachmilewitz, Simon & Schwarts, 1989]. Hemin administration 
was able to attenuate neutrophil infiltration and inflammation with both hemin doses. 
Indeed, after hemin treatment, the decrease of MPO was registered in a dose 
dependent manner. However, a statistical significance difference was only identified in 
the highest hemin dose, where MPO decreased around 60% comparing with non-
treated mice. These results suggest that generation of endogenous HO-1 may possibly 
protect colonic tissue against inflammation. Our findings are also consistent with other 
studies, where hemin or other HO-1 modulators are used in the experimental colitis 
model [Wang et al., 2001; Jun et al., 2006; Varga et al., 2007].  
TNF-α and IL-1β are pro-inflammatory cytokines that can become dysregulated under 
pathological condition of inflammation [Műzes et al., 2012]. Actually, mice with TNBS-
induced colitis exhibited a significant increase of TNF-α and IL-1β levels, at the end of 
experimental study. Nevertheless, hemin treatment significantly decreased the level of 
these cytokines in a dose-dependent manner. Furthermore, IL-10 was also evaluated 
in this study as an anti-inflammatory cytokine. Hemin treated-mice also revealed a 
significant increase in the concentration of this cytokine in a dose dependent manner 
as expected, confirming the obtained results with TNF-α and IL-1β measurements. 
These findings allow concluding that HO-1 induction by hemin treatment can produce 
anti-inflammatory effect, suppressing the production of these pro-inflammatory 
cytokines, too. Moreover, HO-1 induction may still confer a protective effect, since is 
able to increase anti-inflammatory cytokines [Zhang et al., 2014]. 
To assess whether hemin affected TNBS-induced colon damage, there was analyzed 
the colon morphology and quantified its colonic damage. In our study, we observed that 
histological score of hemin treated mice was similar with those of non-treated mice, 
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suggesting that hemin treatment possibly has no effect on the severity and/or extension 
of the intestinal lesion inducted by disease. However, the histological features of the 
lesions suggest that hemin was able to decrease the extension of the lesions, 
suggesting a beneficial effect in the inflammation of tissue due to HO-1 induction 
[Zhang et al., 2014].  
Since IBD can promote extra-intestinal manifestations, the periodic evaluation of renal 
and hepatic functions should be emphasized [Larsen et al., 2010; Oikonomou et al., 
2011; Rojas-Feria et al., 2013]. Single daily dose of hemin significantly recovered the 
renal and hepatic functions to normal levels, similarly to control group, suggesting a 
beneficial effect in the extra-intestinal manifestations due to metabolic and physiologic 
changes induced by the IBD. We also can conclude that hemin does not promote renal 
and/or hepatic changes as adverse drug reaction, in this experimental colitis model 
Mortality rate was also evaluated during the experimental study. We observed that 
hemin treatment was able to reduce the mortality rate. Actually, mice with TNBS-
induced colitis presented around 31.4% of deaths, whereas hemin treated mice 
survived, presenting 0% of deaths. This result suggests that hemin treatment 
considerably reduces the toxicity associated with the illness, producing a statistically 
significant decrease of mortality rate. 
Until nowadays, there is only one published paper relating the hemin treatment with 
TNBS-induced colitis and, therefore, several parameters had never been evaluated 
under these conditions, such as weight loss, colon length, fecal hemoglobin, TNF-α, IL-
1β, IL-10, histological features and extra-intestinal symptoms. Thus, this study was 
innovative, since some new parameters were measured for the first time. Briefly, hemin 
treatment had a positive influence in the development of experimental colitis, but not in 
all evaluated parameters. This drug promoted a reduction of fecal hemoglobin, ALP, 
MPO and pro-inflammatory cytokines (TNF-α and IL-1β). Hemin was also able to 
increase the anti-inflammatory cytokine (IL-10), as well as regulated of renal and 
hepatic functions. In sum, hemin treatment decrease the severity of the disease, since 
is able to improve several inflammation markers, suggesting an anti-inflammatory effect 
of hemin by HO-1 induction. Hemin also decreases the extension of the intestinal 
lesions, corroborated by histological images. These findings suggest that hemin 
significantly inhibits acute inflammatory response in the experimental colitis.  
Regarding future prospects, we believe the findings of our study should be warranted 
by large number of experimental and prospective clinical studies involving these drugs. 
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Future studies are needed to clarify the exact mechanisms beside the anti-
inflammatory property of these drugs, as well as the full pharmacological profile and 
selectivity of these agents awaits further evaluation [Cuzzocrea et al., 2004; Dugo et 
al., 2005; Whittle et al., 2006].  
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CHAPTER 9 – DISCUSSION AND CONCLUSION 
 
IBD is characterized by the presence of one or more genetically determined defects, 
resulting in a mucosal immune system that overreacts to normal constituents of the 
mucosal microflora. Therefore, IBD is produced through a final common 
immunopathologic pathway comprised of a Th1 T cell response mediated inflammation 
(CD) or a Th2 T cell response mediated inflammation (UC). This implies that, 
regardless of the nature of the fundamental defects present, one could potentially treat 
IBD with therapy that addresses an essential element of the final common pathway 
[Strober et al., 2007]. 
 
Within this context, existing conventional treatments such as corticosteroids, 
mesalamine, and immunosuppressants aim broadly to block downstream inflammatory 
events such as the secretion of cytokines and the elaboration of immunocytes and 
neutrophils, regardless of the nature of the underlying T cell response that generated 
these events. These agents have sustained treatment of IBD for many years despite 
shortcomings and toxicities [Hanauer et al., 2002; Adelman, Sandrock & Panzara, 
2005; Feagan et al., 2005; Sandborn et al., 2005; Rutgeerts et al., 2005; Blonski & 
Lichtenstein, 2006]. For many years there have been numerous efforts to find a new 
effective method that would allow controlling specifically unwanted immune responses 
that occur during autoimmune reaction [Szczepanik et al., 2012]. Emerging treatments 
are evaluating the hierarchy of the inflammatory cytokine effect, by targeting IL-12/IL-
23, IFN-γ, or IL-6 or by restoring IL-10 levels [Ito et al., 2004; Mannon et al., 2004; 
Hommes et al., 2006; Braat et al., 2006]. These treatments has been able to induce the 
reduction the inflammatory mediators that cause tissue damage, maintenance of the 
active inflammation, and exacerbation of dysfunction of the epithelial barrier, ultimately 
leading to control of the second secondary effects [Strober et al., 2007]. The future 
treatment options for IBD will not only be extended by simultaneously targeting several 
pathogenetic players through combinations of existing strategies, but also by the 
introduction of drugs with completely new targets [Zundler & Neurath, 2015]. Thus, the 
assessment of the influence of a set of new drugs in IBD, like EPO, TDZD-8 and 
hemin, through of a TNBS-induced colitis model in mice, can facilitate a more effective 
and selective treatment than the currently known.  
A steadily increasing number of experimental animal models have been used for 
preclinical studies, presenting some clinical manifestations similar to those observed in 
PHARMACOLOGICAL MODULATION OF INFLAMMATION ASSOCIATED WITH INFLAMMATORY BOWEL DISEASE 
CHAPTER 9 – DISCUSSION AND CONCLUSION       142 
human IBD. These animal models have recently been developed and have contributed 
greatly to important advances in our current understanding of the immunological, 
pathological, and physiolgical features of chronic intestinal inflammation [Hibi et al., 
2002; Murphy, 2006]. TNBS-induced colitis model is one of the animal models of 
experimental colitis that has been studied and has so far produced much information 
[Borm & Bouma, 2004]. These animal model is an efficient method, since can mimic 
the pattern of inflammation with human IBD, producing a rapid, reliable and 
reproducible disease [Hibi et al., 2002; Linden et al., 2003; Randhawa et al., 2014]. 
However, since the protocols of the TNBS-induced colitis model are not standardized, 
the degree of disease and time required to produce the injury may vary between 
laboratories [Murphy, 2006; Wirtz et al., 2007; Qin et al., 2011].  
In our study, the development of a TNBS-induced colitis model was essencial, as well 
as the standardization and validation of the induction method. Several conditions were 
tested to achieve a standarded induction method, such as the dose of TNBS, the depth 
of TNBS administration, the time point for model evaluation, and the concentration of 
ethanol (as TNBS vehicle). Although IBD is a chronic inflammatory disease, we would 
like to implement an acute intestinal inflammation model, where proof of concept is 
more easily tested. During the induction method were evaluated and monitored several 
parameters, such as clinical symptoms/signs, biochemical markers, histopathological 
analysis and concentration of pro- and anti-inflammatory cytokines. All parameters 
under evaluation corroborated that the damage became maximal at day 4 after the 
induction. So, TNBS-induced colitis was developed in 4 days, providing an acute 
intestinal inflammation model. Beyond the validation of an animal model of TNBS-
induced colitis in mice, the additional findings of this study was evaluating if all tested 
drugs significantly inhibit acute inflammatory response in this experimental colitis 
model.  
EPO is one of these drugs that we tested in our TNBS-induced colitis model. EPO is 
currently being used in the therapy of patients with chronic renal failure suffering from 
anemia, with an initial dose of 50 to 100 IU/kg IV or SC 3 times weekly [Cody et al., 
2001; Nairz et al., 2011; Willis et al., 2012; Jelkmann, 2012]. However, EPO also has 
extrahematopoietic properties, which may be of therapeutic relevance in inflammatory 
disease [Brines & Cerami, 2005; Jelkmann, 2007; Nairz et al., 2011]. In fact, EPO 
decreases the production of NF-κB inducible immune mediators, thus limiting tissue 
damage and ameliorating disease severity [Nairz et al., 2011].  
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After 4 days of daily EPO treatment, our findings clearly demonstrate that EPO exerts 
potent anti-inflammatory effects on this specific experimental colitis model. EPO 
treatment presented a beneficial effect in the development of experimental colitis in all 
evaluated parameters, thus reducing its severity and extension. More precisely, EPO 
reduced the percentage of weight loss, fecal hemoglobin, ALP, MPO, pro-inflammatory 
cytokines (TNF-α and IL-1β) and histopathological score. On the other hand, EPO also 
increased anti-inflammatory cytokine (IL-10), as well as regulated the renal and hepatic 
functions. Furthermore, in our study, we used two different doses of EPO, namely 500 
IU/Kg and 1000 IU/Kg, in the TNBS-induced colitis model, which are considerably 
lower than usually used in these experimental studies. Since it is known that EPO 
treatment can affect the hematocrit level and promote cardiovascular adverse effects, it 
is important to use the lowest possible doses. Moreover, the administrated doses are 
relevant for the clinical practice in a context of translational pharmacology. 
Nevertheless, we evaluated the hematocrit level after EPO treatment and the results 
were normal. This data indicate that EPO significantly inhibits the acute inflammatory 
response in the experimental colitis, without adverse events related to blood viscosity. 
TDZD-8 is another new drug that we tested in the TNBS-induced colitis model. TDZD-8 
is the first non-ATP competitive GSK-3β inhibitors with highly effectivity and selectivity 
[Martinez et al., 2002a; Dugo et al., 2007]. The capacity of TDZD to suppress the 
expression of inflammatory cytokines and present tissue protective action by GSK-3β 
inhibiton suggests that this agent may be effective in the treatment of several 
inflammatory diseases [Luna-Medina et al., 2005]. In IBD, TDZD-8 was only tested 
once in 2006, where promoted a reduction of the colonic inflammation, tissue injury and 
a reduced decline in body weight [Whittle et al., 2006]. However, many GSK-3β 
inhibitors have already been tested in experimental colitis models until nowadays.  
In our study, mice were treated with a daily TDZD-8 dose during 4 days. TDZD-8 
treatment was able to modulate the development of experimental colitis. Particularly, 
TDZD-8 promoted a reduction of fecal hemoglobin, ALP, MPO and pro-inflammatory 
cytokines (TNF-α and IL-1β). Furthermore, it was also able to increase the expression 
of anti-inflammatory cytokines (IL-10), as well as regulated the renal and hepatic 
functions. According to histopathological analysis, TDZD-8 treatment only produced a 
slight decrease in the extension of the disease. However, the obtained results with the 
cytokines concentration also suggest and confirm its beneficial effect in the reduction of 
the severity of the disease. These data indicate that TDZD-8 also significantly inhibits 
the acute inflammatory response in the experimental colitis. 
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Hemin was also tested in the TNBS-induced colitis model. Hemin is well known as a 
HO-1 inducer and, currently, it is commercialized for the treatment of acute porphyria 
[Naito et al., 2011; Bissell & Wang, 2015]. Additionaly, HO-1 expression can also 
confer cytoprotective, antiapoptotic and anti-inflammatory properties through its 
production of biliverdin/bilirubin and CO, suggesting thus that HO-1 can be a possible 
therapeutic target in several kinds of gastrointestinal diseases [Naito et al., 2011]. In 
IBD, HO-1 plays a protective role in the colonic damage induced by TNBS enema 
[Wang et al., 2001].  
Mice were treated with a daily dose of hemin. At the end of experimental period, hemin 
treatment presented a beneficial influence in the development of experimental colitis, 
decreasing its severity and extension. Hemin promoted a reduction of fecal 
hemoglobin, ALP, MPO and pro-inflammatory cytokines (TNF-α and IL-1β). It was also 
able to increase the anti-inflammatory cytokine (IL-10), as well as regulated of renal 
and hepatic functions. Furthermore, hemin treatment produced a statistically significant 
decrease of mortality rate to 0% of deaths, promoting similar results to those obtained 
with healthy mice. These findings suggest that hemin also significantly inhibits acute 
inflammatory response in the experimental colitis, totally reducing the mortality 
associated with the disease. 
That way, our work allows contributing for the scientific knowledge about the impact of 
these drugs in the management of IBD, helping the scientific community to decide 
about its relevance to treat this disease. Therefore, this work is also innovative, 
presenting an additional contribution for the scientific knowledge, since: 
• Mice with TNBS-induced colitis (and without any other comorbidity) were never 
subjected to an EPO treatment and we assess that in this study; 
• We also measured, for the first time, the influence of EPO in the hematocrit level to 
evaluate the risk of cardiovascular events, as well as its beneficial effect in the IL-10 
expression;  
• In the hemin treatment, we implemented a daily administration of hemin, monitoring 
TNF-α, IL-1β and IL-10, which had never been done; 
• Bloody diarrhea is the hallmark of IBD, the determination of fecal hemoglobin can be 
useful in the detection and quantification of lesions accompanied by bleeding [Hirata et 
al., 2007; Kornbluth & Sachar, 2010; Jagtap et al., 2011]. However, this biological 
marker had never been measured in this animal model after the propused treatments. 
In this study, we measured the influence of these new drugs in the reduction of fecal 
hemoglobin;  
PHARMACOLOGICAL MODULATION OF INFLAMMATION ASSOCIATED WITH INFLAMMATORY BOWEL DISEASE 
CHAPTER 9 – DISCUSSION AND CONCLUSION       145 
• Finally, many parameters never evaluated before were were monitored in this study. 
For example, the well-documented extra-intestinal manifestations and complications of 
IBD, as well as the possible renal and hepatic side effects of pharmacotherapy, 
emphasize the need for periodic evaluation of renal and hepatic functions [Larsen et 
al., 2010; Oikonomou et al., 2011; Rojas-Feria et al., 2013]. The assessment of the 
influence of these new drugs in the extra-intestinal manifestations is truly relevant, 
since had never been investigated. For the first time, we monitored the effect of these 
new pharmacological approaches in the renal and hepatic functions. 
 
These findings may provide insight into these potential therapeutic approaches to 
ameriolate the inflammation and to minimize the morbidity and mortality associated 
with IBD. However, as George Bernard Shaw once said, “Science never solves a 
problem without creating ten more”. So, although the experimental data reported are 
impressive, comparison of these results with others publications suggests a slight 
variability in the results. This is quite expected in preclinical studies, due to several 
conditions, such as the type of induction method, administrated doses, treatment 
period, which difficult the translation of the data for the clinical practice. Careful 
attention may be required to translate animal studies to clinical settings by ensuring 
that both safety and efficacy can be modeled [Mizoguchi & Mizoguchi, 2010]. Thus, 
because there are much more to research and the science is a machine that never 
stops, the need to further future research projects to confirm the relevance of these 
drugs for IBD is a reality and, consequently, their application to the clinical situation. In 
any case, robust clinical trials proving such potential benefits will be required before the 
use of these drugs for the management of IBD can be recommended. Inclusively, some 
other interesting and promising examples of conceptually new strategies in IBD 
treatment include the fortification of impaired epithelial barrier, stimulation of innate 
immune processes via TLR agonists or the modulation of the intestinal flora in IBD 
[Neurath, 2014b]. It will be interesting to investigate if these new drugs can eventually 
produce effect in one of these mechanisms. Furthermore, future studies are also 
needed to clarify the relevance of some changes in the drug delivery system could 
promote in the therapeutic effect, since topical application by rectal administration is 
eventually a good strategy to achieve a more effective and selective treatment with less 
adverse reactions. 
 
In conclusion, this study allowed exploring the effect of these new drugs in the 
development of IBD, as well as their influence on response mechanisms to intestinal 
injury. Moreover, it represents a truly innovative contribution to the pharmacological 
PHARMACOLOGICAL MODULATION OF INFLAMMATION ASSOCIATED WITH INFLAMMATORY BOWEL DISEASE 
CHAPTER 9 – DISCUSSION AND CONCLUSION       146 
treatment of IBD, identifying pro- and anti-inflammatory associated responses that can 
modulate the establishment and development of the disease, as well as new 
therapeutic targets that allow decrease or attenuate the IBD and contribute to the 
enrichment of the therapeutic opportunities of this disease. 
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ANNEXE 1 - CROHN´S DISEASE ACTIVITY INDEX 
In 1972, the CDAI (TABLE 18) was first used in clinical trias and was the instrument of 
evaluation in two large trials that resulted from the National Cooperative Crohn´s 
Disease Study [Summers et al., 1979; Singleton et al., 1979]. Today, the CDAI remains 
widely used in clinical research. A random overview of important published clinical trials 
of the past four years [Greenberg et al., 1994; Rutgeerts et al., 1994; Feagan et al., 
1994; Feagan et al., 1995; Targan et al., 1997; Stack et al., 1997] reveals that more 
than 25 years after the CDAI was developed, it remains a popular instrument of 
evaluation of CD. 
The CDAI is a disease-specific index, ie its use is restricted to CD and it is not 
applicable to IBD in general. The CDA attempts to evaluate the activity of CD in several 
domains, each of which evaluates a specific aspect of CD. The CDAI sums up the 
weighted value of each item of the domain and quantifies the global disease severity in 
a final numerical score [Best, Becktel, Singleton & Kern, 1976].  
A value less than 150 was defined as quiescent CD (ie, nonactive disease, clinical 
remission), whereas values greater that 450 were associated with extremely severe 
disease [Best et al., 1976]. 
 
TABLE 18. Crohn´s Disease Activity Index and their weights. 
 
